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A B S T R A C T
Background
Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health Organization (WHO)-recommended rapid nucleic acid amplification
tests (NAATs) widely used for simultaneous detection of Mycobacterium tuberculosis complex and rifampicin resistance in sputum. To
extend our previous review on extrapulmonary tuberculosis (Kohli 2018), we performed this update to inform updated WHO policy (WHO
Consolidated Guidelines (Module 3) 2020).
Objectives
To estimate diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for extrapulmonary tuberculosis and rifampicin resistance in adults with
presumptive extrapulmonary tuberculosis.
Search methods
Cochrane Infectious Diseases Group Specialized Register, MEDLINE, Embase, Science Citation Index, Web of Science, Latin American
Caribbean Health Sciences Literature, Scopus, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, the International
Standard Randomized Controlled Trial Number Registry, and ProQuest, 2 August 2019 and 28 January 2020 (Xpert Ultra studies), without
language restriction.
Selection criteria
Cross-sectional and cohort studies using non-respiratory specimens. Forms of extrapulmonary tuberculosis: tuberculous meningitis and
pleural, lymph node, bone or joint, genitourinary, peritoneal, pericardial, disseminated tuberculosis. Reference standards were culture
and a study-defined composite reference standard (tuberculosis detection); phenotypic drug susceptibility testing and line probe assays
(rifampicin resistance detection).
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Data collection and analysis
Two review authors independently extracted data and assessed risk of bias and applicability using QUADAS-2. For tuberculosis detection,
we performed separate analyses by specimen type and reference standard using the bivariate model to estimate pooled sensitivity and
specificity with 95% credible intervals (CrIs). We applied a latent class meta-analysis model to three forms of extrapulmonary tuberculosis.
We assessed certainty of evidence using GRADE.
Main results
69 studies: 67 evaluated Xpert MTB/RIF and 11 evaluated Xpert Ultra, of which nine evaluated both tests. Most studies were conducted in
China, India, South Africa, and Uganda. Overall, risk of bias was low for patient selection, index test, and flow and timing domains, and
low (49%) or unclear (43%) for the reference standard domain. Applicability for the patient selection domain was unclear for most studies
because we were unsure of the clinical settings.
Cerebrospinal fluid
Xpert Ultra (6 studies)
Xpert Ultra pooled sensitivity and specificity (95% CrI) against culture were 89.4% (79.1 to 95.6) (89 participants; low-certainty evidence)
and 91.2% (83.2 to 95.7) (386 participants; moderate-certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 168
would be Xpert Ultra-positive: of these, 79 (47%) would not have tuberculosis (false-positives) and 832 would be Xpert Ultra-negative: of
these, 11 (1%) would have tuberculosis (false-negatives).
Xpert MTB/RIF (30 studies)
Xpert MTB/RIF pooled sensitivity and specificity against culture were 71.1% (62.8 to 79.1) (571 participants; moderate-certainty evidence)
and 96.9% (95.4 to 98.0) (2824 participants; high-certainty evidence). Of 1000 people where 100 have tuberculous meningitis, 99 would
be Xpert MTB/RIF-positive: of these, 28 (28%) would not have tuberculosis; and 901 would be Xpert MTB/RIF-negative: of these, 29 (3%)
would have tuberculosis.
Pleural fluid
Xpert Ultra (4 studies)
Xpert Ultra pooled sensitivity and specificity against culture were 75.0% (58.0 to 86.4) (158 participants; very low-certainty evidence) and
87.0% (63.1 to 97.9) (240 participants; very low-certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 192 would be
Xpert Ultra-positive: of these, 117 (61%) would not have tuberculosis; and 808 would be Xpert Ultra-negative: of these, 25 (3%) would have
tuberculosis.
Xpert MTB/RIF (25 studies)
Xpert MTB/RIF pooled sensitivity and specificity against culture were 49.5% (39.8 to 59.9) (644 participants; low-certainty evidence) and
98.9% (97.6 to 99.7) (2421 participants; high-certainty evidence). Of 1000 people where 100 have pleural tuberculosis, 60 would be Xpert
MTB/RIF-positive: of these, 10 (17%) would not have tuberculosis; and 940 would be Xpert MTB/RIF-negative: of these, 50 (5%) would have
tuberculosis.
Lymph node aspirate
Xpert Ultra (1 study)
Xpert Ultra sensitivity and specificity (95% confidence interval) against composite reference standard were 70% (51 to 85) (30 participants;
very low-certainty evidence) and 100% (92 to 100) (43 participants; low-certainty evidence). Of 1000 people where 100 have lymph node
tuberculosis, 70 would be Xpert Ultra-positive and 0 (0%) would not have tuberculosis; 930 would be Xpert Ultra-negative and 30 (3%)
would have tuberculosis.
Xpert MTB/RIF (4 studies)
Xpert MTB/RIF pooled sensitivity and specificity against composite reference standard were 81.6% (61.9 to 93.3) (377 participants; low-
certainty evidence) and 96.4% (91.3 to 98.6) (302 participants; low-certainty evidence). Of 1000 people where 100 have lymph node
tuberculosis, 118 would be Xpert MTB/RIF-positive and 37 (31%) would not have tuberculosis; 882 would be Xpert MTB/RIF-negative and
19 (2%) would have tuberculosis.
In lymph node aspirate, Xpert MTB/RIF pooled specificity against culture was 86.2% (78.0 to 92.3), lower than that against a composite
reference standard. Using the latent class model, Xpert MTB/RIF pooled specificity was 99.5% (99.1 to 99.7), similar to that observed with
a composite reference standard.
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Rifampicin resistance
Xpert Ultra (4 studies)
Xpert Ultra pooled sensitivity and specificity were 100.0% (95.1 to 100.0), (24 participants; low-certainty evidence) and 100.0% (99.0 to
100.0) (105 participants; moderate-certainty evidence). Of 1000 people where 100 have rifampicin resistance, 100 would be Xpert Ultra-
positive (resistant): of these, zero (0%) would not have rifampicin resistance; and 900 would be Xpert Ultra-negative (susceptible): of these,
zero (0%) would have rifampicin resistance.
Xpert MTB/RIF (19 studies)
Xpert MTB/RIF pooled sensitivity and specificity were 96.5% (91.9 to 98.8) (148 participants; high-certainty evidence) and 99.1% (98.0 to
99.7) (822 participants; high-certainty evidence). Of 1000 people where 100 have rifampicin resistance, 105 would be Xpert MTB/RIF-positive
(resistant): of these, 8 (8%) would not have rifampicin resistance; and 895 would be Xpert MTB/RIF-negative (susceptible): of these, 3 (0.3%)
would have rifampicin resistance.
Authors' conclusions
Xpert Ultra and Xpert MTB/RIF may be helpful in diagnosing extrapulmonary tuberculosis. Sensitivity varies across diLerent
extrapulmonary specimens: while for most specimens specificity is high, the tests rarely yield a positive result for people without
tuberculosis. For tuberculous meningitis, Xpert Ultra had higher sensitivity and lower specificity than Xpert MTB/RIF against culture. Xpert
Ultra and Xpert MTB/RIF had similar sensitivity and specificity for rifampicin resistance. Future research should acknowledge the concern
associated with culture as a reference standard in paucibacillary specimens and consider ways to address this limitation.
P L A I N   L A N G U A G E   S U M M A R Y
How accurate are tests (Xpert Ultra and Xpert MTB/RIF) for diagnosing tuberculosis outside the lungs (extrapulmonary
tuberculosis) and rifampicin resistance?
Why is using Xpert tests for extrapulmonary tuberculosis important?
Tuberculosis is one of the top 10 causes of death worldwide. Tuberculosis mainly aLects the lungs (pulmonary) but may occur in other
parts of the body (extrapulmonary). When people receive proper and timely treatment, tuberculosis is usually curable. One problem
involved in managing tuberculosis is that the bacteria become resistant to antibiotics. Not recognizing tuberculosis early may result in
delayed diagnosis and treatment and increased illness and death. An incorrect tuberculosis diagnosis may result in increased anxiety and
unnecessary treatment.
What is the aim of this review?
To update the evidence on accuracy of Xpert tests for diagnosing extrapulmonary tuberculosis and rifampicin resistance in adults.
Rifampicin is an important tuberculosis drug. We included tuberculous meningitis and pleural, lymph node, bone or joint, genitourinary,
peritoneal, pericardial, and disseminated tuberculosis.
What was studied in this review?
Xpert Ultra and Xpert MTB/RIF are rapid tests for simultaneously diagnosing tuberculosis and rifampicin resistance. We combined study
results to determine:
- sensitivity: people with tuberculosis (rifampicin resistance) correctly diagnosed as having the condition.
- specificity: people without tuberculosis (rifampicin resistance) correctly identified as not having the condition.
The closer sensitivity and specificity are to 100%, the better the test. We measured Xpert results against culture and a composite reference
standard (neither is a perfect reference standard because extrapulmonary tuberculosis is paucibacillary (few bacteria)).
What are the main results in this review?
69 studies tested lymph node, pleural, and cerebrospinal fluid, and other specimens from people with presumptive extrapulmonary
tuberculosis. Studies were conducted in 28 diLerent countries.
For every 1000 people tested, if 100 had tuberculosis according to the reference standards:
cerebrospinal fluid
-Xpert Ultra (6 studies):
· 89% sensitivity: 168 people would test positive, including 79 without tuberculosis
· 91% specificity: 832 people would test negative, including 11 with tuberculosis
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- Xpert MTB/RIF (30 studies):
· 71% sensitivity: 99 people would test positive, including 28 without tuberculosis
· 97% specificity: 901 people would test negative, including 29 with tuberculosis
pleural fluid
- Xpert Ultra (4 studies):
· 75% sensitivity: 192 people would test positive, including 117 without tuberculosis
· 87% specificity: 808 people would test negative, including 25 with tuberculosis
- Xpert MTB/RIF (25 studies):
· 50% sensitivity: 60 people would test positive, including 10 without tuberculosis
· 99% specificity: 940 would test negative, including 50 with tuberculosis
lymph node fluid
- Xpert Ultra (1 study):
· 70% sensitivity: 70 people would test positive (all have tuberculosis)
· 100% specificity: 930 people would test negative, including 30 with tuberculosis
-Xpert MTB/RIF (4 studies):
· 82% sensitivity:118 people would test positive, including 37 without tuberculosis
· 96% specificity: 882 people would test negative, including 19 with tuberculosis
rifampicin resistance
-Xpert Ultra (4 studies):
· 100% sensitivity: 100 people would test positive (all have rifampicin resistance)
· 100% specificity: 900 people would test negative (none have rifampicin resistance)
- MTB/RIF test (19 studies):
· 97% sensitivity: 105 people would test positive, including eight without rifampicin resistance
· 99% specificity: 895 people would test negative, including three with rifampicin resistance
Who do the results of this review apply to?
People thought to have extrapulmonary tuberculosis.
How confident are we in our results?
Fairly confident for Xpert MTB/RIF in cerebrospinal fluid and less so in lymph node fluid. Less confident for Xpert Ultra, as there were few
studies and few people tested. Both reference standards are imperfect, which may aLect accuracy estimates.
What are the implications of this review?
The Xpert tests may be helpful in diagnosing extrapulmonary tuberculosis. Sensitivity varies across diLerent extrapulmonary specimens,
while for most specimens, specificity is high, the test rarely yielding a positive result for people without tuberculosis (verified by culture).
For tuberculous meningitis, Xpert Ultra had higher sensitivity than Xpert MTB/RIF and lower specificity than Xpert MTB/RIF. The tests had
similar accuracy for diagnosing rifampicin resistance.
How up-to-date is this review?
28 January 2020.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Xpert Ultra and Xpert MTB/RIF in cerebrospinal fluid
Participants: people presumed to have tuberculous meningitis
Prior testing: people who received Xpert Ultra or Xpert MTB/RIF testing may first have undergone a health examination (history and physical examination) and possibly re-
ceived a chest radiograph
Role: initial test, replacement for usual practice
Settings: primarily tertiary care centres (the index test was often run in reference laboratories)
Index tests: Xpert Ultra and Xpert MTB/RIF
Reference standard: solid or liquid culture
Studies: cross-sectional studies
Limitations: participants were evaluated exclusively as inpatients at a tertiary care centre, or, if the clinical setting was not reported, Xpert was performed at a reference
laboratory rather than at primary care facilities and local hospitals
Xpert Ultra pooled sensitivity (95% CrI): 89.4% (79.1 to 95.6); pooled specificity (95% CrI): 91.2% (83.2 to 95.7)
Xpert MTB/RIF pooled sensitivity (95% CrI): 71.1% (62.8 to 79.1); pooled specificity (95% CrI): 96.9% (95.4 to 98.0)
1000 people tested for TB using Xpert Ultra(95% CrI)Xpert Ultra result






































































































































































































































1000 people tested for TB using XpertMTB/RIF (95% CrI)Xpert MTB/RIF result









































Abbreviations: Crl: credible interval; TB: tuberculosis
We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was
35.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 15.2%.
Credible limits were estimated based on those around the point estimates for pooled sensitivity and specificity.
aThere were few participants in this analysis. The very wide 95% CrI around true-positives and false-negatives may lead to diLerent decisions, depending on which credible limits
are assumed. We downgraded two levels for imprecision.
bThe wide 95% CrI around true-negatives and false-positives would likely lead to diLerent decisions, depending on which credible limits are assumed. We downgraded one level
for imprecision.
cThe wide 95% CrI around true-positives and false-negatives may lead to diLerent decisions, depending on which credible limits are assumed. We downgraded one level for
imprecision.
GRADE certainty of the evidence
High: we are very confident that the true eLect lies close to that of the estimate of the eLect.
Moderate: we are moderately confident in the eLect estimate: the true eLect is likely to be close to the estimate of the eLect, but there is a possibility that it is substantially
diLerent.
Low: our confidence in the eLect estimate is limited: the true eLect may be substantially diLerent from the estimate of the eLect.
Very low: we have very little confidence in the eLect estimate: the true eLect is likely to be substantially diLerent from the estimate of eLect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 2.   Xpert Ultra and Xpert MTB/RIF in pleural fluid






























































































































































































Prior testing: people who received Xpert Ultra or Xpert MTB/RIF testing may first have undergone a health examination (history and physical examination) and received a
chest radiograph
Role: initial test, replacement for usual practice, which may include more invasive tests, such as pleural biopsy
Settings: primarily tertiary care centres (the index test was often run in reference laboratories)
Index tests: Xpert Ultra and Xpert MTB/RIF
Reference standard: solid or liquid culture
Studies: cross-sectional studies
Limitations: in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, the test was performed at a reference laborato-
ry
Xpert Ultra pooled sensitivity (95% CrI): 75.0% (58.0 to 86.4); pooled specificity (95% CrI): 87.0% (63.1 to 97.9)
Xpert MTB/RIF pooled sensitivity (95% CrI): 49.5% (39.8 to 59.9); pooled specificity (95% CrI): 98.9% (97.6 to 99.7)
1000 people tested for TB using Xpert Ultra (95% CrI)Xpert Ultra result








































1000 people tested for TB using Xpert MTB/RIF (95% CrI)Xpert MTB/RIF result







































































































































































































(10 to 15) (40 to 60) (80 to 120)
























Abbreviations: CrI: credible interval; TB: tuberculosis.
We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of tuberculosis in the included studies was
46.2%. For Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 19.8%.
aWe were interested in how Xpert Ultra performed in patients presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice. However,
most studies did not report information on the clinical setting. We downgraded one level for indirectness.
bFor individual studies, sensitivity estimates ranged from 48% to 84%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for
inconsistency.
cThere was a low number of participants contributing to this analysis for the observed sensitivity. As we had already downgraded for inconsistency, we downgraded one level
for imprecision.
dFor individual studies, specificity estimates ranged from 65% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for
inconsistency.
eWe thought the wide 95% CrI around false-positives and true-negatives would likely lead to diLerent decisions depending on which confidence limits are assumed. As we had
already downgraded for inconsistency, we downgraded one level for imprecision.
fWe were interested in how Xpert MTB/RIF performed in participants presumed to have extrapulmonary tuberculosis who were evaluated as they would be in routine practice.
However, most studies did not report information on the clinical setting. We downgraded one level for indirectness.
gFor individual studies, sensitivity estimates ranged from 10% to 100%. We could not explain the heterogeneity by study quality or other factors. We downgraded one level for
inconsistency.
hAs we had already downgraded for inconsistency, we did not downgrade further for imprecision.
GRADE certainty of the evidence
High: we are very confident that the true eLect lies close to that of the estimate of the eLect.
Moderate: we are moderately confident in the eLect estimate: the true eLect is likely to be close to the estimate of the eLect, but there is a possibility that it is substantially
diLerent.
Low: our confidence in the eLect estimate is limited: the true eLect may be substantially diLerent from the estimate of the eLect.
Very low: we have very little confidence in the eLect estimate: the true eLect is likely to be substantially diLerent from the estimate of eLect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 3.   Xpert Ultra and Xpert MTB/RIF in lymph node aspirate






























































































































































































Prior testing: people who received Xpert testing may first have undergone a health examination (history and physical examination) and possibly received a chest radi-
ograph
Role: initial test, replacement for usual practice, which may include more invasive tests, such as biopsy of affected organs
Settings: primarily tertiary care centres (the index test was often run in reference laboratories)
Index tests: Xpert Ultra and Xpert MTB/RIF
Reference standard: composite reference standard
Studies: cross-sectional studies
Limitations: in most studies, participants were evaluated at a tertiary care centre, or if the clinical setting was not reported, the test was performed at a reference laborato-
ry performed at a reference laboratory
Xpert Ultra sensitivity (95% CI): 70% (51 to 85); specificity: 100% (92 to 100)
Xpert MTB/RIF pooled sensitivity (95% CrI): 81.6% (61.9 to 93.3); pooled specificity: 96.4% (91.3 to 98.6)
1000 people tested for TB using Xpert Ultra 
(95% Cl)
Xpert Ultra result








True-positives (patients with lymph node TB) 17 (13 to 21) 70 (51 to 85) 140 (102 to 170)
False-negatives (patients incorrectly classified as not having
lymph node TB)
8 (4 to 12) 30 (15 to 49) 60 (30 to 98)
30 (1) ⊕⊝⊝⊝
Very lowa,b
True-negatives (patients without lymph node TB) 975 (897 to 975) 900 (828 to 900) 800 (736 to 800)
False-positives (patients incorrectly classified as having lymph
node TB)
0 (0 to 78) 0 (0 to 72) 0 (0 to 64)
43 (1) ⊕⊝⊝⊝
Very lowa,c
1000 people tested for TB using Xpert MTB/RIF (95% Crl)Xpert MTB/RIF result








True-positives (patients with lymph node TB) 20 (16 to 23) 81 (62 to 92) 162 (124 to 184)
False-negatives (patients incorrectly classified as not having
lymph node TB)
5 (2 to 9) 19 (8 to 38) 38 (16 to 76)
377 (4) ⊕⊕⊝⊝
Lowd,e
































































































































































































False-positives (patients incorrectly classified as having lymph
node TB)
40 (17 to 97) 37 (15 to 89) 33 (14 to 79)
Abbreviations: Crl: credible interval; TB: tuberculosis.
We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the prevalence of tuberculosis in the included study was 41%. For
Xpert MTB/RIF, the median prevalence of tuberculosis in the included studies was 55.5%.
aWe identified only one study, which was conducted at a tertiary referral centre in South Africa, a high TB burden country. Most participants (84%) were seen as outpatients. With
only one study, applicability to other settings comes with some uncertainty. We downgraded one level for indirectness.
bThere were very few participants contributing to this analysis. The 95% CI was very wide. We downgraded two levels for imprecision.
cThere were very few participants contributing to this analysis. The 95% CI was wide. We downgraded two levels for imprecision.
dThe composite reference standard was defined by the primary study authors and therefore, was not uniform. We downgraded one level for risk of bias.
eFor indirectness, regarding applicability, for the patient population, we considered most studies to have unclear concern. We were interested in how Xpert MTB/RIF performed in
patients presumed to have extrapulmonary TB who were evaluated as they would be in routine practice. However, none of the studies reported this information. We downgraded
one level for indirectness.
GRADE certainty of the evidence
High: we are very confident that the true eLect lies close to that of the estimate of the eLect.
Moderate: we are moderately confident in the eLect estimate: the true eLect is likely to be close to the estimate of the eLect, but there is a possibility that it is substantially
diLerent.
Low: our confidence in the eLect estimate is limited: the true eLect may be substantially diLerent from the estimate of the eLect.
Very low: we have very little confidence in the eLect estimate: the true eLect is likely to be substantially diLerent from the estimate of eLect.
The results presented in this table should not be interpreted in isolation from results of the individual included studies contributing to each summary test accuracy measure.
 
 
Summary of findings 4.   Xpert Ultra and Xpert MTB/RIF for rifampicin resistance
Participants: people with tuberculosis detected by Xpert Ultra or Xpert MTB/RIF
Role: initial test, replacement test for standard practice, which includes culture-based drug susceptibility testing or line probe assay
Settings: primarily tertiary care centres, the index test was often run in central (reference laboratories), where drug susceptibility testing for the reference standard could
be performed
Index tests: Xpert Ultra and Xpert MTB/RIF
Reference standard: culture-based drug susceptibility testing using solid or liquid media or line probe assay
Studies: cross-sectional studies
Xpert Ultra pooled sensitivity (95% CrI): 100.0% (95.1 to 100.0); pooled specificity (95% CrI): 100.0% (99.0 to 100.0)
Xpert MTB/RIF pooled sensitivity (95% CrI): 96.5% (91.9 to 98.8); pooled specificity (95% CrI): 99.1% (98.0 to 99.7)








































































































































































































Prevalence of 2% Prevalence of 10% Prevalence of 15%
True-positives (patients correctly classified as rifampicin resistant) 20 (19 to 20) 100 (95 to 100) 150 (143 to 150)
False-negatives (patients incorrectly classified as rifampicin suscepti-
ble)
0 (0 to 1) 0 (0 to 5) 0 (0 to 7)
24 (4) ⊕⊕⊝⊝
Lowa,b
True-negatives (patients correctly classified as rifampicin suscepti-
ble)
980 (979 to 980) 900 (899 to 900) 850 (849 to 850)
False-positives (patients incorrectly classified as rifampicin resistant) 0 (0 to 1) 0 (0 to 1) 0 (0 to 1)
105 (4) ⊕⊕⊕⊝
Moderatea
1000 people tested for rifampicin resistance using Xpert MTB/
RIF (95% Crl)
Xpert MTB/RIF result









True-positives (patients correctly classified as rifampicin resistant) 19 (18 to 20) 97 (92 to 99) 145 (138 to 148)
False-negatives (patients incorrectly classified as rifampicin suscepti-
ble)
1 (0 to 2) 3 (1 to 8) 5 (2 to 12)
148 (19) ⊕⊕⊕⊕
High
True-negatives (patients correctly classified as rifampicin suscepti-
ble)
971 (960 to 977) 892 (882 to 897) 842 (833 to 847)
False-positives (patients incorrectly classified as rifampicin resistant) 9 (3 to 20) 8 (3 to 18) 8 (3 to 17)
822 (19) ⊕⊕⊕⊕
High
Abbreviations: Crl: credible interval; TB: tuberculosis.
We included plausible prevalence estimates for the target condition suggested by the WHO. For Xpert Ultra, the median prevalence of rifampicin resistance in the included studies
was 19.2%. For Xpert MTB/RIF, the median prevalence of rifampicin resistance in the included studies was 11.9%.
aAll these studies were conducted in China (high TB-burden country). Applicability to other settings comes with some uncertainty and therefore we downgraded one level for
indirectness.
bThere was a low number of participants contributing to this analysis for the observed sensitivity. We downgraded one level for imprecision.
GRADE certainty of the evidence
High: we are very confident that the true eLect lies close to that of the estimate of the eLect.
Moderate: we are moderately confident in the eLect estimate: the true eLect is likely to be close to the estimate of the eLect, but there is a possibility that it is substantially
diLerent.
Low: our confidence in the eLect estimate is limited: the true eLect may be substantially diLerent from the estimate of the eLect.
Very low: we have very little confidence in the eLect estimate: the true eLect is likely to be substantially diLerent from the estimate of eLect.
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B A C K G R O U N D
Tuberculosis (TB) causes tremendous suLering worldwide and
has surpassed HIV/AIDS as the world’s leading infectious cause
of death. The World Health Organization (WHO) estimates that
globally in 2019, 10.0 million (range, 8.9 to 11.0 million) people
fell ill with tuberculosis. In 2019, around 1.2 million HIV-negative
people died from tuberculosis and 208,000 HIV-positive people
died from tuberculosis (WHO Global TB Report 2020). When people
receive proper treatment, tuberculosis is treatable and curable. The
WHO estimates that from 2000 to 2019 more than 60 million lives
were saved by diagnosing and treating tuberculosis. However, the
COVID-19 pandemic threatens the gains made over recent years. A
modelling study by the WHO suggests that there could be between
200,000 and 400,000 additional tuberculosis deaths in 2020 if, over
a period of three months, 25% to 50% fewer people were detected
and treated with tuberculosis (WHO Global TB Report 2020).
Of the 7.1 million new cases of tuberculosis notified to the WHO
in 2019, 16% were cases of extrapulmonary tuberculosis, (range,
8% in the WHO Western Pacific Region to 24% in the WHO Eastern
Mediterranean Region) (WHO Global TB Report 2020). Among
countries in the European Union, extrapulmonary tuberculosis
was responsible for 19% of all notified cases (range, 6% to 44%)
(Sandgren 2013). A large retrospective analysis from China found
that of 19,279 hospitalised tuberculosis patients, around 33% had
extrapulmonary tuberculosis (Pang 2019). The number of people
aLected by extrapulmonary tuberculosis is likely to be higher, given
that, according to the WHO, extrapulmonary tuberculosis is notified
as pulmonary tuberculosis when the two forms exist together,
and diagnosing extrapulmonary tuberculosis is challenging,
as described below. Additionally, extrapulmonary tuberculosis
accounts for an increasing proportion of tuberculosis cases in some
countries, in part because of host and genetic considerations, and
the association of extrapulmonary tuberculosis and HIV (Golden
2005; Pai 2016; Perkins 2007; Webster 2014). Based on surveillance
and epidemiological data, extrapulmonary tuberculosis aLects a
greater proportion of children than adults (Nelson 2004).
Drug-resistant tuberculosis is a serious threat to global health.
For the purpose of surveillance and treatment, drug-resistant
tuberculosis is classified as rifampicin-resistant tuberculosis,
multidrug-resistant tuberculosis (MDR-TB), and extensively drug-
resistant tuberculosis. MDR-TB is defined as resistance to at
least isoniazid and rifampicin, the two most important first-line
anti-tuberculosis drugs. Extensively drug-resistant tuberculosis is
defined as MDR-TB plus resistance to at least one drug in the
following two classes of medicines used in treatment of MDR-TB:
fluoroquinolones and second-line injectable agents. In 2019, there
were approximately half a million new cases of rifampicin-resistant
tuberculosis (of which 78% had MDR-TB), with India (27%), China
(14%) and the Russian Federation (9%) accounting for the largest
burden (WHO Global TB Report 2020). In 2019, 12,350 cases of
extensively drug-resistant tuberculosis were reported (WHO Global
TB Report 2020).
In 2014, the World Health Assembly unanimously approved the
WHO End TB Strategy, a 20-year strategy devised to end the global
tuberculosis epidemic (WHO END TB 2014). Early diagnosis of
tuberculosis, including universal drug susceptibility testing (DST)
and systematic screening of contacts and high-risk groups, is a part
of pillar one of the strategy.
Target condition being diagnosed
Extrapulmonary TB
Tuberculosis is caused by infection with Mycobacterium
tuberculosis (M tuberculosis) bacteria. Tuberculosis predominantly
aLects the lungs (pulmonary tuberculosis). Extrapulmonary
tuberculosis refers to tuberculosis in parts of the body other
than the lungs. Extrapulmonary tuberculosis is known to aLect
virtually every part of the body, with lymph nodes and the pleura
being the most common sites (Sharma 2004). Although active
pulmonary tuberculosis is transmissible by droplets spread by
coughing, extrapulmonary tuberculosis is thought to result from
hematogenous spread (spread by way of the bloodstream) from
an initial lung infection and is not infectious. Extrapulmonary
tuberculosis can occur alone or together with pulmonary
tuberculosis.
The various forms of extrapulmonary tuberculosis cause signs and
symptoms related to the structures aLected. Table 1 describes
the forms of extrapulmonary tuberculosis included in this review,
as well as the respective specimens that may be collected for
diagnosis.
Diagnosis of extrapulmonary tuberculosis is challenging for several
reasons. Many forms of extrapulmonary tuberculosis require
invasive diagnostic sampling; gathering adequate specimens
can pose risk of harm to the patient and can be costly.
Most forms of extrapulmonary tuberculosis are paucibacillary
(tuberculosis disease caused by a small number of bacteria),
making diagnosis by various tests less sensitive. Culture, for
example, has reduced sensitivity in paucibacillary disease. In
addition, culture takes several weeks for results and requires
a highly-equipped laboratory. Limitations are also associated
with histology, which relies on highly-trained operators, and
characteristic morphology is shared with other diseases. As a result
of these diLiculties, diagnosis of extrapulmonary tuberculosis
is oNen made on the grounds of clinical suspicion alone,
and many people receive the wrong diagnosis, leading to
unnecessary tuberculosis treatment or poor outcomes from
untreated extrapulmonary tuberculosis.
Tuberculosis treatment regimens must contain multiple drugs
to which the organisms are sensitive to cure tuberculosis
and avoid selection for drug resistance. WHO tuberculosis
treatment guidelines recommend the same drug regimens for
extrapulmonary and pulmonary disease, with notable mention of
tuberculous meningitis and bone or joint tuberculosis, for which
longer treatment regimens are recommended (WHO 2010; WHO
2017; WHO Compendium 2018). For patients with tuberculous
meningitis or tuberculous pericarditis, the use of adjuvant
corticosteroid therapy is recommended in addition to appropriate
tuberculosis treatment regimens (WHO 2017; WHO Compendium
2018). Other tuberculosis treatment guidelines include Sharma
2017b (India), and those issued by the American Thoracic Society,
the Centers for Disease Control and Prevention (CDC), and the
Infectious Diseases Society of America (Nahid 2016). The drugs used
to treat MDR-TB are less potent and more toxic than the drugs
used to treat drug-susceptible tuberculosis, historically requiring
two years or more of therapy. However, in December 2019, based on
new evidence on the management of drug-resistant tuberculosis,
the WHO issued recommendations that all patients with MDR-TB
or rifampicin-resistant tuberculosis, including those who are also
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resistant to fluoroquinolones, may benefit from eLective all-oral
treatment regimens, either shorter or longer (WHO Consolidated
Guidelines (Module 4) 2020).
Rifampicin resistance
Rifampicin inhibits bacterial DNA-dependent RNA polymerase,
encoded by the RNA polymerase gene (rpoB) (Hartmann 1967).
Resistance to this drug has been associated mainly with mutations
in a limited region of the rpoB gene (Telenti 1993). Rifampicin
resistance may occur alone or in association with resistance to
isoniazid and other drugs. In settings with a high burden of MDR-TB,
the presence of rifampicin resistance alone may serve as a proxy for
MDR-TB (WHO 2011). People with drug-resistant tuberculosis can
transmit the infection to others.
Index test(s)
The index tests, Xpert MTB/RIF and Ultra Xpert MTB/RIF (Xpert
Ultra, the newest version) (Cepheid Inc, Sunnyvale, USA), are
nucleic acid amplification tests (NAATs) (i.e. molecular tests) used
for diagnosing tuberculosis and rifampicin-resistant tuberculosis.
Xpert MTB/RIF and Xpert Ultra cartridges are used with the
GeneXpert system (Cepheid 2018; Cepheid 2019). Xpert MTB/RIF
and Xpert Ultra are able to detect both M tuberculosis complex
and rifampicin resistance within two hours aNer starting the
test, with minimal hands-on technical time. Unlike conventional
NAATs, with Xpert MTB/RIF and Xpert Ultra, sample processing
and polymerase chain reaction (PCR) amplification and detection
are integrated into a single, self-enclosed test unit, the GeneXpert
cartridge. Following sample loading, all steps in the assay are
completely automated and self-contained. In addition, the assays'
sample reagent, used to liquefy sputum, has potent tuberculocidal
(the ability to kill tuberculosis bacteria) properties and so largely
eliminates biosafety concerns during the test procedure (Banada
2010). Except as described below for Ultra trace call results, a single
Xpert MTB/RIF or Xpert Ultra run will provide both detection of
tuberculosis and detection of rifampicin resistance. One cannot
deselect testing for rifampicin resistance and only run the assay for
tuberculosis detection.
The development of Xpert MTB/RIF was a major step toward
improving detection of tuberculosis and rifampicin resistance
globally (Boehme 2010; Small 2011). Since Xpert MTB/RIF was
released, there have been four generations (G1, G2, G3, and G4) of
the test involving diLerent soNware and cartridge combinations.
Although in comparison with smear microscopy Xpert MTB/RIF
has increased sensitivity for pulmonary tuberculosis (Steingart
2014), the test has suboptimal sensitivity in people with smear-
negative and HIV-associated tuberculosis. A Cochrane Review
on the diagnostic accuracy of Xpert MTB/RIF for pulmonary
tuberculosis found pooled sensitivity and specificity (95% credible
Interval (CrI)) of 85% (82% to 88%) and 98% (97% to 98%), (70
studies, 37,237 unselected participants; high-certainty evidence)
(Horne 2019). However, Xpert MTB/RIF sensitivity was decreased
in people with smear-negative culture-positive disease, pooled
sensitivity of 67% (62% to 72%), and people living with HIV, pooled
sensitivity of 81% (75% to 86%) (Horne 2019). Xpert MTB/RIF
versions have also had some limitations in detecting rifampicin
resistance.
In order to overcome limitations with Xpert MTB/RIF, Cepheid
developed Xpert Ultra, a re-engineered assay that uses a newly-
developed cartridge but may be run on the same device aNer a
soNware upgrade. To improve sensitivity for tuberculosis detection,
Xpert Ultra incorporates two diLerent multi-copy amplification
targets and a larger DNA reaction chamber than Xpert MTB/RIF
(WHO Xpert Ultra 2017). A laboratory study reported that the limit
of detection (the lowest number of colony-forming units (CFUs)
per sample that can be reproducibly distinguished from negative
samples with 95% confidence) using Xpert Ultra improved to 15.6
CFU/mL of sputum compared to 112.6 CFU/mL for Xpert MTB/RIF
(Chakravorty 2017). Xpert Ultra has added a new result category,
‘trace call', that corresponds to the lowest bacillary load for M
tuberculosis detection (WHO Xpert Ultra 2017). This new category
is reported as 'MTB trace DETECTED'. Interpreting a trace call
result requires a reassessment of clinical symptoms and history
of prior tuberculosis. No rifampicin resistance results are available
(indeterminate) for people with trace results. As with Xpert MTB/RIF
(Miotto 2012), Xpert Ultra detects both live and dead bacteria.
To address limitations in rifampicin resistance detection, Xpert
Ultra uses melting temperature-based analysis, in lieu of real-
time PCR analysis with Xpert MTB/RIF. Melting temperature-
based analysis allows Xpert Ultra to better distinguish resistance-
conferring mutations from silent mutations with improved
diagnostic accuracy for rifampicin resistance detection (Global
Laboratory Initiative 2017).
For sputum specimens, the test procedure may be used either
directly on raw sputum specimens or sputum pellets created
aNer decontaminating and concentrating the sputum (Blakemore
2010). In both cases, the test material is combined with the
assay sample reagent (sodium hydroxide and isopropanol), mixed
by hand or vortex, and incubated at room temperature for 15
minutes. ANer the incubation step, 2 mL of the treated specimen
are transferred to the cartridge and the run is initiated (Helb 2010).
According to the manufacturer, as with Xpert MTB/RIF, Xpert Ultra
may be used with fresh sputum specimens, which may be either
unprocessed sputum or processed sputum sediments. The sample
reagent:sample volume ratio is 2:1 for unprocessed sputum and
3:1 for sputum pellets. The manufacturer does not specifically
mention the use of the index tests with frozen specimens (Cepheid
2018; Cepheid 2019). As with Xpert MTB/RIF, Xpert Ultra using the
GeneXpert sytem requires an uninterrupted and stable electrical
power supply, temperature control, and yearly calibration of the
cartridge modules (Global Laboratory Initiative 2019). Like previous
Xpert cartridge generations, Xpert Ultra can be performed by
operators with minimal technical expertise (Theron 2014a). The
time to run the assay is shorter for Xpert Ultra (around 65 to 87
minutes) than for Xpert MTB/RIF (112 minutes) (Global Laboratory
Initiative 2017). Currently, the manufacturer, Cepheid Incorporated
(Sunnyvale, CA, USA), has made no claim for the use of Xpert
Ultra and Xpert MTB/RIF in non-sputum specimens (Cepheid 2019).
However, there is a standard operating procedure provided by WHO
for processing non-sputum specimens (WHO 2014).
Clinical pathway
Xpert Ultra and Xpert MTB/RIF are used for the diagnosis of
extrapulmonary tuberculosis and rifampicin resistance. Figure 1
shows the clinical pathway and presents the context in which
Xpert Ultra or Xpert MTB/RIF might be used (WHO Operational
Handbook Diagnosis (Module 3) 2020). The target conditions
were extrapulmonary tuberculosis, which includes several forms
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(e.g. tuberculous meningitis, pleural tuberculosis) and rifampicin
resistance.
 
Figure 1.   The clinical pathway describes how patients might present and the point in the pathway at which
they would be considered for testing with Xpert Ultra or Xpert MTB/RIF. This algorithm for the use of a molecular
WHO-recommended rapid diagnostic (WRD), which includes Xpert Ultra and Xpert MTB/ RIF, comes from the WHO
operational handbook on tuberculosis (WHO Operational Handbook Diagnosis (Module 3) 2020). Copyright © [2020]
[World Health Organization]: reproduced with permission. Abbreviations: DST: drug susceptibility testing; INH:
isoniazid; MDR-TB: multidrug-resistant TB; MTB: Mycobacterium tuberculosis; PLHIV: people living with HIV; RIF:
rifampicin; TB: tuberculosis; WRD: WHO-recommended rapid diagnostic, which includes Xpert Ultra and Xpert MTB/
RIF.
 
Before a specimen is tested, patients with presumptive
extrapulmonary tuberculosis would have undergone a health
examination (history and physical examination) and possibly a
chest radiograph. The presentation of extrapulmonary tuberculosis
varies depending on the body site aLected, and it may imitate
other diseases, such as cancer and bacterial and fungal infections.
Signs and symptoms of extrapulmonary tuberculosis are oNen
non-specific and may include fever, night sweats, fatigue, loss of
appetite, and weight loss (as seen in pulmonary tuberculosis) or
specific complaints related to the involved site (e.g. headache for
tuberculous meningitis, back pain for tuberculosis of the spine).
The clinical presentation of extrapulmonary disease may be acute
but is more oNen subacute (falling between acute and chronic) or
chronic, meaning that patients may have symptoms for days to
months before they seek care.
We have described in Table 1 signs and symptoms of the
forms of extrapulmonary tuberculosis included in this review.
The clinician should take a careful history, noting history of
tuberculosis exposure, prior tuberculosis disease, and medical
conditions that increase the risk for tuberculosis disease (e.g.
HIV, diabetes mellitus, low body weight). In comparison with
HIV-negative people, HIV-positive people have higher rates of
extrapulmonary tuberculosis or mycobacteraemia (tuberculosis
bloodstream infection). HIV-positive patients with signs or
symptoms of extrapulmonary tuberculosis should have specimens
taken from the suspected site(s) of involvement to increase the
likelihood of tuberculosis diagnosis. Tuberculous meningitis is
the most severe form of tuberculosis. In tuberculous meningitis,
diagnosis is oNen delayed, with appalling consequences for
patients. For all forms of extrapulmonary tuberculosis, patients
may be evaluated in primary- or secondary-care settings. However,
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if more complex or invasive tests are needed, patients may be
referred to a tertiary medical centre (Iseman 2000; Reuter 2009;
Sharma 2004).
The downstream consequences of testing include the following.
• True-positive (TP): patients would benefit from rapid diagnosis
and appropriate treatment.
• True-negative (TN): patients would be spared unnecessary
treatment and would benefit from reassurance and pursuit of an
alternative diagnosis.
• False-positive (FP): patients would likely experience anxiety and
morbidity caused by additional testing, unnecessary treatment,
and possible adverse eLects; possible stigma associated with a
tuberculosis or MDR-TB diagnosis; and the chance that a false-
positive may halt further diagnostic evaluation.
• False-negative (FN): increased risk of morbidity and mortality
and delayed treatment initiation for patients.
Role of index test(s)
We were interested in the following roles for testing.
I. Xpert Ultra and Xpert MTB/RIF for detection of
extrapulmonary tuberculosis
Index test used as an initial test replacing usual practice
(including conventional microscopy, culture or histopathology)
for the diagnosis of extrapulmonary tuberculosis in adults with
presumptive extrapulmonary tuberculosis (WHO Consolidated
Guidelines (Module 3) 2020). An initial test does not mean that other
tests will follow.
II. Xpert Ultra and Xpert MTB/RIF for detection of rifampicin
resistance
Index test used as an initial test replacing culture and phenotypic
DST for the diagnosis of rifampicin-resistant tuberculosis in
adults with presumptive extrapulmonary tuberculosis (WHO
Consolidated Guidelines (Module 3) 2020).
As mentioned, in high MDR-TB settings the presence of rifampicin
resistance alone may serve as a proxy for MDR-TB. Xpert Ultra and
Xpert MTB/RIF do not eliminate the need for subsequent culture
and phenotypic DST, which are required to monitor treatment
progress and to detect resistance to drugs other than rifampicin.
Alternative test(s)
For a comprehensive review of new tests not yet in widespread use,
we refer the reader to Branigan 2019; Lewinsohn 2017; Unitaid 2017.
Smear microscopy (light microscopy (Ziehl-Neelsen), fluorescence
microscopy, or light-emitting diode (LED) fluorescence microscopy)
is the examination of smears for acid-fast bacilli (tuberculosis
bacteria) under a microscope. Around 5000 to 10,000 organisms
per mL must be present in the specimen for tuberculosis bacteria
to be visible by microscopy (American Thoracic Society 2000). For
extrapulmonary tuberculosis, microscopy can be performed in fluid
or tissue specimens from sites of disease involvement, for example,
in cerebrospinal fluid (CSF) in presumptive tuberculous meningitis
or in lymph node tissue in presumptive lymph node tuberculosis.
For most extrapulmonary sites, because there are usually few
organisms, the sensitivity of smear microscopy is generally low.
Ranges from studies, some with selected cases, are quoted here: 0%
to 10% in pleural fluid; 14% to 39% in pleural tissue; 2% to 30% in
CSF; < 5% in peritoneal fluid; and 0% to 42% in pericardial fluid. In
contrast, the specificity of smear microscopy tends to be quite high,
as can be seen in pulmonary tuberculosis (≥ 90%) (Kilpatrick 1986;
Lewinsohn 2017).
Mycobacterial culture is a method used to grow bacteria on
nutrient-rich media. In comparison with microscopy, a positive
culture requires only around 100 organisms per mL and therefore
can detect lower numbers of tuberculosis bacteria (American
Thoracic Society 2000). Additionally, culture is essential for species
identification and DST. However, culture takes several weeks
and requires a highly-equipped laboratory. Culture has reduced
sensitivity in paucibacillary disease (reference standards have
included culture from a diLerent specimen, such as sputum, smear
microscopy, NAATs, presence of granulomatous inflammation,
clinical criteria, imaging studies, and response to anti-tuberculosis
therapy, done alone or in various combinations): CSF 45% to 70%;
pleural fluid 23% to 58%; urine 80% to 90%; peritoneal tuberculosis
45% to 69%; pericardial tuberculosis 50% to 65% (Lewinsohn
2017); lymph node tuberculosis (excisional biopsy) 18% to 93%;
and lymph node tuberculosis (fine-needle aspirate) 10% to 67%
(Fontanilla 2011).
Histological examination involves examination of tissue specimens
under a microscope. Diagnosis of extrapulmonary tuberculosis
by histological examination is based on finding acid-fast
bacilli and granulomatous inflammation, frequently with caseous
(cheese-like) necrosis (necrotizing granulomas). The sensitivity
of histology has been reported to vary for diLerent forms of
extrapulmonary tuberculosis (reference standards have included
smear microscopy, culture, NAATs, clinical criteria, and imaging
studies, done alone or in various combinations): 59% to 88% for
lymph node tuberculosis (excisional biopsy) (Fontanilla 2011); 69%
to 97% in pleural tissue (closed pleural biopsy); 86% to 94% in
urological tissue; 60% to 70% in endometrial curettage; 79% to
100% in peritoneal biopsy; and 73% to 100% in pericardial tissue
(Lewinsohn 2017). Sensitivity has also been observed to vary for
diLerent diagnostic techniques. Diacon 2003 found thoracoscopy
to be more sensitive (sensitivity of 100%) than closed-needle
biopsy (sensitivity of 66%) for establishing a diagnosis of pleural
tuberculosis (reference standards have included microscopy
smear, culture, or presence of granulomatous inflammation with
caseous necrosis). Specificity has been observed to be low because
of the presence of granulomas in other diseases, both infectious
and non-infectious (Lewinsohn 2017), although the presence of
‘necrotizing' granulomatous inflammation increases specificity
(Woodard 1982). Histological examination carries the additional
concern that invasive procedures that are complex and costly may
be required to obtain the necessary specimens (Golden 2005).
Cytopathological examination of fluid specimens (such as pleural
and peritoneal fluid) may be performed, first to exclude cancer,
and then to obtain material for additional analyses, such
as measurement of levels of adenosine deaminase and free
interferon-gamma (IFN-γ) and cell counts (Lewinsohn 2017; Wright
2009a). Advantages of these tests include that they are rapid and
simple and can be performed in most clinical laboratories (Dinnes
2007). In pleural, pericardial, and peritoneal fluid, a predominance
of lymphocytes, especially in the absence of mesothelial cells, is
highly suggestive of tuberculosis (Wright 2009a). However, in HIV-
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positive people, this pattern may not be observed (Wright 2009a).
Adenosine deaminase, an enzyme involved in purine metabolism,
has been extensively studied for its potential role in the diagnosis
of pleural tuberculosis, peritoneal tuberculosis, and tuberculous
meningitis (Lewinsohn 2017). IFN-γ is released aNer it is sensitized
by T cells in response to specific M tuberculosis antigens. A
recent review of the evidence using GRADE provides the following
recommendations.
• "...cell counts and chemistries be performed on amenable fluid
specimens (including include pleural, cerebrospinal, ascitic, and
joint fluid) collected from sites of suspected extrapulmonary TB
(conditional recommendation, very low-quality evidence).
• ...adenosine deaminase levels be measured, rather than not
measured, on fluid collected from patients with suspected
pleural TB, TB meningitis, peritoneal TB, or pericardial TB
(conditional recommendation, low-quality evidence).
• ...free IFN-γ levels be measured, rather than not measured,
on fluid collected from patients with suspected pleural TB
or peritoneal TB (conditional recommendation, low-quality
evidence)" (Lewinsohn 2017).
NAAT is a molecular technique that can detect small quantities
of genetic material (DNA or RNA) from micro-organisms, such as
M tuberculosis. The key advantage of NAATs is that they are rapid
diagnostic tests, potentially providing results in a few hours. This is
a particularly important feature of the test in life-threatening forms
of extrapulmonary tuberculosis, such as tuberculous meningitis. A
variety of molecular amplification methods are available, of which
PCR is the most common. NAATs are available as commercial kits
and in-house tests (based on a protocol developed in a laboratory)
and are used routinely in high-income countries for tuberculosis
detection. In-house PCR is widely used in low-income countries
because these tests are less expensive than commercial kits. An
older editorial summarizing three systematic reviews (140 studies)
of commercial and in-house NAATs (other than Xpert MTB/RIF) for
diLerent forms of extrapulmonary tuberculosis found relatively low
sensitivity and underscored concerns about the cost and feasibility
of this technology in resource-limited areas (Pai 2008). Similarly,
another systematic review found that NAATs have relatively low
sensitivity for extrapulmonary tuberculosis but high specificity (e.g.
for tuberculous meningitis, for pleural TB), indicating that these
tests cannot be used reliably to rule out tuberculosis (Dinnes 2007).
A recent evidence synthesis reported sensitivities of 72% to 88%
in lymph node tissue, 28% to 81% in pleural fluid, 90% in pleural
tissue, and 31% to 56% in CSF. Specificity ranged from 90% to 100%
(Lewinsohn 2017).
Alternative molecular methods for DST include the commercial
line-probe assays, GenoType MTBDRplus assay (MTBDRplus, Hain
LifeScience, Nehren, Germany), and the Nipro NTM+MDRTB
detection kit 2 (Nipro, Tokyo, Japan), which detect the presence
of mutations associated with drug resistance to isoniazid and
rifampicin (Nathavitharana 2017). MTBDRplus is the most widely
studied line-probe assay. Advantages of line-probe assays are
that they can provide a result for detection of tuberculosis and
drug resistance in one to two days. Drawbacks are that line-
probe assays are expensive and need to be used in intermediate
and central laboratories (Unitaid 2017). The WHO recommends
that for persons with a sputum smear-positive specimen or a
cultured tuberculosis isolate, commercial molecular line-probe
assays may be used as the initial test instead of phenotypic
culture-based DST to detect resistance to rifampicin and isoniazid
(conditional recommendation, moderate certainty in the evidence
for the test’s accuracy) (WHO Consolidated Guidelines (Module 3)
2020). Other molecular assays for detection of tuberculosis and
resistance to rifampicin and isoniazid along with instruments are in
development (Walzl 2018).
Alere Determine™ TB LAM Ag (AlereLAM) Alere Inc, (Waltham, USA) is
a commercially-available point-of-care test for tuberculosis disease
(pulmonary and extrapulmonary tuberculosis). The test detects
lipoarabinomannan (LAM), a component of the bacterial cell wall,
which is present in the urine of some people with tuberculosis.
AlereLAM is performed by placing urine on one end of a test
strip, with results appearing as a band on the strip if tuberculosis
is present. The test is simple, requires no special equipment,
and shows results in 25 minutes. This urine test has potential
advantages over sputum-based testing due to ease of sample
collection. The accuracy of urinary LAM detection is improved
among people living with HIV with advanced immunosuppression
(Bjerrum 2019). In two randomized trials, the use of Alere LAM
in HIV-positive adult inpatients was shown to reduce mortality
(Gupta-Wright 2018; Peter 2016). Based on evidence from the
randomized trials and a Cochrane Review (Bjerrum 2019), the
WHO currently recommends that AlereLAM should be used to
assist in the diagnosis of active tuberculosis in HIV-positive
adults, adolescents, and children (WHO Consolidated Guidelines
(Module 3) 2020). The key change from the WHO 2015 guidelines
is broadening the indication for use of LF-LAM among HIV-
positive inpatients with signs and symptoms of active tuberculosis
(pulmonary and extrapulmonary); the test is now recommended
for all such patients, irrespective of their CD4 count. The full
recommendations, which diLer for inpatients and outpatients, are
described here (WHO Consolidated Guidelines (Module 3) 2020).
Fujifilm SILVAMP TB LAM (FuijiLAM, co-developed by Foundation
for Innovative New Diagnostics (FIND), Geneva, Switzerland and
Fujifilm, Tokyo, Japan) is a new, urine-based, point-of-care test for
tuberculosis diagnosis in people living with HIV. In an individual
participant data meta-analysis that included five cohorts of people
living with HIV, FujiLAM was found to have superior sensitivity,
70.7% (95% CI 59.0% to 80.8%), compared to AlereLAM sensitivity
of 42.3% (31.7% to 51.8%), against a microbiological reference
standard; FujiLAM had lower specificity, 90.9% (87.2 to 93.7),
compared to AlereLAM specificity of 95.3% (92.2 to 97.7) (Broger
2020). At the time of writing, additional prospective clinical trials of
FuijiLAM are ongoing to generate data for an updated WHO policy
review.
Rationale
Xpert Ultra and Xpert MTB/RIF are rapid tests that may provide
benefits for patients (earlier diagnosis and the opportunity to begin
earlier, appropriate treatment), especially in high tuberculosis-
burden countries.
Since 2010, the WHO has recommended the use of Xpert MTB/RIF
as the preferred initial diagnostic test for people thought to have
MDR-TB or HIV-associated tuberculosis (strong recommendation,
moderate-certainty evidence) (WHO Xpert MTB/RIF Policy 2011).
In 2013, the WHO expanded the recommendations, stating that
Xpert MTB/RIF may be used rather than conventional microscopy
and culture as the initial diagnostic test in all adults suspected of
having tuberculosis (conditional recommendation acknowledging
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resource implications, high-quality evidence) (WHO Xpert MTB/
RIF Policy Update 2013). The 2013 recommendations extended
to the diagnosis of several forms of extrapulmonary tuberculosis,
including tuberculous meningitis and lymph nodes and other
tissue. In addition, the WHO recommended that following an Xpert
MTB/RIF test that demonstrates rifampicin resistance, subsequent
DST (e.g. using a line-probe assay to second-line drugs) remains
essential to detect resistance to drugs other than rifampicin (WHO
Xpert MTB/RIF Policy Update 2013). In 2017, based on a non-
inferiority analysis of Xpert Ultra compared with Xpert MTB/RIF
(Dorman 2018), the WHO stated that recommendations on the use
of Xpert MTB/RIF also apply to the use of Xpert Ultra as the initial
diagnostic test for all adults and children with signs and symptoms
of tuberculosis (WHO Xpert Ultra 2017).
In December 2019, the WHO convened a Guideline Development
Group to update the recommendations on the use of molecular
assays intended as initial tests for the diagnosis of pulmonary
and extrapulmonary tuberculosis and rifampicin resistance. To
extend the work of our previous Cochane Review (Kohli 2018),
we performed this review update to inform the WHO policy (WHO
Consolidated Guidelines (Module 3) 2020).
The Background and Methods sections of this review include some
text that overlaps with some of our other reviews for Xpert MTB/RIF
Ultra and Xpert MTB/RIF for diagnosing tuberculosis (Horne 2019;
Kay 2020; Shapiro 2020; Vonasek 2020).
O B J E C T I V E S
To estimate the diagnostic accuracy of Xpert Ultra and Xpert MTB/
RIF for a) extrapulmonary tuberculosis by site of disease and b)
rifampicin resistance, in adults with presumptive extrapulmonary
tuberculosis. Presumptive tuberculosis refers to a patient who
presents with symptoms or signs suggestive of tuberculosis.
Secondary objectives
• To compare the diagnostic accuracy of Xpert Ultra and Xpert
MTB/RIF for a) extrapulmonary tuberculosis by site of disease,
and b) rifampicin resistance.
• To investigate the eLects of potential sources of heterogeneity
on test accuracy across the included studies.
For potential sources of heterogeneity, for extrapulmonary
tuberculosis, we included smear status, HIV status, and prevalence
of extrapulmonary tuberculosis. For cerebrospinal fluid (CSF), we
considered the presence of a concentration step and specimen
volume.
For rifampicin resistance, we planned to assess the impact of the
prevalence of rifampicin resistance on accuracy estimates, but we
had insuLicient data for this analysis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included cross-sectional and cohort studies. In addition, we had
planned to include randomized controlled trials that evaluated the
use of the index(s) test on patient health outcomes, but that also
reported sensitivity and specificity. Although the study design was
a randomized trial for the purpose of determining the impact of
the test on participant outcomes, the study design was a cross-
sectional study for the purpose of determining the diagnostic
accuracy of the index tests in this review. However, we did not
identify any randomized controlled trials. We used abstracts to
identify published studies and included these when they met the
inclusion criteria. We only included studies that reported data
comparing the index test(s) to an acceptable reference standard
from which we could extract true-positive (TP), true-negative (TN),
false-positive (FP), and false-negative (FN) values. We excluded
case-control studies and case reports.
Participants
We included studies where at least 85% of the participants
enrolled were adults aged 15 years or older with presumptive
extrapulmonary tuberculosis from all settings and countries.
Restricting the age group to adults diLers from the original review,
where we also included children (Kohli 2018). We did this because
children are now included in a separate Cochrane Review (Kay
2020). We excluded studies where we could not disaggregate data
on adults from those in children and studies where we could not tell
the age of the participants enrolled.
We included non-respiratory specimens (such as CSF, pleural fluid,
lymph node aspirate or tissue). We excluded sputum and other
respiratory specimens, such as fluid obtained from bronchial
alveolar lavage and tracheal aspiration. As we anticipated finding
many studies, we set a bar to exclude smaller studies to reduce
unnecessary work. We therefore required studies to provide data
for at least five specimens for a given form of extrapulmonary
tuberculosis included in the review. We excluded studies evaluating
the use of Xpert Ultra and Xpert MTB/RIF to diagnose relapse of
previously-treated extrapulmonary tuberculosis, so as to avoid the
selection bias that may arise by limiting to a group that is already
at elevated risk of extrapulmonary tuberculosis. We attempted to
identify studies that included participants who were not taking
anti-tuberculosis drugs or had taken anti-tuberculosis drugs for
less than seven days.
Index tests
The index tests were Xpert Ultra and Xpert MTB/RIF.
Index test results are automatically generated (i.e. there is a single
threshold), and the user is provided with a printable test result as
follows.
Xpert Ultra
• MTB (M tuberculosis) DETECTED HIGH; RIF (rifampicin)
Resistance DETECTED
• MTB DETECTED MEDIUM; RIF Resistance DETECTED
• MTB DETECTED LOW; RIF Resistance DETECTED
• MTB DETECTED VERY LOW; RIF Resistance DETECTED
• MTB DETECTED HIGH; RIF Resistance NOT DETECTED
• MTB DETECTED MEDIUM; RIF Resistance NOT DETECTED
• MTB DETECTED LOW; RIF Resistance NOT DETECTED
• MTB DETECTED VERY LOW; RIF Resistance NOT DETECTED
• MTB DETECTED HIGH; RIF Resistance INDETERMINATE
• MTB DETECTED MEDIUM; RIF Resistance INDETERMINATE
• MTB DETECTED LOW; RIF Resistance INDETERMINATE
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• MTB DETECTED VERY LOW; RIF Resistance INDETERMINATE
• MTB Trace DETECTED; RIF Resistance INDETERMINATE
• INVALID (the presence or absence of MTB cannot be determined)
• ERROR (the presence or absence of MTB cannot be determined)
• NO RESULT (the presence or absence of MTB cannot be
determined)
Xpert Ultra incorporates a semi-quantitative classification for
results: trace, very low, low, moderate, and high. ‘Trace'
corresponds to the lowest bacterial burden for detection of M
tuberculosis (Chakravorty 2017). We considered a trace result to
mean MTB (M tuberculosis) DETECTED. However, no rifampicin-
resistance result was available for participants with trace results
because the trace sample is always reported as 'INDETERMINATE'
for rifampin resistance (Cepheid 2018).
Xpert MTB/RIF
• MTB (M tuberculosis) DETECTED; Rif (rifampicin) resistance
DETECTED
• MTB DETECTED; Rif resistance NOT DETECTED
• MTB detected; Rif resistance INDETERMINATE
• MTB NOT DETECTED
• INVALID (the presence or absence of MTB cannot be determined)
• ERROR (the presence or absence of MTB cannot be determined)
• NO RESULT (the presence or absence of MTB cannot be
determined)
Target conditions
The target conditions were extrapulmonary tuberculosis and
rifampicin resistance. We included eight common forms of
extrapulmonary tuberculosis and considered subcategories of the
target condition as separate diagnostic classifications (CDC 2018;
Sandgren 2013; Sharma 2004).
• Tuberculous meningitis.
• Pleural tuberculosis.
• Lymph node tuberculosis.
• Genitourinary tuberculosis.




Table 1 lists the forms of extrapulmonary tuberculosis and
specimens used for diagnosis in the review. We excluded
less common forms, such as cutaneous tuberculosis, ocular
tuberculosis, female genital tuberculosis, and tuberculosis of the
breast, ear, and paranasal sinuses (Sharma 2004).
Reference standards
Detection of extrapulmonary tuberculosis
We included two reference standards.
• Solid or liquid mycobacterial culture.
* ‘Tuberculosis' was defined as a positive M tuberculosis
culture
* ‘Not tuberculosis' was defined as a negative M tuberculosis
culture
• Composite reference standard.
* 'Tuberculosis' was defined as a positive M tuberculosis
culture or positive composite reference test.
* ‘Not tuberculosis' was defined as a negative M tuberculosis
culture and a negative composite reference test.
The composite reference standard might be based on the results
of microbiological tests, culture or NAAT other than Xpert Ultra
and Xpert MTB/RIF; imaging studies; histology; and clinical
characteristics, and include at least one component test that is
positive, according to the definition of the primary study authors.
For pleural tuberculosis, we defined the composite reference
standard as the presence of granulomatous inflammation or a
positive culture. We proposed this definition because we found
evidence to support including histopathological examination in
the definition. Around 60% of patients undergoing pleural biopsy
will show granulomatous inflammation (American Thoracic Society
2000). In a prospective cohort study of participants with clinical and
radiological findings consistent with pleural tuberculosis, Conde
2003 found that histological examination of tissue obtained from
pleural biopsy had a higher diagnostic yield (78%; 66/84) than that
of culture (62%; 52/84).
Culture is considered the best reference standard for tuberculosis.
However, culture may lead to misclassification of some cases
of extrapulmonary tuberculosis as ‘not tuberculosis', owing to
the paucibacillary nature of the disease. This means that culture
may have low sensitivity for extrapulmonary tuberculosis overall
and further that culture sensitivity may diLer for diLerent
forms of extrapulmonary tuberculosis (Lewinsohn 2017). This
misclassification by culture may lead to biased estimates
(overestimation or underestimation) of the diagnostic accuracy of
Xpert Ultra and Xpert MTB/RIF. The extent of bias will depend on
the frequency of errors by culture and the degree of correlation in
errors by culture and the Xpert assays because culture and Xpert
Ultra or Xpert MTB/RIF are likely to pick up cases with a higher
bacterial load, and are likely to miss cases with a lower bacterial
load. Ignoring this dependence could lead to an overestimation of
the sensitivity of Xpert Ultra or Xpert MTB/RIF.
• ELect of low sensitivity of culture on Xpert sensitivity: the
low sensitivity of culture means that index test FNs may be
misclassified as TNs when culture is used as the reference
standard. Therefore, when Xpert Ultra or Xpert MTB/RIF is
evaluated against culture, the number of FNs (classified as
negative by the index test and positive by the reference test)
may be decreased and the sensitivity of the index test may be
overestimated.
• ELect of low sensitivity of culture on Xpert specificity: the
low sensitivity of culture means that index test TPs may be
misclassified as FPs when culture is used as the reference
standard. Therefore, when Xpert Ultra or Xpert MTB/RIF is
evaluated against culture, the number of FPs (classified as
positive by the index test and negative by the reference test)
may be increased and specificity of the index test may be
underestimated.
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In contrast to culture, a composite reference standard that
includes culture, other tests, and clinical characteristics may
correctly classify index test results as TPs (instead of as FPs
with respect to culture), especially in people with paucibacillary
disease in whom culture may be negative. However, because of
the uncertainties that surround a clinical diagnosis of tuberculosis
and, in some instances, the conditional dependence of the index
tests and other tests in the composite reference standard (for
example, for most of these tests, detection of tuberculosis depends
on bacillary load), a reference standard that uses additional
tests and clinical characteristics (in culture-negative people)
may incorrectly classify people without tuberculosis as having
tuberculosis (Naaktgeboren 2013). An additional challenge with
including a composite reference standard is that the definition of
the composite reference standard may vary across studies, making
it diLicult to interpret the accuracy estimates.
Thus both reference standards, culture and composite, are
imperfect and may aLect accuracy estimates. In an attempt to
improve the estimation of diagnostic accuracy, we applied a latent
class meta-analysis model to the three most commonly studied
forms of extrapulmonary tuberculosis. This approach provides the
sensitivity and specificity of culture in addition to the accuracy of
the index tests, thus adjusting for imperfect culture accuracy.
Detection of rifampicin resistance
The reference standard was culture-based DST using solid or liquid
media or line-probe assays, as recommended by the WHO (WHO
2012; WHO Consolidated Guidelines (Module 3) 2020).
Search methods for identification of studies
We attempted to identify all relevant studies, regardless of
language or publication status (published, unpublished, in press,
or ongoing). We monitored abstracts to see if these studies were
published during the time we performed the review. We included
only published studies in the review.
Electronic searches
For the original review, we searched the literature on 7 August 2017.
For this review update, we searched the literature on 2 August 2019
and again on 28 January 2020, specifically for studies of Xpert Ultra
(studies could include Xpert Ultra alone or both Xpert Ultra and
Xpert MTB/RIF), using the search terms and strategy described in
Appendix 1. We searched the following databases:
• Cochrane Infectious Diseases Group Specialized Register;
• MEDLINE (OVID, from 1966);
• Embase (OVID, from 1974);
• Science Citation Index - Expanded (from 1900);
• Conference Proceedings Citation Index - Science (CPCI-S, from
1990);
• BIOSIS Previews (from 1926), all three from the Web of Science;
• Scopus (Elsevier, from 1970);
• Latin American Caribbean Health Sciences Literature (LILACS)
(BIREME, from 1982).
We also searched ClinicalTrials.gov, the WHO International
Clinical Trials Registry (ICTRP) Platform (www.who.int/trialsearch),
and the International Standard Randomized Controlled Trials
Number (ISRCTN) registry (www.isrctn.com/) for trials in progress,
and ProQuest Dissertations & Theses A&I (www.proquest.com/
pqdtglobal, from 1990) for dissertations.
To identify other systematic reviews and meta-analyses, we
performed an additional search on 28 May 2020 in MEDLINE
(PubMed), Embase (OVID), and the Cochrane Library, applying
filters for systematic reviews (www.sign.ac.uk/search-filters.html)
to search terms for Xpert and tuberculosis.
Searching other resources
We reviewed reference lists of included articles and any relevant
review articles identified through the above methods. We also
contacted researchers at FIND and other experts in the field
of tuberculosis diagnostics for information on ongoing and
unpublished studies.
Data collection and analysis
Selection of studies
We used Covidence to manage the selection of studies (Covidence
2017). Two review authors independently scrutinized titles and
abstracts identified by electronic literature searching to identify
potentially eligible studies. We selected any citation identified by
either review author as potentially eligible for full-text review. The
same review authors independently assessed full-text papers for
study eligibility using predefined inclusion and exclusion criteria,
and resolved any discrepancies by discussion. We recorded all
studies excluded aNer full-text assessment and their reasons for
exclusion in Characteristics of excluded studies. We illustrated the
study selection process in a PRISMA diagram (Moher 2009).
Data extraction and management
Using a previously-developed form (Appendix 2), two review
authors worked independently to extract data on the following
characteristics.
• Author; publication year; country; setting (outpatient, inpatient,
or both outpatient and inpatient); study design; manner of
participant selection; number of participants enrolled; number
of participants for whom results are available.
• Characteristics of participants: gender; age; HIV status; history of
prior tuberculosis; receipt of anti-tuberculosis treatment.
• Index test.
• Target condition and subcategories.
• Type of reference standard.
• Quality Assessment of Studies of Diagnostic Accuracy - Revised
(QUADAS-2) items.
• Details of specimen: type (such as CSF, pleural fluid, or lymph
node aspirate or tissue); condition (fresh or frozen); smear-
positive or smear-negative.
• Specimen preparation; homogenization step (for tissue
specimens); concentration step and specimen volume (for CSF);
adherence to WHO standard operating procedures.
• Number of TP, FP, FN, TN (i.e. true-positives, false-positives,
false-negatives, and true-negatives), and trace results; number
of inconclusive results for detection of extrapulmonary
tuberculosis; number of indeterminate results for detection of
rifampicin resistance.
• Number of missing or unavailable test results.
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We classified country income status as either low- and middle-
income or high-income, according to the World Bank List of
Economies (World Bank 2020).
We extracted TP, FP, FN, and TN values for the following specimens:
CSF, pleural fluid and tissue, lymph node aspirate and tissue
(the latter specimen acquired by surgical biopsy), bone or joint
aspirate and tissue, urine, peritoneal fluid and tissue, pericardial
fluid and tissue, and blood. We extracted these values for each of
the specimen types separately. For example, we used one 2 × 2
table for lymph node aspirate, and another 2 × 2 table for lymph
node tissue. In situations in which a participant contributed more
than one specimen but of diLerent types, we extracted data for all
specimens. When a study included data for both raw specimens
and concentrated sediment involving the same participants, we
preferentially extracted data for raw specimens, except in the case
of CSF, for which we extracted data for concentrated sediment as
recommended by the WHO (WHO 2014). We extracted accuracy
data according to the defined reference standards (see Reference
standards). We did not encounter any situations in which a subset
of participants in a study received the reference standard but
others did not. Hence, there was no need to make corrections for
verification bias in the statistical analysis (Begg 1983).
In most studies, the number of specimens was the same as the
number of participants. However, in some studies, the number of
specimens exceeded the number of participants or study authors
reported only the number of specimens. In the previous review
(Kohli 2018), we added post hoc a sensitivity analysis limiting
inclusion to studies that used one specimen per participant. In this
review, we performed a similar sensitivity analysis for Xpert Ultra.
We contacted authors of primary studies for missing data or
clarifications. We entered all data into MicrosoN Excel 2014.
Assessment of methodological quality
We used the QUADAS-2 tool, tailored to this review, to assess
the quality of the included studies (Appendix 3) (Whiting 2011).
QUADAS-2 consists of four domains: patient selection, index
test, reference standard, and flow and timing. We assessed all
domains for risk of bias and the first three domains for concerns
about applicability. Two review authors independently completed
QUADAS-2 and resolved disagreements through discussion. We
present the results of this quality assessment in text, tables, and
graphs.
We followed Cochrane policy, which states that "authors of primary
studies will not extract data from their own study or studies.
Instead, another author will extract these data, and check the
interpretation against the study report and any available study
registration details or protocol".
Statistical analysis and data synthesis
We performed descriptive analyses of the characteristics of
included studies using Stata 15 (Stata 2017), and we present key
study characteristics in the Characteristics of included studies
table. We used data reported in the TP, FP, FN, and TN format to
calculate sensitivity and specificity estimates and 95% confidence
intervals (CIs) for individual studies. We present individual study
results graphically by plotting the estimates of sensitivity and
specificity (and their 95% CIs) in forest plots and receiver operating
characteristic (ROC) space using Review Manager 5 (RevMan 5)
(RevMan 2014).
When data were suLicient, we performed meta-analyses to
estimate pooled sensitivity and specificity and corresponding 95%
credible interval (CrI, defined below) using an adaptation of the
bivariate random-eLects approach of Reitsma 2005, which uses the
exact binomial likelihood for the observed proportions (Chu 2006).
The bivariate random-eLects approach allowed us to calculate
the pooled estimates of sensitivity and specificity while dealing
with potential sources of variation caused by (1) imprecision of
sensitivity and specificity estimates within individual studies; (2)
correlation between sensitivity and specificity across studies; and
(3) variation in sensitivity and specificity between studies. The
model has a hierarchical structure, with the logit sensitivity in
individual studies assumed to come from a common probability
distribution the mean of which is the pooled logit sensitivity, and
the standard deviation is the between-study standard deviation,
and likewise for the specificity. This structure allows for borrowing
strength across studies. In the absence of suLicient studies, we
simply present descriptive statistics. In addition, we determined
predictive values at a pretest probability of 10%, a value suggested
by the WHO.
We performed separate analyses grouped by type of
extrapulmonary specimen (e.g. CSF, pleural fluid, peritoneal fluid)
rather than determine summary accuracy estimates for all forms
of extrapulmonary tuberculosis combined, because we considered
the former approach to be most clinically meaningful. In addition,
we performed separate analyses by reference standard.
Comparison of Xpert Ultra and Xpert MTB/RIF
We performed comparative meta-analyses by restricting the
analyses to only those studies that made direct comparisons
between Xpert Ultra and Xpert MTB/RIF within the same
participants (Takwoingi 2013). We extracted the median and the
95% CrI for the diLerence in the pooled sensitivities and the
diLerence in the pooled specificities, respectively, of Xpert Ultra
versus Xpert MTB/RIF. We also calculated the probability that the
diLerence exceeds zero in each case.
For analysis of Xpert MTB/RIF or Xpert Ultra accuracy for detection
of rifampicin resistance, we include participants who (1) were
culture-positive; (2) had a valid culture-based DST or line-
probe assay (LPA) result; (3) were Xpert MTB/RIF or Xpert Ultra
tuberculosis-positive; and (4) had a valid Xpert MTB/RIF or Xpert
Ultra result for rifampicin resistance, detected or not detected
(susceptible).
• Sensitivity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance
detected/phenotypic DST or LPA rifampicin-resistant.
• Specificity = Xpert MTB/RIF (or Xpert Ultra) rifampicin resistance
not detected/phenotypic DST or LPA rifampicin-susceptible.
For detection of rifampicin resistance, when a study included
multiple types of specimens, we based our determination of Xpert
Ultra and Xpert MTB/RIF and sensitivity and specificity on all
available data in the study, including data for specimens that we did
not include in the primary analyses for detection of extrapulmonary
tuberculosis. For example, if a study provided data for several
specimen types combined (e.g. all tissue specimens) and we could
not disaggregate the data for a specific specimen type, we included
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
all data (for all tissue specimens) in the analysis for rifampicin
resistance detection. We did this because we did not expect the
accuracy of Xpert Ultra or Xpert MTB/RIF for rifampicin resistance to
vary by specimen type. We used the bivariate random-eLects model
to estimate pooled sensitivity and specificity.
We estimated all models using a Bayesian approach with low-
information prior distributions using OpenBUGS soNware (Version
3.2.3) (Lunn 2009), along with R (R Core Team 2019). Under the
Bayesian approach, all unknown parameters must be provided
a prior distribution that defines the range of possible values of
the parameter and the weight of each of those values, based
on information external to the data. To allow observed data
to dominate the final results, we chose to use low-information
prior distributions. We defined prior distributions on the log-
odds scale over the pooled sensitivity and specificity parameters,
their corresponding between-study standard deviations, and the
correlation between the sensitivities and specificities across
studies. For the pooled log odds of the sensitivity or the pooled
log odds of the specificity, we used a normal prior distribution
with mean 0 and a wide variance of 4 (or a precision of 0.25).
This corresponds to a roughly uniform distribution over the pooled
sensitivity and pooled specificity on the probability scale. For the
between-study precision, we used a gamma distribution with a
shape parameter of 2 and a rate parameter of 0.5. This corresponds
to a 95% prior CrI for the between-study standard deviation in
the log odds of sensitivity or the log odds of specificity ranging
from roughly 0.29 to 1.44, corresponding to moderate to high
values of between-study heterogeneity. Covariance terms followed
a uniform prior distribution whose upper and lower limits were
determined by the sensitivity of the two tests. The OpenBUGS
model used appears in Appendix 4. It is known that meta-analysis
models can be sensitive to the choice of prior distributions
over between-study standard deviation parameters. We therefore
carried out sensitivity analyses and considered alternative prior
distributions that are less informative, allowing a wider range
of possible values. To study the sensitivity of all results to the
choice of prior distributions given above, we considered alternative
prior distributions that were less informative, allowing a wider
range of possible values. We increased the variance of the normal
distributions over the pooled log odds of sensitivity or specificity
to 100. We used a uniform prior distribution ranging from 0 to 3
over the between-study standard deviation on the log odds scale
(see programme in Appendix 4). We noted no appreciable change in
pooled accuracy parameters but found that the posterior CrIs and
prediction intervals were slightly wider, as expected.
We combined information from the prior distribution with the
likelihood of the observed data, in accordance with Bayes’
theorem, using the OpenBUGS programme, which provides a
sample from the posterior distribution of each unknown parameter.
We were particularly interested in the pooled sensitivity and
specificity of Xpert and between-study variance in the sensitivity
and specificity of Xpert on the log-odds scale. Using a sample
from the posterior distribution, we calculated various descriptive
statistics of interest. We estimated the median pooled sensitivity
and specificity and their 95% CrI. The median or the 50% quantile
is the value below which 50% of the posterior sample lies. We
report the median because the posterior distributions of some
parameters may be skewed and the median would be considered a
better point estimate of the unknown parameter than the mean in
such cases. The 95% CrI is the Bayesian equivalent of the classical
(frequentist) 95% confidence interval (CI) (we will indicate 95%
CI for individual study estimates and 95% CrI for pooled study
estimates as appropriate). The 95% CrI may be interpreted as an
interval that has a 95% probability of capturing the true value of the
unknown parameter, given observed data and prior information.
We prepared summary receiver operating characteristic (SROC)
curves for each meta-analysis model, using the methods described
in Harbord 2007.
We also determined the predicted sensitivity and specificity of
Xpert MTB RIF and Xpert Ultra and their 95% CrIs. Predicted values
represent our best guess for sensitivity and specificity in a future
study and will be close to the pooled estimates. However, their CrIs
may be diLerent. If there is no heterogeneity at all between studies,
the CrI around the predicted estimate will be the same as the CrI
around the pooled estimate. On the other hand, if considerable
heterogeneity is observed between studies, the CrI around the
predicted estimate will be much wider than the CI around the
pooled estimate.
In addition, we performed latent class analysis for three forms
of extrapulmonary tuberculosis: tuberculous meningitis, pleural
tuberculosis, and lymph node tuberculosis, using data from the
two-by-two tables comparing the index test to culture as a
reference standard. Latent class analysis is a statistical modelling
technique that allows estimation of test accuracy in the absence
of an adequate reference standard to define the presence or
absence of disease (Van Smeden 2014). The latent class meta-
analysis model expands the traditional meta-analysis model in two
ways: (1) we added parameters for the sensitivity and specificity
of culture; and (2) we added covariance terms to adjust for the
dependence between the index test and culture among disease-
positive and disease-negative participants in each study. We
used hierarchical prior distributions over the logit sensitivity and
logit specificity of culture. In other words, we assumed that the
logit sensitivities in the individual studies come from a common
probability distribution whose mean is the pooled mean logit
sensitivity of culture and whose standard deviation is the between-
study standard deviation. Likewise for the specificities. We used
the same low-information prior distributions over the pooled logit
mean and between-study standard deviation parameters as we
had for the corresponding parameters for the index test. We used
uniform prior distributions for covariance terms over their ranges,
which are determined by the sensitivities and the specificities of the
two tests in each study (see Appendix 4 for the OpenBUGS model).
We found that we did not need to augment observed data with
prior information from other sources for most models. However, in
a post hoc analysis Xpert MTB/RIF in lymph node aspirate in which
we suspected a systematic bias in the performance of culture, we
used informative prior distributions over the specificity of culture
(ranging from 99% to 100%) and the specificity of Xpert MTB/RIF
(ranging from 98% to 100%) (see Appendix 4). We added the SROC
plots of the latent class meta-analyses to the SROC plots resulting
from the models in which culture was treated as a perfect test, so
they could be compared.
Based on work evaluating Xpert MTB/RIF for childhood tuberculosis
(Schumacher 2016), we anticipated that latent class meta-analyses
would lead to a decrease in the estimated pooled sensitivity of
Xpert Ultra and Xpert MTB/RIF and an increase in the estimated
pooled specificity of Xpert Ultra and Xpert MTB/RIF compared with
the primary analyses. In other words, this method should help to
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correct the biases in Xpert Ultra and Xpert MTB/RIF sensitivity and
specificity resulting from treating culture as a perfect reference
standard, which we detailed earlier in the section on the reference
standard.
Approach to inconclusive index test results
The proportion of inconclusive (non-determinate) rate for
detection of pulmonary tuberculosis is the number of tests
classified as ‘invalid', ‘error', or ‘no result' divided by the total
number of index tests performed. The proportion of inconclusive
(indeterminate) rate for detection of rifampicin resistance is the
number of tests classified as ‘MTB DETECTED; Rif (rifampicin)
resistance INDETERMINATE' divided by the total number of index
test-positive results. For Xpert Ultra, we determined the proportion
of inconclusive index test results = number of inconclusive test
results divided by the total number of tests. In our previous review,
we used a Bayesian hierarchical model for a single proportion to
estimate the pooled proportion of inconclusive MTB/RIF test results
(Kohli 2018). We reported these findings again in this review update.
As we found very few inconclusive results reported, we excluded
these results from the quantitative analysis.
Investigations of heterogeneity
Initially, we investigated heterogeneity through visual examination
of forest plots of sensitivities and specificities and through visual
examination of the ROC space of the raw data. When data allowed,
we evaluated potential sources of heterogeneity using subgroup
analyses and bivariate meta-regression. We included the following
covariates.
• HIV status.
• For tuberculous meningitis, concentration step used for
preparing specimen (yes or no).
• CSF specimen volume used for Xpert MTB/RIF or Xpert Ultra
testing.
We had planned to investigate smear status, history of tuberculosis,
and whether WHO standard procedures for preparing tissue
specimens were followed. However, we had insuLicient data to do
this.
The impact of the prevalence of extrapulmonary tuberculosis on
sensitivity and specificity is an important consideration. In a post
hoc meta-regression analysis, for Xpert MTB/RIF we explored this
question for CSF, pleural fluid, and lymph node aspirate. For Xpert
Ultra we explored this question for CSF. We did not conduct other
analyses, owing to an insuLicient number of studies. For detection
of rifampicin resistance, owing to a small number of studies, we
could not assess the impact of prevalence of rifampicin resistance
on accuracy estimates.
Nontuberculous mycobacteria
Nontuberculous mycobacteria (NTM), such as M avium complex
and M intracellulare, constitute a multi-species group of human
pathogens that are ubiquitous in water and soil. NTM can
cause severe diseases that share clinical signs with tuberculosis
but are treated diLerently. People living with HIV with severe
immunosuppression are particularly vulnerable to infections
caused by NTM (Gopinath 2010). Previous studies have shown
that Xpert does not cross-react with other mycobacterial
species (Blakemore 2010; Helb 2010). In our original review,
we summarized data for NTM separately by determining the
percentage of false-positive Xpert MTB/RIF results in specimens
that grew NTMs (Kohli 2018). In this updated review, we therefore
summarize data for NTM only for Xpert Ultra.
Sensitivity analyses
For Xpert Ultra testing in CSF, we performed sensitivity analyses
to explore whether the overall findings were robust to potentially
influential decisions. We did this by limiting inclusion in the meta-
analysis to the following.
• Studies that used consecutive or random selection of
participants.
• Studies in which the reference standard results were interpreted
without knowledge of the index test results.
• Studies that included only one specimen per participant.
For Xpert Ultra, in CSF, we also planned to perform a sensitivity
analysis by limiting studies to those that included only untreated
participants. However, we were unable to confirm that studies
met this criterion. We planned similar sensitivity analyses for
pleural fluid and lymph node aspirate, but these analyses were
not carried out owing to an insuLicient number of studies. For all
other specimen types, we had an insuLicient number of studies for
sensitivity analyses.
For Xpert MTB/RIF, in the original review we performed sensitivity
analyses by type of extrapulmonary specimen and found that for
most analyses, the sensitivity analyses made little diLerence to any
of these findings (Kohli 2018). However, for Xpert MTB/RIF in CSF,
in comparison with all studies, (sensitivity of 71.1% (60.9 to 80.4),
and specificity of 98.0% (97.0 to 98.8)), studies that evaluated only
one specimen per participant had lower pooled sensitivity at 63.5%
(47.6 to 76.3) and lower pooled specificity at 96.1% (94.2 to 97.4).
Assessment of reporting bias
We did not perform a formal assessment of publication bias using
methods such as funnel plots or regression tests because such
techniques have not been helpful for diagnostic test accuracy
studies (Macaskill 2010).
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of evidence using the GRADE approach
for diagnostic studies (Balshem 2011; GRADEpro GDT 2015;
Schünemann 2008; Schünemann 2016). As recommended, we
rated the certainty of evidence as either high (not downgraded),
moderate (downgraded by one level), low (downgraded by two
levels), or very low (downgraded by more than two levels) based on
five domains: risk of bias, indirectness, inconsistency, imprecision,
and publication bias. For each outcome, the certainty of evidence
started as high when there high-quality studies (cross-sectional
or cohort studies) that enrolled participants with diagnostic
uncertainty. If we found a reason for downgrading, we used our
judgement to classify the reason as either serious (downgraded by
one level) or very serious (downgraded by two levels).Two review
authors discussed judgments and applied GRADE in the following
way (Schünemann 2020a; Schünemann 2020b).
• Assessment of risk of bias. We used QUADAS-2 to assess risk of
bias.
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• Indirectness. We assessed indirectness in relation to the
population (including disease spectrum), setting, interventions,
and outcomes (accuracy measures). We also used prevalence as
a guide to whether there was indirectness in the population.
• Inconsistency. GRADE recommends downgrading for
unexplained inconsistency in sensitivity and specificity
estimates. We carried out prespecified analyses to investigate
potential sources of heterogeneity and downgraded when we
could not explain inconsistency in the accuracy estimates.
• Imprecision. We considered a precise estimate to be one that
would allow a clinically meaningful decision. We considered
the width of the CrI (or CI) and asked, “Would we make a
diLerent decision if the lower or upper boundary of the CrI
(or CI) represented the truth?” In addition, we worked out
projected ranges for TP, FN, TN, and FP for a given prevalence of
tuberculosis and made judgements on imprecision from these
calculations.
• Publication bias. We rated publication bias as undetected
(not serious) for several reasons: the comprehensiveness of
the literature search and extensive outreach to tuberculosis
researchers to identify studies; the presence only of studies
that produced precise estimates of high accuracy despite small
sample size; and our knowledge about studies that were
conducted but not published.
For the 'Summary of findings' tables for CSF and pleural fluid, we
provide evidence using culture as the reference standard, which is
considered the best reference standard for tuberculosis (Lewinsohn
2017). For lymph node aspirate, we provide evidence using a
composite reference because, based on findings from the original
review (Kohli 2018), we believe a composite reference standard is
preferable for estimating accuracy.
R E S U L T S
Results of the search
We identified and screened a total of 735 records for inclusion
in this review update. Of these, we assessed 142 full-text papers
against our inclusion criteria. We excluded 120 papers, mainly for
the following reasons: study did not evaluate Xpert Ultra (n = 54);
could not extract 2 x 2 values (n = 14); inappropriate reference
standard (n = 13); could not extract data by specimen type (n = 12);
did not include extrapulmonary specimen (n = 10): duplicate data
(n = 4); case-control study (n = 4); index test other than Xpert MTB/
RIF or Xpert Ultra (n = 3); study included children (n = 2); screening
study (n = 2); case report (n = 1); and fewer than five specimens for a
given specimen type (n = 1). From our previous review, we included
47 studies.
Thus, we included 69 unique studies that met the inclusion criteria
in this review update.
Sixty-seven studies evaluated Xpert MTB/RIF (Ablanedo-Terrazas
2014; Ajbani 2018; Al-Ateah 2012; Azevedo 2018; Bahr 2015; Bahr
2017; Bera 2015; Biadglegne 2014; Blaich 2014; Causse 2011; Che
2017; Chen 2019; Chin 2019; Christopher 2013; Cresswell 2018;
Cresswell 2020; Dhasmana 2014; Dhooria 2016; Donovan 2020; Du
2015; El-Din 2019; Feasey 2013; Friedrich 2011; Ghariani 2015; Gu
2015; Hanif 2011; Heemskerk 2018; Hillemann 2011; Iram 2015;
Kim 2015a; Li 2017; Liang 2019; Ligthelm 2011; Lusiba 2014;
Malbruny 2011; Meldau 2014; Meldau 2019; Metcalf 2018; Nataraj
2016; Nhu 2014; Ozkutuk 2014; Pandie 2014; Patel 2013; Peñata
2016; Rakotoarivelo 2018; Rufai 2015; Rufai 2017a; Rufai 2017b;
Safianowska 2012; Sarfaraz 2018; Scott 2014; Sharma 2014; Sharma
2016; Sharma 2018; Siddiqi 2019; Sun 2019; Suzana 2016; Tadesse
2015; Trajman 2014; Ullah 2017; Vadwai 2011; Van Rie 2013; Wang
2019; Wang 2020; Wu 2019; Zeka 2011; Zmak 2013). Eleven studies
evaluated Xpert Ultra. Of these 11 studies, nine evaluated both
Xpert MTB/RIF and Xpert Ultra (Bahr 2017; Chin 2019; Cresswell
2020; Donovan 2020; Meldau 2019; Sun 2019; Wang 2019; Wang
2020; Wu 2019) and two studies evaluated Xpert Ultra alone (Antel
2020; Perez-Risco 2018). All studies but two (one in Spanish: Peñata
2016, and one in Turkish: Ozkutuk 2014), were written in English.
Figure 2 shows the flow of studies in the review. We recorded the
excluded studies, including those listed in the previous Cochrane
Review (Kohli 2018) and the reasons for their exclusion in the
Characteristics of excluded studies table.
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Figure 2.
 
Methodological quality of included studies
Studies evaluating Xpert MTB/RIF and Xpert Ultra for detection
of extrapulmonary tuberculosis
Figure 3 and Figure 4 show risk of bias and applicability concerns
for each of the 69 studies included for tuberculosis detection. Risk
of bias and applicability concerns are also presented specifically for
studies evaluating Xpert Ultra and Xpert MTB/RIF for tuberculous
meningitis (Appendix 5), pleural tuberculosis (Appendix 6), and
lymph node tuberculosis (Appendix 7).
 
Figure 3.   Risk of bias and applicability concerns graph for tuberculosis detection: review authors' judgements
about each domain presented as percentages across included studies.
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Figure 4.   Risk of bias and applicability concerns summary for tuberculosis detection: review authors' judgements
about each domain for each included study.
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Figure 4.   (Continued)
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Figure 4.   (Continued)
 
In the patient selection domain, we thought that 53 studies (77%)
had low risk of bias, and five studies (7%) had high risk of bias for the
following reasons: one study selected participants by convenience
(Malbruny 2011) and four studies had inappropriate exclusions (Du
2015; Perez-Risco 2018; Siddiqi 2019; Ullah 2017). We thought that
11 studies (16%) had unclear risk of bias for the following reasons:
the manner of patient selection was unclear in ten studies (Azevedo
2018; Gu 2015; Li 2017; Liang 2019; Rufai 2015; Rufai 2017a; Rufai
2017b; Sarfaraz 2018; Wu 2019; Zmak 2013), and it was unclear
whether the study avoided inappropriate exclusions: one study
(Bera 2015). Regarding applicability (patient characteristics and
setting), we thought that 17 studies (25%) had low concern because
participants were evaluated in local hospitals or primary health
settings: three studies (Pandie 2014; Sarfaraz 2018; Trajman 2014),
or in the case of tuberculous meningitis, tertiary centres: 14 studies
(Ajbani 2018; Azevedo 2018; Bahr 2015; Bahr 2017; Chin 2019;
Cresswell 2018; Cresswell 2020; Donovan 2020; Heemskerk 2018;
Metcalf 2018; Nhu 2014; Patel 2013; Rufai 2017b Siddiqi 2019). Three
studies (4%) had high concern because participants were evaluated
exclusively as inpatients at a tertiary care centre (Che 2017; Du
2015; Gu 2015); and 52 (75%) studies had unclear or high concern
because we could not tell the clinical setting or a high percentage of
participants had received prior testing for tuberculosis (Antel 2020).
In the index test domain, we thought that all studies had low
risk of bias because the results of the index tests (Xpert Ultra and
Xpert MTB/RIF) are automatically generated, the user is provided
with printable test results, and the test threshold is prespecified.
Regarding applicability, with respect to Xpert Ultra, we thought
that 9/11 studies (82%) had low risk of bias (Antel 2020; Bahr 2017;
Cresswell 2020; Donovan 2020; Meldau 2019; Perez-Risco 2018; Sun
2019; Wang 2019; Wang 2020) and 2/11 studies (18%) had high
risk of bias because the index test was not performed according
to WHO standard operating procedures (Chin 2019; Wu 2019). With
respect to Xpert MTB/RIF, we thought that 45/67 studies (67%)
had low concern because at least 75% of the specimen types in
these studies were processed according to WHO recommendations;
17/67 studies (25%) had high concern because fewer than 50%
of the specimen types in these studies were processed according
to WHO recommendations (Causse 2011; Che 2017; Chin 2019;
Dhasmana 2014; Feasey 2013; Friedrich 2011; Heemskerk 2018;
Lusiba 2014; Malbruny 2011; Nhu 2014; Rufai 2015; Rufai 2017a;
Rufai 2017b; Suzana 2016; Ullah 2017; Wu 2019; Zeka 2011). We
thought that 5/67 studies (7%) had unclear concern because either
the manner of specimen processing was not reported (four studies:
Ajbani 2018; Azevedo 2018; Bera 2015; Cresswell 2018), or only
50% of the specimen types were processed according to WHO
recommendations (one study: Christopher 2013).
In the reference standard domain, 34 studies (49%) had low risk
of bias because results of the reference standard were interpreted
without knowledge of results of the index test and only non-sterile
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specimens were decontaminated (Ajbani 2018; Antel 2020; Bahr
2015; Bahr 2017; Bera 2015; Che 2017; Chin 2019; Christopher 2013
; Cresswell 2018; Cresswell 2020; Dhooria 2016; Donovan 2020;
Feasey 2013; Heemskerk 2018; Iram 2015; Liang 2019; Ligthelm
2011; Malbruny 2011; Meldau 2014; Meldau 2019; Nhu 2014;
Ozkutuk 2014; Pandie 2014; Patel 2013; Rufai 2017b; Scott 2014;
Sharma 2018; Siddiqi 2019; Suzana 2016; Trajman 2014; Ullah
2017; Van Rie 2013; Wu 2019; Zeka 2011). Five studies (7%) had
high risk of bias because results of the reference standard were
interpreted with knowledge of results of the index test (Blaich
2014; Hanif 2011; Peñata 2016; Safianowska 2012; Zmak 2013).
Thirty studies (43%) had unclear risk of bias for the following
reasons: seven studies did not report whether there was blinding
of the reference standard (Azevedo 2018; El-Din 2019; Lusiba 2014;
Metcalf 2018; Perez-Risco 2018; Wang 2019; Wang 2020); 21 studies
decontaminated specimens generally considered to be sterile (Al-
Ateah 2012; Biadglegne 2014; Causse 2011; Chen 2019; Dhasmana
2014; Du 2015; Friedrich 2011; Ghariani 2015; Gu 2015; Hillemann
2011; Kim 2015a; Li 2017; Nataraj 2016; Rakotoarivelo 2018; Rufai
2015; Rufai 2017a; Sharma 2014; Sharma 2016; Sun 2019; Tadesse
2015; Vadwai 2011); and two studies did not report blinding
and decontaminated specimens generally considered to be sterile
(Ablanedo-Terrazas 2014; Sarfaraz 2018).
Regarding applicability of the reference standard, we thought that
53 studies (77%) had low concern because these studies performed
a test to identify M tuberculosis species (speciation) and 16 studies
(23%) had unclear concern because we could not tell whether
the study performed speciation (Azevedo 2018; Bera 2015; Chin
2019; Christopher 2013; Cresswell 2018; Dhooria 2016; El-Din 2019;
Iram 2015; Lusiba 2014; Metcalf 2018; Peñata 2016; Sarfaraz 2018;
Trajman 2014; Ullah 2017; Wang 2019; Wu 2019).
In the flow and timing domain, we considered almost all studies to
have low risk of bias, noting that all participants were accounted
for in the analysis. One study included fewer than 50% of eligible
participants in the analysis (Trajman 2014).
Studies evaluating Xpert Ultra for detection of rifampicin
resistance
Figure 5 and Figure 6 show risk-of-bias and applicability concerns
for each of the five studies included for rifampicin resistance
detection.
 
Figure 5.   Risk of bias and applicability concerns graph for rifampicin resistance detection in comparative studies
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Figure 6.   Risk of bias and applicability concerns summary for rifampicin resistance detection in comparative studies
of Xpert Ultra and Xpert MTB/RIF: review authors' judgements about each domain for each included study.
 
In the patient selection domain, we thought that four studies (80%)
had low risk of bias (Chin 2019; Sun 2019; Wang 2019; Wang 2020)
and one study (20%) had unclear risk of bias as the manner of
patient selection was unclear (Wu 2019). We thought that one
study (20%) had low concern because participants were evaluated
exclusively as inpatients at a tertiary care centre (Chin 2019) and
four studies (80%) had unclear concern because we could not tell
the details of the clinical setting (Sun 2019; Wang 2019; Wang 2020;
Wu 2019).
In the index test domain, we thought that all studies had low risk
of bias because the results of the index tests are automatically
generated, the user is provided with printable test results, and
the test threshold is prespecified. For applicability, with respect to
Xpert Ultra, we thought that three studies (60%) had low concern
because at least 75% of the specimen types in these studies were
processed according to WHO recommendations (Sun 2019; Wang
2019; Wang 2020); two studies (40%) had high concern because
fewer than 50% of the specimen types in these studies were
processed according to WHO recommendations (Chin 2019; Wu
2019).
In the reference standard domain, two studies (40%) had low risk
of bias because results of the reference standard were interpreted
without knowledge of results of the index test and only non-sterile
specimens were decontaminated (Chin 2019; Wu 2019). Three
studies (60%) had unclear risk of bias as it was unclear whether
blinding of the reference standard was performed (Sun 2019; Wang
2019; Wang 2020). For applicability of the reference standard, we
thought that all studies had low concern because detection of
rifampicin resistance occurs only when the M tuberculosis target is
present within the specimen.
In the flow and timing domain, we considered all studies to have
low risk of bias, noting that all participants were accounted for in
the analysis.
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Findings
The 69 studies were conducted in 28 diLerent countries. Most of
the studies were conducted in China (n = 10), India (n = 13), South
Africa (n = 10), and Uganda (n = 6). Seven studies exclusively or
mainly included HIV-positive participants (Ablanedo-Terrazas 2014;
Azevedo 2018; Bahr 2015; Bahr 2017; Cresswell 2020; Feasey 2013;
Van Rie 2013). Most studies performed the index tests and culture
on the same specimen type, except for one study in which Xpert
MTB/RIF was performed on blood and culture was performed on
sputum (Feasey 2013). Most studies did not report the exact number
of cultures used to confirm a diagnosis of tuberculosis, but it is
likely that many studies used a single culture. We present key
characteristics of the included studies in the Characteristics of
included studies table.
I. Detection of extrapulmonary tuberculosis
Xpert Ultra: of the 11 studies, the number evaluating diLerent
specimens was as follows: tuberculous meningitis (CSF) six
studies; pleural tuberculosis (pleural fluid) four studies; lymph
node tuberculosis (lymph node aspirate) one study; genitourinary
tuberculosis (urine) one study; bone or joint tuberculosis (bone or
joint aspirate) two studies; and peritoneal tuberculosis (peritoneal
fluid) one study.
Xpert MTB/RIF: of the 67 studies, the number of studies evaluating
diLerent specimens was as follows: tuberculous meningitis (CSF)
33 studies; pleural tuberculosis (fluid) 27 studies; lymph node
tuberculosis (aspirate 15 studies, biopsy 11 studies); genitourinary
tuberculosis (urine) 15 studies; bone or joint tuberculosis (aspirate
12 studies, tissue 3 studies); peritoneal tuberculosis (fluid 17
studies, tissue 1 study); pericardial tuberculosis (fluid 14 studies,
tissue 2 studies); and disseminated tuberculosis (blood 2 studies).
Several studies included more than one type of specimen.
Table 2 presents Xpert Ultra and Xpert MTB/RIF pooled sensitivity
and specificity estimates and predictive values by reference
standard for all forms of extrapulmonary tuberculosis and
specimen types included in the review.




Six studies evaluated Xpert Ultra in cerebrospinal fluid (CSF)
specimens against culture (Bahr 2017; Chin 2019; Cresswell 2020;
Donovan 2020; Perez-Risco 2018; Wang 2020). Xpert Ultra sensitivity
ranged from 80% to 100% and specificity ranged from 50% to
100% (Figure 7). Chin 2019 reported the lowest specificity (50%).
In this study, the investigators inoculated uncentrifuged CSF which
could have led to lower culture positivity, thus resulting in a higher
number of false positives. Perez-Risco 2018 (specificity 100%)
contributed only one participant to this analysis. In CSF, Xpert
Ultra pooled sensitivity and specificity (95% Crl) against culture
were 89.4% (79.1 to 95.6) and 91.2% (83.2 to 95.7), (6 studies; 475
participants, 89 (18.7%) with tuberculosis); Table 2.
 
Figure 7.   Forest plots of Xpert Ultra sensitivity and specificity in cerebrospinal fluid by reference standard. The
squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-
negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Composite reference standard
In CSF, Xpert Ultra pooled sensitivity and specificity against a
composite reference standard were 62.7% (45.7 to 77.0) and 99.1%
(96.6 to 99.9), (4 studies; 496 participants); Table 2, Figure 7.
Latent class meta-analysis
We had insuLicient data to obtain robust parameter estimates
using the latent class model for Xpert Ultra in CSF.
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Xpert MTB/RIF
Culture reference standard
Thirty-three studies evaluated Xpert MTB/RIF in CSF specimens
against culture (Ajbani 2018; Al-Ateah 2012; Azevedo 2018; Bahr
2015; Bahr 2017; Blaich 2014; Causse 2011; Chin 2019; Cresswell
2018; Cresswell 2020; Donovan 2020; Hanif 2011; Hillemann 2011;
Kim 2015a; Li 2017; Malbruny 2011; Metcalf 2018; Nataraj 2016; Nhu
2014; Ozkutuk 2014; Patel 2013; Peñata 2016; Rakotoarivelo 2018;
Rufai 2017b; Safianowska 2012; Sharma 2014; Siddiqi 2019; Suzana
2016; Ullah 2017; Vadwai 2011; Wang 2019; Zeka 2011; Zmak 2013).
Xpert MTB/RIF sensitivity ranged from 0% to 100% and specificity
ranged from 78% to 100% (Figure 8). For sensitivity, we thought
that diLerences in CSF volume and processing could partly explain
the heterogeneity. Three studies (Al-Ateah 2012; Hillemann 2011;
Safianowska 2012) did not contribute data to the meta-analysis
because sensitivity was not estimable.
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Figure 8.   Forest plots of Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid by reference standard.
The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-
negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
In CSF, Xpert MTB/RIF pooled sensitivity and specificity (95% Crl)
against culture were 71.1% (62.8 to 79.1) and 96.9% (95.4 to
98.0), respectively (30 studies; 3395 participants, 571 (16.8%) with
tuberculosis); Table 2, Figure 8.
Composite reference standard
In CSF, Xpert MTB/RIF pooled sensitivity and specificity against a
composite reference standard were 42.3% (32.1 to 52.8) and 99.8%
(99.3 to 100.0), (14 studies; 2203 participants); Table 2, Figure 8.
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Latent class meta-analysis
Based on the latent class meta-analysis model, Xpert MTB/
RIF pooled sensitivity and specificity (95% Crl) for tuberculous
meningitis were 74.7% (65.5 to 84.0) and 99.5% (99.1 to 99.7)
(30 studies; 3395 participants); Table 3. The pooled sensitivity of
culture at 80.8% (72.5 to 88.5) was estimated to be lower than 100%.
The pooled specificity of culture was estimated to be 99.2% (98.7 to
99.5); Table 3.
Xpert Ultra versus Xpert MTB/RIF
In comparative accuracy studies evaluating both index tests, Xpert
Ultra pooled sensitivity and specificity (95% CrI) against culture
were 89.0% (77.9 to 95.2) and 91.0% (82.7 to 95.6) and Xpert
MTB/RIF pooled sensitivity and specificity were 62.2% (43.7 to
78.1) and 96.8% (93.4 to 98.6), (5 studies; 471 participants), direct
comparison, Table 2; Figure 9; Figure 10. For CSF, the diLerence
between the sensitivities of Xpert Ultra and Xpert MTB/RIF was
26.2% (9.1 to 44.4). We estimated the probability that the pooled
sensitivity of Xpert Ultra exceeds that of Xpert MTB/RIF was 0.997.
The diLerence between the specificities of Xpert Ultra and Xpert
MTB/RIF was −5.6% (−12.9 to −0.1). We estimated the probability
that the pooled specificity of Xpert Ultra was less than that of Xpert
MTB/RIF was 0.978; Table 4.
 
Figure 9.   Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid,
comparative studies. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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Figure 10.   Summary plots of the sensitivity and specificity of Xpert Ultra (A) (5 studies) and Xpert MTB/RIF (B) (5
studies) in cerebrospinal fluid for detection of tuberculous meningitis. Each individual study is represented by a
shaded square. The size of the square is proportional to the sample size of the study such that larger studies are
represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The




Xpert Ultra versus Xpert MTB/RIF testing in people living with HIV
We identified two studies that directly compared Xpert Ultra and
Xpert MTB/RIF, both against culture, in people living with HIV.
Sensitivity (95% CI) was 90% (55 to 100) (Bahr 2017) and 89%
(71 to 98) (Cresswell 2020) for Xpert Ultra and 60% (26 to 88)
(Bahr 2017) and 70% (50 to 86) (Cresswell 2020) for Xpert MTB/RIF.
Specificity (95% CI) was 90% (83 to 95) (Bahr 2017) and 92% (86 to
95) (Cresswell 2020) for Xpert Ultra and 97% (95% CI 92 to 99) (Bahr
2017) and 97% (93 to 99) (Cresswell 2020) for Xpert MTB/RIF; Figure
11.
 
Figure 11.   Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in cerebrospinal fluid in HIV-
positive people, with respect to culture. The squares represent the sensitivity and specificity of one study, the black
line its confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive. .
 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Specimen concentration
Xpert Ultra
We found that concentrating CSF improved both Xpert Ultra
sensitivity and specificity. Xpert Ultra pooled sensitivity in
concentrated specimens was 90.5% (76.7 to 97.0) (3 studies;
421 participants) versus 88.4% (67.8 to 97.5) (3 studies; 54
participants) in unconcentrated specimens. Xpert Ultra pooled
specificity in concentrated specimens was 91.9% (84.5 to 96.1)
versus 88.6% (58.4 to 99.0) in unconcentrated specimens; Table
5. The probability that Xpert Ultra sensitivity and specificity are
higher with concentrated CSF compared to unconcentrated CSF
were 0.630 and 0.653, respectively.
Xpert MTB/RIF
We found that concentrating CSF improved both Xpert MTB/
RIF sensitivity and specificity. Xpert MTB/RIF pooled sensitivity
in concentrated specimens was 77.6% (67.2 to 85.9) (14, 2279
participants) versus 59.4% (48.3 to 70.5) (17,1123 participants) in
unconcentrated specimens. Xpert MTB/RIF pooled specificity in
concentrated specimens was 97.4% (96.1 to 98.4) versus 96.8%
(94.0 to 98.7) in unconcentrated specimens, Table 5. The probability
that Xpert MTB/RIF sensitivity and specificity are higher with
concentrated CSF compared to unconcentrated CSF were 0.989 and
0.696, respectively.
Cerebrospinal fluid collection volumes
Xpert Ultra
Two studies reported the volume of CSF collected for Xpert Ultra
testing, 3 mL in both studies. Sensitivities were similar: 90% (55 to
100) in Bahr 2017 and 89% (71 to 98) in Cresswell 2020. Specificities
were also similar 90% (83 to 95) in Bahr 2017 and 92% (86 to 95) in
Cresswell 2020.
Impact of tuberculosis prevalence on sensitivity and specificity
For Xpert Ultra, we found lower sensitivity in settings with higher
tuberculosis prevalence (threshold 30%) than in those with lower
tuberculosis prevalence: pooled sensitivity (95% CrI) of 88.3% (68.3
to 97.0) versus 90.8% (77.3 to 96.9). We found lower specificity
in settings with higher tuberculosis prevalence than in those with
lower tuberculosis prevalence: pooled specificity of 88.0% (64.3 to
97.9) versus 91.9% (82.5 to 96.6). In both analyses, the 95% Crls
overlapped; Table 6.
Similarly, for Xpert MTB/RIF, we found lower sensitivity in settings
with higher tuberculosis prevalence than in those with lower
tuberculosis prevalence: pooled sensitivity of 67.0% (49.0 to
81.5) versus 72.0% (62.4 to 81.2). We found lower specificity in
settings with higher tuberculosis prevalence than in those with
lower tuberculosis prevalence: pooled specificity of 94.1% (86.8
to 97.9) versus 97.3% (95.9 to 98.3). In both analyses, the 95%
Crls overlapped; Table 6. When we repeated the analysis at lower
tuberculosis prevalence (threshold 10%), in the case of specificity,
accuracy in the two groups was significantly diLerent (probability
of specificity being lower in the high tuberculosis prevalence group
= 0.999); Table 6.
Sensitivity analyses
Overall, the sensitivity analyses made little diLerence to the
findings; Table 7
Inconclusive Xpert Ultra and Xpert MTB/RIF results
Xpert Ultra
None of the studies evaluating Xpert Ultra for tuberculous
meningitis reported this information.
Xpert MTB/RIF
We previously reported that for CSF, of 2096 tests performed, the
pooled proportion of inconclusive Xpert MTB/RIF results was 0.9%
(95% CrI 0.3 to 1.9) (Kohli 2018).




Four studies evaluated Xpert Ultra in pleural fluid with respect to
culture (Perez-Risco 2018; Wang 2019; Wang 2020; Wu 2019). Xpert
Ultra sensitivity ranged from 48% to 84% and specificity ranged
from 65% to 100%; Figure 12.
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Figure 12.   Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in pleural fluid and tissue by
reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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Figure 12.   (Continued)
 
In pleural fluid, Xpert Ultra pooled sensitivity and specificity against
culture were 75.0% (58.0 to 86.4) and 87.0% (63.1 to 97.9), (4 studies;
398 participants, 158 (39.7%) with tuberculosis); Table 2; Appendix
8.
Composite reference standard
Two studies evaluated Xpert Ultra in pleural fluid with respect to
a composite reference standard (Meldau 2019; Wang 2019); Figure
12; Appendix 8. Sensitivity ranged from 38% to 61%, and specificity
ranged from 96% to 99%. We could not explain the variability in the
sensitivity estimates and did not perform a meta-analysis.
Latent class meta-analysis
We had insuLicient data to obtain robust parameter estimates
using the latent class model for Xpert Ultra in pleural fluid.
Xpert MTB/RIF
Culture reference standard
Twenty-eight studies evaluated Xpert MTB/RIF in pleural fluid
with respect to culture (Al-Ateah 2012; Causse 2011; Che 2017;
Christopher 2013; Du 2015; Friedrich 2011; Hanif 2011; Hillemann
2011; Iram 2015; Kim 2015a; Li 2017; Malbruny 2011; Meldau 2014;
Nataraj 2016; Ozkutuk 2014; Peñata 2016; Rakotoarivelo 2018; Rufai
2015; Safianowska 2012; Scott 2014; Sharma 2014; Suzana 2016;
Vadwai 2011; Wang 2019; Wang 2020; Wu 2019; Zeka 2011; Zmak
2013). Xpert MTB/RIF sensitivity ranged from 0% to 100% and
specificity ranged from 82% to 100% (Figure 12). Three studies
(Christopher 2013; Hillemann 2011; Iram 2015) did not contribute
data to the meta-analysis because sensitivity was not estimable.
In pleural fluid, Xpert MTB/RIF pooled sensitivity and specificity
against culture were 49.5% (39.8 to 59.9) and 98.9% (97.6 to 99.7)
(25 studies; 3065 participants, 644 (21.0%) with tuberculosis); Table
2; Appendix 8.
Composite reference standard
In pleural fluid, Xpert MTB/RIF pooled sensitivity and specificity
against a composite reference standard were 18.9% (11.5 to 27.9)
and 99.3% (98.1 to 99.8), (10 studies; 1024 participants) Table 2;
Figure 12.
Latent class meta-analysis
Based on the latent class meta-analysis model, Xpert MTB/RIF
pooled sensitivity and specificity (95% Crl) in pleural fluid were
53.1% (42.8 to 64.1) and 99.6% (99.3 to 99.8) (25 studies; 3065
participants) Table 3. Xpert MTB/RIF pooled sensitivity was slightly
higher and its pooled specificity comparable to what was obtained
when culture was treated as having perfect accuracy, with pooled
sensitivity of 49.5% (39.8 to 59.9) and pooled specificity of 98.8%
(97.6 to 99.7). The pooled sensitivity of culture at 89.5% (80.5 to
96.3) was estimated to be lower than 100%. The pooled specificity
of culture was estimated to be 99.0% (98.2 to 99.5).
Xpert Ultra versus Xpert MTB/RIF
We had insuLicient data for this analysis.
Impact of tuberculosis prevalence on sensitivity and specificity
For Xpert Ultra, we had insuLicient data for this analysis.
For Xpert MTB/RIF, we found higher sensitivity in settings
with higher tuberculosis prevalence than in those with lower
tuberculosis prevalence: pooled sensitivity (95% CrI) of 20.7% (11.2
to 33.7) versus 15.5% (6.5 to 30.1). We found similar specificity
in settings with higher tuberculosis prevalence and in those with
lower tuberculosis prevalence: pooled specificity of 99.6% (97.9 to
99.9) versus 99.0% (96.9 to 99.8). In both analyses, the 95% Crls
overlapped; Table 6.
Sensitivity analyses
For Xpert Ultra, we had insuLicient data for these analyses.
Inconclusive Xpert Ultra and Xpert MTB/RIF results
Xpert Ultra
Of the total 1013 tests performed, the percentage of inconclusive
Xpert Ultra results was 0.3%. Only one study reported this
information (Wang 2019).
Xpert MTB/RIF
We previously reported that for pleural fluid, of 1416 tests
performed the pooled proportion of inconclusive Xpert MTB/RIF
results was 1.2% (95% CrI 0.4 to 2.6) (Kohli 2018).
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We did not identify any studies evaluating Xpert Ultra in pleural
tissue against culture.
Composite reference standard
We did not identify any studies evaluating Xpert Ultra in pleural
tissue against a composite reference standard.
Xpert MTB/RIF
Culture reference standard
Four studies evaluated Xpert MTB/RIF in pleural tissue with respect
to culture (Christopher 2013; Du 2015; Ozkutuk 2014; Suzana 2016).
Xpert MTB/RIF sensitivity ranged from 0% to 85% and specificity
ranged from 97% to 100%; Figure 12. One study reported zero
tuberculosis cases (Suzana 2016). We did not perform a meta-
analysis.
Composite reference standard
In pleural tissue, Xpert MTB/RIF sensitivity and specificity against a
composite reference standard were 0% (0 to 23) and 98% (87 to 100)
(1 study; 55 participants; Christopher 2013); Figure 12.
D: Xpert MTB/RIF and Xpert Ultra testing in lymph node aspirate
for lymph node tuberculosis
Xpert Ultra
Culture reference standard
In lymph node aspirates, Xpert Ultra sensitivity and specificity
against culture were 78% (40 to 97) and 78% (66 to 87), (1 study; 73
participants; 9 (12.3%) with tuberculosis; Antel 2020); Figure 13.
 
Figure 13.   Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in lymph node aspirate by
reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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Composite reference standard
In lymph node aspirates, Xpert Ultra sensitivity and specificity
against a composite reference standard were 70% (51 to 85)
and 100% (92 to 100), (1 study; 73 participants; 9 (12.3%) with
tuberculosis; Antel 2020); Figure 13. Of note, with a composite
reference standard, specificity was higher (100%) than that
observed when using culture as the reference standard (78%).
Latent class meta-analysis
We had insuLicient data to obtain robust parameter estimates
using the latent class model for Xpert Ultra in lymph node aspirate.
Xpert MTB/RIF
Culture reference standard
FiNeen studies evaluated Xpert MTB/RIF in lymph node aspirates
with for culture (Al-Ateah 2012; Biadglegne 2014; Blaich 2014;
Dhasmana 2014; Dhooria 2016; Ghariani 2015; Hanif 2011; Kim
2015a; Ligthelm 2011; Nataraj 2016; Scott 2014; Sharma 2014;
Tadesse 2015; Ullah 2017; Van Rie 2013). Xpert MTB/RIF sensitivity
ranged from 59% to 100% and specificity from 57% to 100%;
Figure 13. Xpert MTB/RIF specificity in lymph node aspirates was
considerably more heterogeneous than in CSF and pleural fluid.
The variability in Xpert MTB/RIF specificity in lymph node aspirates
was unexpected and may be the result of a systematic, unexplained
bias in some studies. One study did not contribute data to the meta-
analysis because sensitivity was not estimable (Kim 2015a).
In lymph node aspirates, Xpert MTB/RIF pooled sensitivity and
specificity against culture were 88.9% (82.7 to 93.6) and 86.2%
(78.0 to 92.3) (14 studies; 1588 participants, 627 (39.5%) with
tuberculosis); Table 2.
Composite reference standard
In lymph node aspirates, Xpert MTB/RIF pooled sensitivity and
specificity against a composite reference standard were 81.6% (61.9
to 93.3) and 96.4% (91.3 to 98.6), (4 studies; 679 participants);
Table 2; Figure 13. Of note, with a composite reference standard,
specificity was less variable and pooled specificity higher than that
observed when using culture as the reference standard (86.0%).
Latent class meta-analysis
Based on the latent class meta-analysis model, Xpert MTB/RIF
pooled sensitivity and specificity (95% Crl) in lymph node aspirate
were 91.3% (84.9 to 96.3) and 99.5% (99.1 to 99.7) (14 studies; 1588
participants); Table 3. Xpert MTB/RIF pooled sensitivity and pooled
specificity were higher than when culture was treated as having
perfect accuracy, with pooled sensitivity of 88.9% (82.7 to 93.6) and
pooled specificity of 86.2% (78.0 to 92.3). The pooled sensitivity of
culture at 84.9% (74.0 to 92.8) was estimated to be lower than 100%.
The pooled specificity of culture was estimated to be 98.8% (97.7
to 99.4); Table 3. The latent class meta-analysis resulted in high
precision in the specificity of Xpert MTB/RIF across studies. This
was the result of adjustments for the imperfect and heterogeneous
accuracy of culture across studies.
Xpert Ultra versus Xpert MTB/RIF
We had insuLicient data for this analysis.
Impact of tuberculosis prevalence on sensitivity and specificity
For Xpert Ultra, we had insuLicient data for this analysis.
For Xpert MTB/RIF, we found higher sensitivity in settings
with higher tuberculosis prevalence than in those with lower
tuberculosis prevalence: pooled sensitivity (95% CrI) of 93.1% (88.9
to 96.3) versus 72.2% (64.9 to 87.2). We found lower specificity
in settings with higher tuberculosis prevalence than in those with
lower tuberculosis prevalence: pooled specificity of 83.2% (69.5
to 92.1) versus 90.0% (78.3 to 95.9). In the case of sensitivity,
accuracy in the two groups was significantly diLerent (probability
of sensitivity being lower in the high tuberculosis prevalence group
= 0.999); Table 6.
Sensitivity analyses
For Xpert Ultra, we had insuLicient data for these analyses.
Inconclusive Xpert MTB/RIF and Xpert Ultra results
Xpert Ultra
None of the studies reported this information.
Xpert MTB/RIF
We previously reported that for lymph node aspirates, in the 1134
tests performed, the pooled proportion of inconclusive Xpert MTB/
RIF results was 1.0% (95% CrI 0.4 to 2.0) (Kohli 2018).




In lymph node biopsies, Xpert Ultra sensitivity and specificity
against culture were 90% (55 to 100) and 87% (77 to 94) (Antel 2020)
and 100% (75 to 100) and 38% (22 to 55) (Wu 2019), (2 studies; 131
participants, 23 (17.6%) with tuberculosis); Figure 14.
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Figure 14.   Forest plots of Xpert Ultra and Xpert MTB/RIFsensitivity and specificity in lymph node biopsy by
reference standard. The squares represent the sensitivity and specificity of one study, the black line its confidence
interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Composite reference standard
In lymph node biopsies, Xpert Ultra sensitivity and specificity
against a composite reference standard were 73% (50 to 89) and
96% (88 to 100) (Antel 2020), (1 study; 81 participants); Figure 14.
Xpert MTB/RIF
Culture reference standard
Eleven studies evaluated Xpert MTB/RIF in lymph node biopsies
against culture (Blaich 2014; Causse 2011; Ghariani 2015; Kim
2015a; Ozkutuk 2014; Peñata 2016; Sarfaraz 2018; Sharma 2014;
Suzana 2016; Wu 2019; Zeka 2011). Xpert MTB/RIF sensitivity ranged
from 50% to 100% and specificity ranged from 0% to 100%; Figure
14. We could not explain the heterogeneity in accuracy estimates by
study quality, small numbers, or other factors.
In lymph node biopsies, Xpert MTB/RIF pooled sensitivity and
specificity against culture were 82.4% (73.5 to 89.7) and 80.3%
(60.3 to 91.5), (11 studies; 786 participants, 220 (28.0%) with
tuberculosis); Table 2.
Composite reference standard
In lymph node biopsies, Xpert MTB/RIF sensitivity and specificity
against a composite reference standard were 33% (27 to 40) and
85% (73 to 93) (Sarfaraz 2018) and 76% (50 to 93) and specificity of
100% (66 to 100) (Zeka 2011) (2 studies; 288 participants); Figure 14.




In urine, Xpert Ultra sensitivity and specificity against culture were
100% (74 to 100) and 100% (74 to 100), (1 study; 24 participants, 12
(50%) with tuberculosis) (Perez-Risco 2018); Figure 15.
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Figure 15.   Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in urine by reference standard.
The squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-
negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Composite reference standard
We did not identify any studies that evaluated Xpert Ultra in urine
against a composite reference standard.
Xpert MTB/RIF
Culture reference standard
FiNeen studies evaluated Xpert MTB/RIF in urine against culture
(Blaich 2014; Causse 2011; Chen 2019; Hanif 2011; Hillemann
2011; Kim 2015a; Li 2017; Malbruny 2011; Nataraj 2016; Ozkutuk
2014; Safianowska 2012; Sharma 2014; Suzana 2016; Zeka 2011;
Zmak 2013). Xpert MTB/RIF sensitivity ranged from 0% to 100%
(sensitivity of 0% was reported by Zeka 2011 that had only one
culture positive, which was Xpert negative) and specificity from
33% to 100% (Figure 15). Six studies (Blaich 2014; Causse 2011;
Malbruny 2011; Nataraj 2016; Sharma 2014; Zmak 2013) did not
contribute data to the meta-analysis because either sensitivity or
specificity was not estimable.
In urine, Xpert MTB/RIF pooled sensitivity and specificity against
culture were 85.9% (71.4 to 94.3) and 98.1% (93.1 to 99.7) (9 studies;
943 participants, 72 (7.6%) with tuberculosis); Table 2.
Composite reference standard
In urine, Xpert MTB/RIF sensitivity and specificity against a
composite reference standard were 33% (1 to 91) and 100% (92 to
100) (Sharma 2014), and 41% (33 to 50 ) and 100% (99 to 100) (Chen
2019) (2 studies; 463 participants); Figure 15.
G: Xpert Ultra and Xpert MTB/RIF testing in bone or joint
aspirate for bone or joint tuberculosis
Xpert Ultra
Culture reference standard
In bone or joint aspirate, Xpert Ultra sensitivity and specificity
against culture were 88% (47 to 100) (specificity was not estimable)
(Perez-Risco 2018), and 96% (87 to 100) and 97% (85 to 100) (Sun
2019) (2 studies; 94 participants, 60 (63.8%) with tuberculosis);
Appendix 9.
Composite reference standard
In bone or joint aspirate, Xpert Ultra sensitivity and specificity
against a composite reference standard were 96% (91 to 99) and
97% (85 to 100), (1 study; 145 participants; Sun 2019); Appendix 9.
Xpert MTB/RIF
Culture reference standard
Twelve studies evaluated Xpert MTB/RIF in bone or joint fluid
for culture (Al-Ateah 2012; Blaich 2014; Gu 2015; Kim 2015a;
Li 2017; Malbruny 2011; Nataraj 2016; Ozkutuk 2014; Peñata
2016; Safianowska 2012; Sun 2019; Suzana 2016). Xpert MTB/RIF
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sensitivity ranged from 96% to 100% and specificity ranged from
53% to 100%; Appendix 9.
In bone or joint aspirate, Xpert MTB/RIF pooled sensitivity and
specificity against culture were 97.9% (93.1 to 99.6) and 97.4%
(80.2 to 100.0); (6 studies; 471 participants, 110 (23.4%) with
tuberculosis); Table 2
Composite reference standard
In bone or joint aspirate, Xpert MTB/RIF sensitivity and specificity
against a composite reference standard were 82% (69 to 91) and
100% (69 to 100) (Gu 2015), and 94% (87 to 97) and 100% (90 to 100)
(Sun 2019); (2 studies; 205 participants); Appendix 9.




We did not identify any studies that evaluated Xpert Ultra in tissue
for bone or joint tuberculosis against culture.
Composite reference standard
We did not identify any studies that evaluated Xpert Ultra in




Three studies evaluated Xpert MTB/RIF in bone or joint tissue
against culture. Xpert MTB/RIF sensitivity ranged from 50% to 100%
and specificity ranged from 94% to 100% (Appendix 9).
In bone or joint tissue, Xpert MTB/RIF sensitivity and specificity
(95% CI) against culture were 100% (3 to 100) and 100% (48 to 100)
(Malbruny 2011), 100% (3 to 100) and 100% (40 to 100) (Ozkutuk
2014), and 50% (1 to 99) and 94% (71 to 100) (Peñata 2016); (3
studies; 30 participants, 4 (13.3%) with tuberculosis).
Composite reference standard
We did not identify any studies that evaluated Xpert MTB/RIF in
tissue for bone or joint tuberculosis against a composite reference
standard.




In peritoneal fluid, Xpert Ultra sensitivity against culture was 33% (1
to 91) and specificity was not estimable (Perez-Risco 2018) (1 study;
3 participants); Appendix 10.
Composite reference standard
We did not identify any studies that evaluated Xpert Ultra in
peritoneal fluid against a composite reference standard.
Xpert MTB/RIF
Culture reference standard
Seventeen studies evaluated Xpert MTB/RIF in peritoneal fluid
against culture (Al-Ateah 2012; Causse 2011; Iram 2015; Kim 2015a;
Li 2017; Malbruny 2011; Ozkutuk 2014; Peñata 2016; Rufai 2017a;
Safianowska 2012; Scott 2014; Sharma 2014; Suzana 2016; Ullah
2017; Vadwai 2011; Zeka 2011; Zmak 2013). Four studies (Al-Ateah
2012; Causse 2011; Iram 2015; Safianowska 2012) did not contribute
data to the meta-analysis because sensitivity was not estimable.
In individual studies, Xpert MTB/RIF sensitivity ranged from 33% to
100% and specificity ranged from 90% to 100%; Figure 16; Appendix
10.
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Figure 16.   Forest plots of Xpert MTB/RIF sensitivity and specificity for peritoneal TB (fluid and tissue) by reference
standard. The squares represent the sensitivity and specificity of one study, the black line its confidence interval.
FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
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In peritoneal fluid, Xpert MTB/RIF pooled sensitivity and specificity
against culture were 59.1% (42.1 to 76.2) and 97.6% (95.4 to 98.9),
(13 studies; 580 participants, 94 (16.2%) with tuberculosis); Table 2.
Composite reference standard
We did not identify any studies that evaluated Xpert MTB/RIF in
peritoneal fluid against a composite reference standard.




We did not identify any studies that evaluated Xpert Ultra in
peritoneal tissue against culture.
Composite reference standard
We did not identify any studies that evaluated Xpert Ultra in
peritoneal tissue against a composite reference standard.
Xpert MTB/RIF
Culture reference standard
In peritoneal tissue, Xpert MTB/RIF sensitivity and specificity
against culture were 50% (7 to 93) and 92% (73 to 99) (1 study; 28
participants; Bera 2015); Appendix 10.
Composite reference standard
We did not identify any studies that evaluated Xpert MTB/RIF in
peritoneal tissue against a composite reference standard.




We did not identify any studies that evaluated Xpert Ultra in
pericardial fluid against culture.
Composite reference standard
We did not identify any studies that evaluated Xpert Ultra in
pericardial fluid against a composite reference standard.
Xpert MTB/RIF
Culture reference standard
Fourteen studies evaluated Xpert MTB/RIF in pericardial fluid
against culture (Al-Ateah 2012; Blaich 2014; Causse 2011; Kim
2015a; Ozkutuk 2014; Pandie 2014; Peñata 2016; Safianowska 2012;
Sharma 2014; Suzana 2016; Ullah 2017; Vadwai 2011; Zeka 2011;
Zmak 2013). Xpert MTB/RIF sensitivity ranged from 0% to 100% and
specificity ranged from 69% to 100% (Appendix 10). Nine studies
(Al-Ateah 2012; Blaich 2014; Causse 2011; Kim 2015a; Ozkutuk 2014;
Peñata 2016; Safianowska 2012; Vadwai 2011; Zmak 2013) did not
contribute data to the meta-analysis because either sensitivity or
specificity was not estimable.
In pericardial fluid, Xpert MTB/RIF pooled sensitivity and specificity
against culture were 61.4% (32.4 to 82.4) and 89.7% (74.9 to 99.0),
(5 studies; 181 participants, 57 (31.5%) with tuberculosis); Table 2;
Appendix 10.
Composite reference standard
We did not identify any studies that evaluated Xpert MTB/RIF in
pericardial fluid against a composite reference standard.




We did not identify any studies that evaluated Xpert Ultra in blood
against culture.
Composite reference standard
We did not identify any studies that evaluated Xpert Ultra in blood
against a composite reference standard.
Xpert MTB/RIF
Culture reference standard
Two studies evaluated Xpert MTB/RIF in blood against culture
(Feasey 2013; Zmak 2013). However, only one of these studies
reported tuberculosis culture-positives. Xpert MTB/RIF sensitivity
and specificity against culture were 56% (21 to 86) and 94% (85 to
98) (1 study; 74 participants, 9 (12.2%) with tuberculosis (Feasey
2013)); Appendix 10.
Composite reference standard
We did not identify any studies that evaluated Xpert MTB/RIF in
blood against a composite reference standard.
Nontuberculous mycobacteria
For Xpert Ultra, two studies provided data on a variety of NTMs
that grew from the specimens tested to look for evidence of
cross-reactivity. Donovan 2020 assessed Xpert Ultra specificity
in CSF from more than 100 participants with nontuberculous
meningitis and found zero positive Xpert Ultra results in those with
a probable or possible diagnosis of tuberculous meningitis and
in any participant with a confirmed diagnosis of nontuberculous
meningitis. Perez-Risco 2018 assessed Xpert Ultra specificity using
20 culture-positive NTM specimens (covering a total of 18 species)
and found that Xpert Ultra was negative for all specimens.
For Xpert MTB/RIF, we previously reported that in 10 studies
involving 6975 specimens with 141 NTMs, Xpert MTB/RIF was
negative in all specimens (Kohli 2018).
II. Detection of rifampicin resistance
Xpert Ultra and Xpert MTB/RIF testing for rifampicin resistance
Xpert Ultra
Five studies evaluated Xpert Ultra for detection of rifampicin
resistance. Xpert Ultra sensitivity estimates varied from 50% to
100%; specificity varied from 93% to 100%; Figure 17. One study
reported zero participants with rifampicin resistance and thus
sensitivity was not estimable (Chin 2019). Four studies contributed
data to the bivariate meta-analysis (Sun 2019; Wang 2019; Wang
2020; Wu 2019). Xpert Ultra pooled sensitivity and specificity were
100.0% (95.1 to 100.0) and 100.0% (99.0 to 100.0), (4 studies; 129
participants, 24 (18.6%) with rifampicin resistance); Table 2.
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Figure 17.   Forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity for rifampicin resistance. The
squares represent the sensitivity and specificity of one study, the black line its confidence interval. FN: false-
negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Xpert MTB/RIF
Xpert MTB/RIF pooled sensitivity and specificity were 96.5% (91.9
to 98.8) and 99.1% (98.0 to 99.7) (19 studies; 970 participants, 148
(15.3%) with rifampicin resistance); Table 2; Figure 17.
Indeterminate Xpert Ultra and Xpert MTB/RIF results for rifampicin
resistance
Xpert Ultra
Of the total 391 tests positive by Xpert Ultra, the proportion of
indeterminate Xpert Ultra results for RIF resistance was 36.1%. All
of these indeterminate results were Xpert Ultra trace-positive.
Xpert MTB/RIF
We previously reported that for rifampicin resistance testing, of
1003 tests performed, the pooled proportion of indeterminate
Xpert MTB/RIF results was 2.6% (95% CrI 1.4 to 4.3) (Kohli 2018).
D I S C U S S I O N
Summary of main results
This systematic review update summarizes the current literature
and includes 69 unique studies on the accuracy of Xpert Ultra
and Xpert MTB/RIF for extrapulmonary tuberculosis and rifampicin
resistance. We identified 11 studies evaluating Xpert Ultra, an
increase of 10 new studies since the original review (Kohli 2018).
Unlike the original review, we limited inclusion to adults aged 15
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years and older. We also include a composite reference standard
in addition to a culture reference standard, and have stratified all
analyses by type of reference standard. Major findings from our
review include the following.
• Xpert Ultra sensitivity for tuberculosis varied across diLerent
types of specimens (from 75.0% in pleural fluid to 89.4% in
cerebrospinal fluid); Table 2
• Xpert MTB/RIF sensitivity for tuberculosis varied across diLerent
types of specimens (from 49.5% in pleural fluid to 97.9% in bone
or joint aspirate); Table 2
• Xpert MTB/RIF specificity in cerebrospinal fluid, pleural fluid,
urine, bone or joint aspirate, and peritoneal fluid was ≥ 96.9%,
against culture; overall, Xpert Ultra specificities were lower than
those of Xpert MTB/RIF against culture, but against a composite
reference standard results for both index tests were similar;
Table 2
• In cerebrospinal fluid, Xpert Ultra sensitivity and specificity were
89.4% (79.1 to 95.6) and 91.2% (83.2 to 95.7) against culture;
Summary of findings 1.
• In cerebrospinal fluid, Xpert MTB/RIF sensitivity and specificity
were 71.1% (62.8 to 79.1) and 96.9% (95.4 to 98.0) against
culture; Summary of findings 1
• In pleural fluid, Xpert Ultra sensitivity and specificity were 75.0%
(58.0 to 86.4) and 87.0% (63.1 to 97.9) against culture; Summary
of findings 2
• In pleural fluid, Xpert MTB/RIF sensitivity and specificity were
49.5% (39.8 to 59.9) and 98.9% (97.6 to 99.7) against culture;
Summary of findings 2
• In lymph node aspirate, Xpert Ultra sensitivity and specificity
were 70% (51 to 85) and 100% (92 to 100) against a composite
reference standard (1 study); Summary of findings 3
• In lymph node aspirate, Xpert MTB/RIF sensitivity and specificity
were 81.6% (61.9 to 93.3) and 96.4% (91.3 to 98.6) against a
composite reference standard; Summary of findings 3
• For rifampicin resistance, Xpert Ultra sensitivity and specificity
were 100.0% (95.1 to 100.0) and 100.0% (99.0 to 100.0);
Summary of findings 4
• For rifampicin resistance, Xpert MTB/RIF sensitivity and
specificity were 96.5% (91.9 to 98.8) and 99.1% (98.0 to 99.7);
Summary of findings 4
Xpert Ultra and Xpert MTB/RIF testing in cerebrospinal fluid
(Summary of findings 1)
Xpert Ultra
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have tuberculosis meningitis on culture,
168 would be Xpert Ultra-positive: of these, 79 (47%) would
not have tuberculosis (false-positives); and 832 would be Xpert
Ultra-negative: of these, 11 (1%) would have tuberculosis (false-
negatives).
Xpert MTB/RIF
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have tuberculosis meningitis on culture,
99 would be Xpert MTB/RIF-positive: of these, 28 (28%) would not
have tuberculosis (false-positives); and 901 would be Xpert MTB/
RIF-negative: of these, 29 (3%) would have tuberculosis (false-
negatives).
Rapid diagnosis of tuberculous meningitis is critical so that
lifesaving treatment can be started promptly. Around 50% of
those aLected die or experience disabling consequences (Thwaites
2013). Xpert Ultra was designed to improve tuberculosis detection,
in particular in people with paucibacillary disease. The limit
of detection for MTB is lower with Xpert Ultra (16 bacterial
colony-forming units (cfu) per mL) than with Xpert MTB/RIF
(131 cfu per mL) (Chakravorty 2017). In studies that compared
Xpert Ultra and Xpert MTB/RIF in the same participants, we
found Xpert Ultra to have higher pooled sensitivity (89.0%) than
Xpert MTB/RIF (62.2%), and lower pooled specificity (91.0%) than
Xpert MTB/RIF (96.8%) for tuberculous meningitis. In addition,
in subgroup analyses we found slightly higher Xpert Ultra
accuracy in studies that concentrated the cerebrospinal fluid (CSF):
pooled sensitivity of 90.5% in concentrated specimens versus
88.4% in unconcentrated specimens; and pooled specificity of
91.9% in concentrated specimens versus 88.6% in unconcentrated
specimens. We note that subgroup findings should be interpreted
with caution, as there were only three studies and a small
number of tuberculous meningitis cases included. The Tuberculous
Meningitis International Research Consortium has recommended
increasing the volume of CSF collected for diagnosis followed
by centrifugation as a way of improving Xpert MTB/RIF assay
sensitivity (Bahr 2016); however, we did not have suLicient data
to investigate CSF collection volume. Increased Xpert MTB/RIF
sensitivity in HIV-positive people compared with HIV-negative
people has been reported, with the increased bacterial burden in
tuberculosis and HIV co-infection proposed as the reason (Patel
2013). We had limited data to investigate this for Xpert Ultra as we
identified only two studies in HIV-positive people, with sensitivities
of 90% (Bahr 2017) and 89% (Cresswell 2020).
Xpert Ultra and Xpert MTB/RIF testing in pleural fluid
(Summary of findings 2)
Xpert Ultra
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have pleural tuberculosis on culture,
192 would be Xpert Ultra-positive: of these, 117 (61%) would
not have tuberculosis (false-positives); and 808 would be Xpert
Ultra-negative: of these, 25 (3%) would have tuberculosis (false-
negatives).
Xpert MTB/RIF
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have pleural tuberculosis on culture,
60 would be Xpert MTB/RIF-positive: of these, 10 (17%) would not
have tuberculosis (false-positives); and 940 would be Xpert MTB/
RIF-negative: of these, 50 (5%) would have tuberculosis (false-
negatives).
With the bivariate model, we found Xpert Ultra to have higher
pooled sensitivity (75.0%) than Xpert MTB/RIF (49.6%) and
lower pooled specificity (87.0%) than Xpert MTB/RIF (98.7%) in
pleural fluid against a culture reference standard, between-study
comparison. Based on the latent class meta-analysis model, Xpert
Ultra pooled sensitivity was comparable (76.0%) and specificity
higher (99.5%) than what was obtained when culture was treated
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as having perfect accuracy. Xpert Ultra pooled sensitivity in pleural
fluid was lower than that of CSF. One reason for the lower sensitivity
of Xpert Ultra in pleural fluid could be the paucibacillary nature of
pleural tuberculosis. Other possible reasons are contamination of
blood or the presence of certain polymerase chain reaction (PCR)
inhibitors in the pleural fluid (Pai 2004; Woods 2001). However,
Theron and colleagues found that extrapulmonary specimens
showed less evidence of PCR inhibition than pulmonary specimens,
with bacterial load being more important for a positive Xpert MTB/
RIF result (Theron 2014b). Given that false-negative results were
common (low sensitivity), a negative Xpert Ultra or Xpert MTB/RIF
result may not be relied on to exclude tuberculosis.
Xpert Ultra testing in lymph node aspirates
Xpert Ultra
Results of these studies indicate that in theory, for a population of
1000 people where 100 have lymph node tuberculosis verified by
a composite reference standard, 70 would be Xpert Ultra-positive:
of these, 0 (0%) would not have tuberculosis (false-positives); and
930 would be Xpert Ultra-negative: of these, 30 (3%) would have
tuberculosis (false-negatives).
Xpert MTB/RIF
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have lymph node tuberculosis verified
by a composite reference standard, 118 would be Xpert MTB/RIF-
positive: of these 37 (31%) would not have tuberculosis (false-
positives); and 882 would be Xpert MTB/RIF-negative: of these 19
(2%) would have tuberculosis (false-negatives).
Regarding Xpert testing for lymph node aspirate, it important
to point out that although tissue biopsy provides material for
histological examination which may be of substantial diagnostic
value, a fluid specimen may be collected more easily. In addition,
fine-needle aspiration of lymph nodes is well suited for use in
resource-limited settings because the procedure is simple, easy to
learn, minimally invasive, and inexpensive (Wright 2009b). Thus
clinicians may want to consider fine-needle aspiration of lymph
nodes before surgical biopsy.
In our review, using a standard bivariate meta-analysis model,
Xpert MTB/RIF pooled specificity (defined by culture) in lymph
node aspirate was 86.0%, whereas with a composite reference
standard pooled specificity increased to 95.9%. Using a latent
class meta-analysis model with informative priors, Xpert MTB/RIF
pooled specificity increased to 99.5%. In previous meta-analyses,
Xpert MTB/RIF specificity for lymph node tuberculosis (aspirate and
tissue) against culture as a reference standard was 94% (Denkinger
2014), 93% (Maynard-Smith 2014), and 92% (Penz 2015). See Table
8. Using a composite reference standard (defined by the primary
study authors), Denkinger 2014 found increased Xpert MTB/RIF
specificity of 99% for lymph node tuberculosis (5 studies, 728
specimens). Thus, it appears that accuracy results depend in
part on the choice of reference standard. Regarding the use of a
composite reference standard, owing to diLering definitions and
diLiculty in interpreting them, there is a risk of bias (Schiller 2016)
(see section Strengths and weaknesses of the review).
We considered several reasons why the specificity of Xpert Ultra
(78%) and Xpert MTB/RIF (86.0%) in lymph node aspirate against
culture would be lower than in other extrapulmonary specimens.
Although not always reported, studies may have included
participants receiving tuberculosis treatment. We previously
reported that in a sensitivity analysis limiting inclusion to studies
that involved participants not receiving tuberculosis treatment,
specificity increased from 86% to 89% (Kohli 2018). We considered
the type of culture used in the included studies because liquid
culture is more sensitive than solid culture (American Thoracic
Society 2000). Most studies used liquid culture or a combination
of solid and liquid culture. The single study evaluating Xpert Ultra
used liquid culture. Only two of the 15 studies (13%) evaluating
Xpert MTB/RIF exclusively used solid culture. Culture results may
also be negative owing to ineLicient specimen collection or errors
in sampling, diLering bacterial load, and contamination (Wright
2009b). Negative culture results in lymph node tuberculosis have
previously been reported (Fontanilla 2011).
Another reason for negative culture results is that there may have
been a decrease in live tuberculosis bacteria during processing
with N-acetyl-L-cysteine-sodium hydroxide, which is routinely
used to homogenize, decontaminate, and liquefy non-sterile
specimens, such as sputum, for mycobacterial culture (American
Thoracic Society 2000). Harsh decontamination practices have
been noted to contribute to false-negative culture results,
especially in paucibacillary specimens (FIND 2017). Standards
specify, "specimens collected from normally sterile sites may
be placed directly into the culture medium” (American Thoracic
Society 2000). CSF, pleural fluid, and lymph node aspirates are
usually considered to be sterile specimens. It is our understanding
that some laboratories do decontaminate sterile site specimens
as a precaution against non-sterile collection procedures. In this
review, 47% of the studies reported decontaminating lymph node
aspirates before culture inoculation. We did not have suLicient data
to further investigate laboratory practices.
In summary, several factors probably contributed to low Xpert MTB/
RIF specificity against culture in lymph node aspirate. The 'true'
specificity of Xpert MTB/RIF in lymph node aspirate is likely to
be higher owing to the aforementioned reasons. Xpert MTB/RIF
specificity was higher against a composite reference standard and
with application of latent class analysis, similar to that found in CSF,
pleural fluid, and other specimens (Table 2; Table 3).
We investigated the prevalence of extrapulmonary tuberculosis
(confirmed by culture) as a potential source of heterogeneity
because changes in disease prevalence have oNen been found to be
associated with other important changes, such as changes in the
disease spectrum, which may aLect diagnostic accuracy estimates
(Leeflang 2013). For Xpert MTB/RIF, for pleural fluid and lymph node
aspirate, we found that pooled sensitivity was higher in settings
with higher tuberculosis prevalence. In all analyses, for both Xpert
Ultra (CSF) and Xpert MTB/RIF (CSF, pleural fluid, and lymph node
aspirate), specificity in settings with higher tuberculosis prevalence
was similar or lower than in settings with lower tuberculosis
prevalence. Findings from additional analyses are available in the
previous version of this review (Kohli 2018).
Xpert Ultra and Xpert MTB/RIF testing for rifampicin resistance
(Summary of findings 4)
Xpert Ultra
Results of these studies indicate that in theory, for a population
of 1000 people where 100 have rifampicin resistance, 100 would
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be Xpert Ultra-positive (resistant): of these, zero (0%) would not
have rifampicin resistance (false-positives); and 900 would be
Xpert Ultra-negative (susceptible): of these, zero (0%) would have
rifampicin resistance.
Xpert MTB/RIF
Results of these studies indicate that in theory, for a population of
1000 people where 100 have rifampicin resistance, 105 would be
Xpert MTB/RIF-positive (resistant): of these, 8 (8%) would not have
rifampicin resistance; and 895 would be Xpert MTB/RIF-negative
(susceptible): of these, 3 (0.3%) would have rifampicin resistance.
For detection of rifampicin resistance in extrapulmonary
specimens, we found the sensitivity of Xpert Ultra (100%) and Xpert
MTB/RIF (96.7%) and the specificity of Xpert Ultra (100%) and Xpert
MTB/RIF (99.1%), to be comparable to estimates in pulmonary
specimens: sensitivity (96%) and specificity (98%) (Horne 2019).
We caution that the results for Xpert Ultra are based on only
four studies, involving 129 participants, 24 (18.6%) with rifampicin
resistance. Nonetheless, these findings suggest that the use of
Xpert Ultra and Xpert MTB/RIF in extrapulmonary specimens could
assist in rapid diagnosis of rifampicin-resistant tuberculosis and
early initiation of treatment for multidrug-resistant tuberculosis
(MDR-TB).
Notably, concerns have been raised about rapid drug susceptibility
testing (DST) methods, in particular automated mycobacteria
growth indicator tube (MGIT) 960 for tuberculosis drug resistance
using the recommended critical concentrations. As a priority, the
WHO is planning to re-evaluate the critical concentrations for
rifampicin (WHO 2018).
For Xpert Ultra, we found a high rate (36.1%) of indeterminate
rifampicin resistance results, all owing to trace call results. This
finding was expected since, for trace call results, rifampicin
resistance cannot be determined. Xpert Ultra incorporates two new
multi-copy amplification targets (IS6110 and IS1081). Trace call
indicates that only the multi-copy targets were detected, and not
the tuberculosis-specific regions in the rpoB gene. Resistance to
rifampicin has mainly been associated mainly with mutations in a
limited region of the rpoB gene (Telenti 1993).
People-important outcomes, such as mortality, are especially
relevant to patients, decision-makers, and the wider tuberculosis
community. While performing this systematic review, we did not
identify direct evidence of studies linking true-positives, false-
positives, true-negatives, and false-negatives to people-important
outcomes when either Xpert Ultra or Xpert MTB/RIF was used
to diagnose extrapulmonary tuberculosis. To our knowledge, for
pulmonary tuberculosis, there have been two systematic reviews
of randomized trials on the impact of the use of Xpert MTB/
RIF on health outcomes. Both reviews compared the eLect of
Xpert MTB/RIF and smear microscopy on all-cause mortality; Di
Tanna and colleagues summarized the accuracy of Xpert MTB/
RIF in an individual patient-level data meta-analysis (3 trials, 8143
participants) (Di Tanna 2019) and Haraka and colleagues performed
a random-eLects meta-analysis, (5 trials, 10,409 participants
(Haraka 2018; WHO Consolidated Guidelines (Module 3) 2020). In
both reviews, Xpert MTB/RIF did not show a statistically significant
eLect on all-cause mortality, although the direction of eLect was
towards mortality reduction. InsuLicient power to detect mortality
in randomized trials measuring the impact of diagnostic tests on
patient-important outcomes has been discussed previously as a
limitation of such trials (Di Tanna 2019; Schumacher 2019). Larger
sample sizes are needed to evaluate the eLect of Xpert MTB/RIF on
mortality, but achieving this is diLicult in pragmatic situations. For
example, Schumacher 2019 showed that a sample size of 31,000
participants would be needed if researchers were to plan a cluster-
randomized diagnostic trial using the baseline mortality and eLect
size demonstrated by the individual patient data from Di Tanna
2019.
This review represents the most comprehensive review of the
diagnostic accuracy of Xpert Ultra and Xpert MTB/RIF for
extrapulmonary tuberculosis in adults. For Xpert MTB/RIF, our
previous review (Kohli 2018) provides additional findings. These
reviews provide evidence that may help countries to make
decisions about scaling up the tests for programmatic management
of tuberculosis and drug-resistant tuberculosis. Although the
information in this review will help to inform such decisions,
other factors such as resource requirements and feasibility
(including stable electrical power supply, temperature control, and
maintenance of the cartridge modules) will also be important
considerations.
Strengths and weaknesses of the review
Completeness of evidence
This is a reasonably complete data set. We included any non-
English studies that we found from which we could obtain accuracy
data. However, we acknowledge that we may have missed some
studies despite the comprehensive search and our outreach to
investigators. We included eight common forms of extrapulmonary
tuberculosis in the review. However, for some of these forms,
such as disseminated tuberculosis, data were insuLicient to
allow us to determine summary accuracy estimates. We did not
include less common forms, such as cutaneous tuberculosis, ocular
tuberculosis, female genital tuberculosis, and tuberculosis of the
breast. We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses of Diagnostic Test Accuracy (PRISMA-
DTA) (McInnes 2018).
Accuracy of the reference standards used
In a systematic review of diagnostic test accuracy studies, the
reference standard is the best available test to determine the
presence or absence of the target condition. In this review, we
used two reference standards: culture and a composite reference
standard, both of which are known to be imperfect. While the
composite reference standard is designed to have improved
accuracy compared to culture alone, it may still lead to biased
accuracy estimates of the index test, depending on various factors
such as the accuracy of the diLerent components; decision
rules for combining them; prevalence of the target condition;
and conditional dependence between the components and the
index test (Schiller 2016). Conditional dependence between two
imperfect tests arises when both tests make the same false-positive
or false-negative errors more oNen than expected by chance
(Naaktgeboren 2013). Hence, conditional dependence may arise
between the index test and both reference standards we have
used, as they are imperfect. As a consequence, we may over-
or underestimate the diagnostic accuracy of the index tests. An
additional challenge with including a composite reference standard
is that the definition of the composite reference standard may
vary across studies, making it diLicult to interpret the accuracy
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estimates. To adjust for the imperfect accuracy of culture, we
applied a latent class model when evaluating Xpert MTB/RIF
sensitivity and specificity, for which there were a larger number
of studies. We added parameters for the sensitivity and specificity
of culture and terms for conditional dependence to adjust for the
dependence between Xpert MTB/RIF and culture among disease-
positive and disease-negative participants. In this way, we were
able to improve estimation of both the pooled sensitivity and
specificity of Xpert MTB/RIF, as well as between-study variability.
An adequate number of studies is needed for a suLiciently robust
model to estimate these additional parameters. We therefore found
that we were unable to do the same for meta-analyses of the
accuracy for Xpert Ultra owing to the small number of studies, many
of which had small sample sizes resulting in zero cell counts.
Several factors may have contributed to false-negative culture
results for the accuracy of the reference standard for lymph node
aspirate in particular, including ineLicient specimen collection
and overly harsh decontamination. For this particular analysis, we
were able to take advantage of the Bayesian estimation approach
to incorporate prior information on Xpert MTB/RIF and culture
specificity. This allowed us to make the best use of data from the
included studies and our knowledge of the performance of Xpert
MTB/RIF. We had insuLicient data to apply the latent class model
to data from the single study evaluating Xpert Ultra in lymph node
aspirates.
Establishing a diagnosis of extrapulmonary tuberculosis would
ideally include pursuing the diagnosis of pulmonary tuberculosis
as well, because participants with tuberculosis may have both
pulmonary and extrapulmonary tuberculosis and the lung may
be the only site where the presence of tuberculosis can be
established. Because of the diLiculties involved in diagnosing HIV-
associated tuberculosis, it is recommended that multiple cultures
from sputum and other types of specimens be evaluated in people
living with HIV (Bjerrum 2019; Shah 2016b). Given the limitations
in the reference standard, we recommend that future studies
consider using liquid culture because this is more sensitive than
solid culture, and that researchers obtain multiple specimens for
culture to confirm the diagnosis of extrapulmonary tuberculosis
(Drain 2019).
Most studies included in this review used culture-based DST (either
Löwenstein-Jensen (LJ) or mycobacteria growth indicator tube
(MGIT) 960) as the reference standard for detection of rifampicin
resistance. Concerns have been raised about rapid DST methods,
in particular automated MGIT 960, for tuberculosis drug resistance
using the recommended critical concentrations. The WHO is
planning to prioritise a re-evaluation of the critical concentrations
for rifampicin (WHO 2018).
We assessed the number of specimens with nontuberculous
mycobacteria (NTMs) that were Xpert Ultra-positive. In two studies
that reported 120 NTMs, Xpert Ultra was negative in all specimens.
In the previous version of this review, among 10 studies that
reported information comprising 141 NTMs, Xpert MTB/RIF was
negative in all specimens (Kohli 2018).
Quality and quality of reporting of the included studies
Risk of bias was low for the participant selection, index test, and
flow and timing domains and was high or unclear for the reference
standard domain (most of these studies performed specimen
decontamination before culture inoculation). A limitation was
that several studies included more than one specimen per
participant, which artificially inflated the sample size of the study
and may have led to overestimation or underestimation of the
accuracy estimates. In general, studies were fairly well reported,
although we corresponded with almost all primary study authors
to ask for additional data and missing information. In several
studies, accuracy data by site of extrapulmonary disease were
not reported, and in a minority of studies, blinding was not
reported. We strongly encourage the authors of future studies to
follow the recommendations provided in the updated Standards
for Reporting Diagnostic Accuracy (STARD) statement to improve
the quality of reporting (Bossuyt 2015).
Interpretability of subgroup analyses
We investigated potential sources of heterogeneity in the diLerent
extrapulmonary specimens. Importantly, we found slightly higher
Xpert Ultra accuracy in studies with concentrated cerebrospinal
fluid (CSF) in comparison to unconcentrated specimens. We note
that subgroup findings should be interpreted with caution, as
there were only three studies and a small number of tuberculous
meningitis cases included in these analyses.
Comparison with other systematic reviews
We are aware of several systematic reviews previously published
on this topic that estimated summary accuracy of Xpert MTB/
RIF for distinct forms of extrapulmonary tuberculosis, as well as
diLerent forms of extrapulmonary tuberculosis combined (Table
8). We identified one systematic review that estimated summary
accuracy of Xpert Ultra that found, for all forms of extrapulmonary
tuberculosis combined, pooled sensitivity and specificity of 85.1%
(95% CI 76.7 to 90.8%) and 95.7% (95% CI 87.9 to 98.6%), (7 studies;
1500 specimens) (Zhang 2020).
Compared with previous systematic reviews, our review extends
the date of the search for potential studies for inclusion. Our strict
inclusion criteria, e.g. excluding case-control studies, meant that
some of the studies included in other reviews were excluded from
ours.
Applicability of findings to the review question
For the participant selection domain, most studies had high or
unclear concern for applicability because either participants were
evaluated exclusively as inpatients in tertiary care or we were not
sure about the clinical settings. We therefore cannot be sure about
the applicability of our findings to primary care. Studies that take
place in referral settings may include participants whose condition
is more diLicult to diagnose than are seen at lower levels of the
health system. However, we recognize that classifying studies as
primary, secondary, or tertiary care may not adequately account
for diLerences in disease spectrum (Leeflang 2013). For the index
and reference test domains, most studies had low concern for
applicability.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In people presumed to have extrapulmonary tuberculosis, Xpert
Ultra and Xpert MTB/RIF may be helpful in confirming the diagnosis.
Sensitivity varies across diLerent extrapulmonary specimens, while
for most specimens specificity is high, the test rarely yielding a
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positive result for people without tuberculosis. For tuberculous
meningitis, Xpert Ultra had higher pooled sensitivity and lower
pooled specificity than Xpert MTB/RIF against culture. Xpert Ultra
and Xpert MTB/RIF had similar sensitivity and specificity for
rifampicin resistance.
Implications for research
Future studies should perform comparisons of diLerent tests,
including Xpert Ultra, as this approach will reveal which tests (or
strategies) yield superior diagnostic accuracy. For these studies, the
preferred study design is one in which all participants receive all
available diagnostic tests or are randomly assigned to receive one
or another of the tests. Studies should include children and people
living with HIV. Future research should acknowledge the concern
associated with culture as a reference standard in paucibacillary
specimens, and should consider ways to address this limitation.
Rapid point-of-care diagnostic tests for extrapulmonary
tuberculosis are critically needed. Research groups should focus
on developing diagnostic tests and strategies that use readily-
available clinical specimens, such as urine, rather than specimens
that require invasive procedures for collection.
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Country: Mexico
World Bank Income Classification: middle income
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ported
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results in-
terpreted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
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Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: neck rigidity, vomit-
ing, fever, headache and seizures
Age: 13 and older
Sex, female: 46%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 13
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: not
reported
Decontamination: no
Target condition and reference standard(s) TB meningitis
MGIT
Speciation: yes
Flow and timing  
Comparative  
Ajbani 2018 
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Ajbani 2018  (Continued)
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Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients suspected
of having extrapulmonary TB




Clinical setting: tertiary care centre (laboratory-based
evaluation)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 67
Laboratory level: central
Country: Saudi Arabia
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB
Reference standards for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-
drug susceptibility testing (DST)
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Al-Ateah 2012 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Comparative  
Notes Site of extrapulmonary disease was not reported for




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Al-Ateah 2012  (Continued)
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: suspected tuberculosis
adenitis




Clinical setting: tertiary referral centre, inpatients and
outpatients, most participants (84%) were seen as outpa-
tients, high percentage received prior testing for tubercu-
losis, see note
Past history of TB: 24%
Patients on anti-TB treatment: 21%
Number of specimens evaluated: 99
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert Ultra
Target condition and reference standard(s) Target condition: lymph node tuberculosis, specimen col-
lected by fine-needle biopsy and core-needle biopsy
Reference standard: MGIT
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Decontamination: no
Flow and timing  
Comparative  
Notes "A high proportion of participants had tuberculosis inves-
tigations prior to referral and the frequency of positive re-
sults were: sputum Xpert 3/22, urinary LAM 1/5, and tuber-
culosis culture (5/15) (by site: urine 0/1, blood 1/2, sputum
4/12, lymph node 0/1 (tissue)). Chest x-ray had been per-
formed in 36% and reported as ‘suggestive of tuberculo-




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
Antel 2020  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection not
reported, retrospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected meningitis
Age: > 16 years
Sex, female: not reported
Children: no
HIV infection: 100%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 101
Laboratory level: central, university medical centre
Country: Brazil
Azevedo 2018 
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World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: not
reported
Target condition and reference standard(s) TB meningitis










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
Azevedo 2018  (Continued)
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DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients
presenting with symptoms of meningitis being evaluat-
ed for cryptococcal meningitis. All persons who were CSF
cryptococcal antigen-negative had a TB workup




Clinical setting: tertiary care centre (Inpatient)
Past history of TB: 22%
Participants on anti-TB treatment: yes, 11%
Number of specimens evaluated: 80
Laboratory level: central
Bahr 2015 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Country: Uganda
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  





Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Bahr 2015  (Continued)
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Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients
presenting with symptoms of meningitis being eval-
uated for cryptococcal meningitis. All persons who
were CSF cryptococcal antigen-negative had a TB
workup
Age: TB meningitis: median 32 years (IQR 30 to 34);




Clinical setting: tertiary care centre (inpatient)
Past history of TB: 6%
Bahr 2017 
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Participants on anti-TB treatment: yes, 2%
Number of specimens evaluated: 129
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF and Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard for TB detection: MGIT




Flow and timing  
Comparative  
Notes This study evaluated Xpert MTB/RIF and Xpert MTB/
RIF Ultra.





Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
Bahr 2017  (Continued)
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DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with exudative
ascites (lymphocytic ascites and ascitic fluid protein con-
tent > 2.5 g/dL)
Age: mean 43 years (standard deviation (SD) 15 years)
Sex, female: 29%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre (outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 28
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: not re-
ported
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: peritoneal TB
Reference standard for TB detection: LJ and MGIT




Flow and timing  
Comparative  
Notes "The study included only smear-negative specimens,
however, the study excluded specimens that were nega-
tive for malignant cells on prior testing (i.e. cytology)"
Methodological quality
Bera 2015 
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Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Bera 2015  (Continued)
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Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with enlarged
lymph nodes not responding to a 2-week course of antibi-
otics and clinically suspected for TB lymphadenitis
Age: ≤ 14 years: 15%; > 14 years: 85%
Sex, female: 57%
Children: 15%
HIV infection: not reported
Clinical setting: tertiary care centres (multicentre study)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 213
Laboratory level: intermediate
Country: Ethiopia
World Bank Income Classification: low income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: LJ and Gottsascker
and BacT/ALERT 3D




Flow and timing  
Comparative  
Biadglegne 2014 
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Notes Total number of participants: 231; included: 213 (exclud-




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
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Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion of
extrapulmonary TB
Age: median 34 (IQR 30 to 52)
Sex, female: 46%
Children: no
HIV infection: yes, 8%
Clinical setting: university hospital (inpatient and outpa-
tient)
Past history of TB: yes, 11%
Patients on anti-TB treatment: no
Number of specimens evaluated: 20
Laboratory level: central
Country: Switzerland
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for
lymph node aspirate, bone and joint fluid, urine, peritoneal
fluid, and lymph node tissue; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, lymph node
TB, pericardial TB, genitourinary TB, bone and joint TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Blaich 2014 
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Decontamination: yes, NALC-NaOH for all specimens except
pleural fluid and CSF
Flow and timing  
Comparative  
Notes Study included 1 bone marrow specimen that consisted of




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpreta-
tion differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
No    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  High risk  
Blaich 2014  (Continued)
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Are there concerns that the target condition as defined by the ref-
erence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 45 years, range 5 to 83 years
Sex, female: 31%
Children: yes, 15%
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 261
Laboratory level: central
Country: Spain
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB
meningitis, peritoneal TB, pericardial TB, genitouri-
nary TB
Causse 2011 
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Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: not re-
ported
Speciation: yes
Decontamination: yes, NALC-NaOH for all specimens
except pleural fluid and CSF






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Causse 2011  (Continued)
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Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, prospective, and consecutive
Patient characteristics and setting Presenting signs and symptoms: patients with evi-
dence of pleural effusion demonstrated by X-ray, sus-
pected to have tuberculosis pleurisy




Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 78
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Che 2017 
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Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
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For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients who had
symptoms suggestive of urinary tract TB or a urine ab-
normality




Clinical setting: multicentre, hospital-based
Past history of TB: 31%
Participants on anti-TB treatment: no
Number of specimens evaluated: 302
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
Chen 2019 
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WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) Genitourinary TB










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
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For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected TB meningitis admitted to the neurology ward
Age: adults, range 20 to 41 years
Sex, female: not reported
Children: not reported
HIV infection: 18%
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Participants on anti-TB treatment: 1 participant had
received treatment
Number of specimens evaluated: 11
Laboratory level: central
Country: Uganda
World Bank Income Classification: low
High TB burden: no
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF and Xpert Ultra
Chin 2019 
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WHO SOP or manufacturer's protocol followed: no




Flow and timing  
Comparative  
Notes "CSF (2  ml) should be slowly pipetted directly into
the Xpert Ultra cartridge. CSF should only be dilut-
ed with the manufacturer-supplied sample reagent if
less than 2  ml of CSF are available for Xpert Ultra test-
ing." See the following article for full description of




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: clinical symptoms and
radiographic evidence of a pleural effusion
Age: median 46 years (IQR 33 to 57)
Sex, female: 20%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre (Inpatient and out-
patient)
Past history of TB: yes, 18%
Patients on anti-TB treatment: not reported
Number of specimens evaluated against culture: 142
Christopher 2013 
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World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for
pleural tissue, no for pleural fluid
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results in-
terpreted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with
headache and objective meningism





Past history of TB: not reported
Cresswell 2018 
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Participants on anti-TB treatment: not reported
Number of specimens evaluated: 118
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: not
reported




Flow and timing  
Comparative  





Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Cresswell 2018  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Unclear
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected meningitis (headache for > 3 days or altered
mental status (Glasgow Coma Scale < 15) with clinical
signs of meningism at examination, i.e. neck stiffness
or Kernig’s sign
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Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 204
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIFand Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? No    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: all participants un-
dergoing endobronchial ultrasound (EBUS) for medi-
astinal lymphadenopathy
Dhasmana 2014 
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Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 116
Laboratory level: central
Country: United Kingdom
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
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Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, retrospective
Dhooria 2016 
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Patient characteristics and setting Presenting signs and symptoms: patients with en-
larged mediastinal or hilar lymph nodes (≥ 1 cm in
short axis) on computed tomography of the chest who
underwent EBUS-guided transbronchial needle aspi-
ration




Clinical setting: tertiary care centre (outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 147
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Dhooria 2016  (Continued)
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Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    




Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Study characteristics
Patient Sampling Cross-sectional, random, prospective
Patient characteristics and setting Presenting signs and symptoms: patients aged 16
years or older with suspected tuberculous meningi-
tis based on clinical and CSF findings (clear or mildly
cloudy CSF, plus > 5 days of symptoms consistent with
tuberculous meningitis8 or low CSF glucose or raised
CSF lactate concentrations)





Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 205
Laboratory level: central
Country: Vietnam
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: no
High MDR-TB burden: yes
Index tests Xpert MTB/RIF and Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes










Risk of bias Applicability
concerns
Donovan 2020 
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Donovan 2020  (Continued)
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Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients found to be smear-
negative on prior testing with radiographic evidence of pleur-
al effusion and those subsequently undergoing thoracocente-
sis and pleural biopsy




Clinical setting: 4 tertiary care centres (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 126
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: LJ and MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Du 2015 
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Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Study included specimens found to be smear-negative on pri-
or testing. In the present study, 4 specimens were smear-posi-
tive specimens for pleural fluid and 15 were smear-positive for
pleural tissue
The reference standard for both pleural fluid and pleural tis-




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not
match the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Unclear    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard re-
sults interpreted without knowledge of the results of the index test?
Yes    
Du 2015  (Continued)
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Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional. consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected pleural TB based on clinical history and radio-
logic evidence of pleural effusion
Age: 32.7 years ± 13.6
Sex, female: 31%
Children: no
HIV infection: not reported
Clinical setting: not reported
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: not reported
Laboratory level: not reported
Country: Egypt
World Bank Income Classification: middle income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
Specimens processed according to manufacturer's in-
structions
El-Din 2019 
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Target condition and reference standard(s) Pleural TB
Confirmed TB was defined if acid-fast bacilli were
detected by any mean (microscopic evaluation/my-
cobacterial culture (type not reported)) of either
pleural tissue or pleural fluid
Speciation: not reported
Decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
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For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients
with clinical suspicion of tuberculosis




Clinical setting: tertiary care centre
Past history of TB: no
Patients on anti-TB treatment: no
Number of specimens evaluated: 74
Laboratory level: central
Country: Malawi
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Feasey 2013 
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Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: disseminated TB (blood)
Reference standard for TB detection: Bactec Myco/F
Lytic culture
Reference standard for rifampicin resistance: not re-
ported
Speciation: yes
Decontamination: yes, NALC-NaOH for sputum speci-
mens






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Feasey 2013  (Continued)
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Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with undi-






Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated against culture: 24




World Bank Income Classification: middle income
Friedrich 2011 
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High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT
Speciation: yes
Decontamination: yes, NALC-NaOH






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
Friedrich 2011  (Continued)
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DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with clinical
suspicion of TB




Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: 18%
Patients on anti-TB treatment: yes, 3%




Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
World Bank Income Classification: middle income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
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Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection not
reported, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with suspi-
cion of bone and joint TB




HIV infection: not reported
Clinical setting: tertiary care centre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: yes, 100%
Number of specimens evaluated: 60
Gu 2015 
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Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: bone and joint TB
Reference standard for TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    High
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Gu 2015  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion
of TB due to symptoms such as fever, cough or weight loss
or both, or because they were not responding to initial
therapy for other diseases




Clinical setting: national reference laboratory
Past history of TB: not reported
Hanif 2011 
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Patients on anti-TB treatment: not reported
Number of specimens evaluated: 29
Laboratory level: central
Country: Kuwait
World Bank Income Classification: middle income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol: yes for lymph node
aspirate, pleural fluid, and urine; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis, lymph node TB, pleural
TB, genitourinary TB
Reference standard for TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Hanif 2011  (Continued)
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Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
No    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  High risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients who were of-
fered lumbar puncture as a part of routine care for sus-
pected brain infection
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HIV infection: 31%
Clinical setting: multicentre, hospital-based (both refer-
ral and local)
Past history of TB:
Participants on anti-TB treatment:
Number of specimens evaluated: 610
Laboratory level: central in South Africa
Country: South Africa, Vietnam, Indonesia
World Bank Income Classification: middle
High TB burden: South Africa yes; Vietnam yes; Indonesia
yes
High TB/HIV burden: South Africa yes; Vietnam no; In-
donesia yes
High MDR-TB burden: South Africa yes; Vietnam yes; In-
donesia yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no (as
performed in Nhu 2014)
Target condition and reference standard(s) TB meningitis
CRS: clinical TB meningitis, diagnosis (definite, probable
and possible TB meningitis); MGIT (MODS Indonesia)
Speciation yes
Decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Heemskerk 2018  (Continued)
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Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results in-
terpreted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected M tuberculosis or nontuberculous mycobacter-
ial infection on the basis of clinical criteria
Hillemann 2011 
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Age: not reported
Sex, female: not reported
Children: 5%
HIV infection: not reported
Clinical setting: national reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 200
Laboratory level: central
Country: Germany
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: yes, donation of index
test
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, genitouri-
nary TB
Reference standard for TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Hillemann 2011  (Continued)
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Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Iram 2015 
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Patient characteristics and setting Presenting signs and symptoms: patients with clinical
presentation, radiological findings, and histopatho-
logical evidence of extrapulmonary TB




Clinical setting: teaching hospital
Past history of TB: 53%
Patients on anti-TB treatment: yes, 3%
Number of specimens evaluated: 18
Laboratory level: intermediate
Country: Pakistan
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: no
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, peritoneal TB
Reference standard for TB detection: LJ
Reference standard for rifampicin resistance: LJ-DST
Speciation: not reported
Decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Iram 2015  (Continued)
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Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Patient Sampling Cross-sectional, consecutive, retrospective
Patient characteristics and setting Presenting signs and symptoms: not reported




Clinical setting: tertiary care centre
Past history of TB: 9%
Patients on anti-TB treatment: no
Number of specimens evaluated: 1209
Laboratory level: central
Country: Korea
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB, TB
meningitis, peritoneal TB, pericardial TB, bone and
joint TB, genitourinary TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Kim 2015a  (Continued)
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Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Study characteristics
Patient Sampling Cross-sectional, manner of participant selection not re-
ported, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with suspect-
ed extrapulmonary TB
Age: mean 48 years (SD 10 years)
Sex, female: 39%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 414
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for
pleural fluid, bone and joint TB fluid, urine, and peri-
toneal fluid; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal
TB, bone and joint TB, genitourinary TB
Reference standard for TB detection: LJ
Reference standard for rifampicin resistance: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
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Item Authors' judge-
ment
Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results in-
terpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Li 2017  (Continued)
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Patient Sampling Cross-sectional, manner of patient selection not re-
ported, retrospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected pleural TB based on standard clinical and ra-
diological criteria, including a persistent cough of
2 weeks or more, unexplained fever for 2 weeks or
more, weight loss, and radiological evidence of pleur-
al effusion
Age: mainly adult; 12% < 25 years
Sex, female: 22%
Children: not reported
HIV infection: not reported
Clinical setting: national TB referral hospital
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 219
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) Pleural TB
CRS: clinically diagnosed and microbiologically con-
firmed






Risk of bias Applicability
concerns
Liang 2019 
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Liang 2019  (Continued)
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Study characteristics
Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with suspicion
of lymph node TB
Age: < 5 years 4%; 5 to 20 years 13%; > 20 years 83%
Sex, female: 58%
Children: estimated < 15%
HIV infection: 19%
Clinical setting: university hospital (inpatient and outpa-
tient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 48
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MTBDRplus
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes "It is unlikely that our patient cohort had exacerbated dis-
ease compared to patients presenting at primary health
care clinics, as these patients are routinely referred from
the primary health care clinic to the referral centre for
FNAB (fine needle aspiration biopsy)"
Ligthelm 2011 
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Ligthelm 2011  (Continued)
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Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with sus-
pected pleural TB based on clinical signs and symp-
toms and radiological evidence of a pleural effusion
that was considered large enough for a pleural biopsy




Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 116
Laboratory level: central
Country: Uganda
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: LJ and MGIT
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Lusiba 2014  (Continued)
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection by
convenience, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with clinical
suspicion of TB
Age: median 52 years
Sex, female: 40%
Children: 7%
HIV infection: not reported
Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 67
Laboratory level: central
Country: France
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, bone and
joint TB, peritoneal TB, genitourinary TB
Reference standard for TB detection: MGIT and Colet-
sos slants
Reference standard for rifampicin resistance: MGIT-
DST
Malbruny 2011 
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Speciation: yes
Decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? No    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
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Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients presumed to
have pleural TB with any symptoms, including cough,
fever, night sweats, loss of weight, haemoptysis, and chest
pain, along with features consistent with a pleural effu-
sion on chest X-ray
Age: definitive TB: median 39 years (IQR 29 to 55 years);




Clinical setting: tertiary care hospital
Past history of TB: 13%
Patients on anti-TB treatment: no
Number of specimens evaluated against culture: 76




World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
Meldau 2014 
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WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard for TB detection: MGIT
Reference standard for rifampicin resistance: MGIT-DST
Speciation: yes
Decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
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Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with any TB
symptoms including any cough, fever, night sweats,
loss of weight, haemoptysis or chest pain or both, and
features consistent with a pleural effusion on chest x-
ray
Age: Adult; median 39 years (IQR 28 to 57)
Sex, female: 11%
Children: not reported
HIV infection: definite TB: 7%
Clinical setting: tertiary care hospital
Past history of TB: 6%
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 149
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle
High TB burden: yes
Meldau 2019 
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High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF and Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) Pleural tuberculosis
Composite reference standard: MGIT culture and/or
histology






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients presenting
with a suspected diagnosis of TB meningitis





Past history of TB: 30%
Participants on anti-TB treatment: no
Number of specimens evaluated: 37
Metcalf 2018 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Laboratory level: central
Country: Peru
World Bank Income Classification: middle income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) TB meningitis
MGIT, Ogawa
Speciation: not reported






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
Metcalf 2018  (Continued)
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DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with clinical suspicion
of extrapulmonary TB
Age: < 14 years 13%; 15 to 45 years 52%; > 45 years 34%; range 2
months to 78 years
Sex, female: 44%
Children: 13%
HIV infection: not reported
Clinical setting: tertiary care centre (inpatient and outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
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World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningitis,
bone and joint TB, genitourinary TB
Reference standard TB detection: LJ
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes Patients on treatment may have been included, although the
number was not reported: "Of the two specimens that were
smear-positive and smear-negative on both culture and Xpert,
one was pleural fluid from a patient who had been receiving Cat-
egory II anti-tuberculosis treatment for 2 months and the other




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the
results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
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Could the conduct or interpretation of the index test have in-
troduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Unclear    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard re-
sults interpreted without knowledge of the results of the index
test?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients suspected
of having TB meningitis with at least 5 days of menin-
gitis symptoms, nuchal rigidity, and CSF abnormali-
ties
Age: > 18 years
Sex, female: not reported
Children: no
HIV infection: 21%
Clinical setting: university hospital
Nhu 2014 
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Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 379
Laboratory level: central
Country: Vietnam
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: no
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: yes, donation of index
test
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT




Flow and timing  
Comparative  




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Nhu 2014  (Continued)
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Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 54 years, range 1 to 99 years
Sex, female: 47%
Children: 3%
HIV infection: not reported
Ozkutuk 2014 
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Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 1022
Laboratory level: central
Country: Turkey
World Bank Income Classification: middle
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB
meningitis, genitourinary TB, bone and joint TB, peri-
cardial TB, peritoneal TB
Reference standard TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Ozkutuk 2014  (Continued)
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Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with pres-
ence of a large pericardial effusion amenable to safe
pericardiocentesis (> 10 mm echo-free space around
the heart in diastole)
Pandie 2014 
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Clinical setting: 4 district hospitals and 1 tertiary cen-
tre (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 134
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pericardial TB
Reference standard TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
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Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with clinical
suspicion of meningitis
Patel 2013 
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Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: 31%
Patients on anti-TB treatment: no
Number of specimens evaluated: 59
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT




Flow and timing  
Comparative  




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
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Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective and retro-
spective
Peñata 2016 
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Patient characteristics and setting Presenting signs and symptoms: patients with clinical
suspicion of extrapulmonary tuberculosis




Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 236
Laboratory level: intermediate
Country: Colombia
World Bank Income Classification: middle income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, pleural TB, TB
meningitis, peritoneal TB, pericardial TB, bone and
joint TB
Reference standard TB detection: Ogawa medium










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Peñata 2016  (Continued)
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Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
No    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
No    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  High risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Study characteristics
Patient Sampling Study design unclear, manner of patient selection not
reported, retrospective
Patient characteristics and setting Presenting signs and symptoms: Smear-negative ex-
trapulmonary patients
Age: adult
Sex, female: not reported
Children: 0%
HIV infection: not reported
Clinical setting: laboratory-based evaluation
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: CSF 3; pleural fluid
24; urine 24; bone or joint fluid 24
Laboratory level: central
Country: Spain
World Bank Income Classification: high
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) Target condition: TB meningitis, pleural TB, genitouri-
nary TB, bone or joint TB
Reference standard TB detection: MGIT and LJ culture
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes The specimens were collected between May 1999 and




Risk of bias Applicability
concerns
Perez-Risco 2018 
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Unclear    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Perez-Risco 2018  (Continued)
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Study characteristics
Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with a febrile illness
and chronic respiratory symptoms, pleural effusion, chronic
abdominal pain or ascites, chronic meningitis, or other symp-
toms suggestive of extrapulmonary TB




Clinical setting: tertiary care centre
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: CSF: 77; pleural: 50
Laboratory level: central
Country: Madagascar
World Bank Income Classification: low income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) TB meningitis; pleural TB
Reference standard: LJ
Composite reference standard: proven and probable cases
(culture-positive cases or clinical response to anti-TB treat-
ment without any other diagnosis or other treatment)
Speciaiton: yes
decontamination: yes
Flow and timing  
Comparative  
Notes The criteria of Marais were used for the diagnosis of tubercu-
lous meningitis (Marais 2010). This classification and strati-
fication of cases was independent of Xpert MTB/RIF and the
panel was blinded to these results.
Rakotoarivelo 2018 
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Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Unclear    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard re-
sults interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
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Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection not report-
ed, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with high suspi-
cion of pleural TB. Enrolment was based on standard clini-
cal and radiological criteria, including a persistent cough of
2 weeks or longer, unexplained fever for 2 weeks or longer,
unexplained weight loss with or without night sweats, chest
pain, and radiological evidence of pleural effusion
Age: men: mean 42 years (SD 19 years); women: mean 39




Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 161
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard TB detection: MGIT
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Decontamination: yes, NALC-NaOH






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpreta-
tion differ from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the ref-
erence standard does not match the question?
    Low concern
Rufai 2015  (Continued)
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DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection not
reported, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with clinical
or radiological suspicion of abdominal TB
Age: men: mean 41 years (SD 19 years); women: mean




Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 67
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: peritoneal TB
Reference standard TB detection: MGIT
Rufai 2017a 
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
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Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, manner of participant selection not
reported, prospective
Patient characteristics and setting Presenting signs and symptoms: fatigue, malaise,
low-grade fever, confusion, nausea and vomiting,
lethargy, irritability, and unconsciousness
Age: men: mean 38 years (SD 10 years); women: mean
34 years (SD 22 years)
Sex, female: 41%
Children: 6%
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: yes, 4%
Number of specimens evaluated: 267
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Rufai 2017b 
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Target condition and reference standard(s) Target condition: TB meningitis
Reference standard TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Rufai 2017b  (Continued)
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Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective





Clinical setting: university hospital
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 51
Laboratory level: intermediate
Country: Poland
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Safianowska 2012 
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Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB
meningitis, peritoneal TB, pericardial TB, genitouri-
nary TB, bone and joint TB
Reference standard TB detection: LJ










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
No    
Safianowska 2012  (Continued)
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For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
No    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  High risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, manner of selection not reported, prospective
Patient characteristics and setting Presenting signs and symptoms: patients presenting with
1 or more superficial lymph nodes (i.e. cervical, axillary,
and inguinal nodes) measuring > 2 cm in largest diame-
ter and persisting for more than 1 month, with or without
constitutional symptoms of fever, anorexia, and weight
loss





Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 261
Laboratory level: central
Country: Pakistan
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: no
Sarfaraz 2018 
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High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) Lymph node TB, tissue
MGIT; LJ











Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not
match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Sarfaraz 2018  (Continued)
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DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Unclear    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: not reported
Age: median 39 years, range < 1 year to 96 years
Sex, female: 45%
Children: 4%
HIV infection: not reported
Clinical setting: reference laboratory
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 696
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden: yes
Scott 2014 
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High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
for lymph node aspirate, pleural fluid, and peritoneal
fluid; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB
meningitis, peritoneal TB
Reference standard TB detection: MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
Scott 2014  (Continued)
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with clinical
suspicion of EPTB
Age: mean 35 years (SD 15 years)
Sex, female: 50%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
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World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol: yes for body
fluids and LN tissue; no for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB
meningitis, peritoneal TB, pericardial TB, genitouri-
nary TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection:
LJ-DST
Speciation: yes
Decontamination: yes, NALC-NaOH (for all specimens
except CSF, pleural fluid, and urine)






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Sharma 2014  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: women being evalu-
ated for infertility and suspected to have TB
Age: mean 29 years, range 19 to 41 years
Sex, female: 100%
Children: no
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Sharma 2016 
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Number of specimens evaluated: 240
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: genitourinary TB
Reference standard TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Sharma 2016  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, random selection, prospective
Patient characteristics and setting Presenting signs and symptoms: participants with
persistent cough and unexplained fever for 2 weeks or
more, unexplained weight loss, pleuritic chest pain,
anorexia – among others, positive Mantoux test and
the suggestive radiological
findings




Clinical setting: university hospital
Sharma 2018 
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Past history of TB:
Participants on anti-TB treatment: no
Number of specimens evaluated: 78
Laboratory level: central
Country: India
World Bank Income Classification: middle-income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol: yes
Target condition and reference standard(s) Pleural tuberculosis, pleural fluid
Composite reference standard: combination of smear,
culture, clinical findings, radiology, histology, cytol-
ogy, response to ATT
Speciation: yes
decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
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If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, manner of patient selection not reported, prospective
Patient characteristics and setting Presenting signs and symptoms: presented with signs and symptoms
concerning for TB meningitis and already received a lumbar puncture
as part of routine care
Age: age 18 years and older; TB meningitis culture positive: median 35




Clinical setting: university teaching hospital
Siddiqi 2019 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
Past history of TB: 20%
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 550
Laboratory level: central
Country: Zambia
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) TB meningitis
MGIT
Rifampicin resistance
Samples found to be rifampin resistant by Xpert MTB/RIF had confirma-
tory DST for rifampin and isoniazid conducted separately
Speciation: yes
Decontamination: No
Flow and timing  
Comparative  
Notes After a lumbar puncture was completed, study staL identified patients
from the microbiology laboratories who had 3 ml of excess CSF remain-
ing after routine testing composed of Gram stain, India ink stain, crypto-
coccal antigen testing, and bacterial culture on a blood agar plate.
A composite reference standard was defined as probable TB meningi-
tis = patients with a CSF white blood cell count between 10 and 500, CSF
total protein of 100 mg/dl, and CSF glucose of 40 mg/dl. These values
were adapted from a uniform case definition of probable TBM for use in
clinical research (Marais 2010). However, sensitivity and specificity were
only determined using culture as the reference standard
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Unclear    
Was a case-control design avoided? Yes    
Siddiqi 2019  (Continued)
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Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and set-
ting do not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or
interpretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Unclear    
Could the reference standard, its conduct, or its inter-
pretation have introduced bias?
  Low risk  
Are there concerns that the target condition as defined
by the reference standard does not match the ques-
tion?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with symp-
toms such as pain, swelling in the joints, tenderness,
effusion, restriction of movements, and systematic
symptoms such as fever, loss of weight/appetite, el-
evated erythrocyte sedimentation rate, and cough,
breathlessness, and history of TB
Age: osteoarticular TB: median 51 years (range 16 to
86)
Sex, female: osteoarticular TB: 55%
Children: no
HIV infection: 0%
Clinical setting: national level TB referral centre
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 166
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF and Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes
Target condition and reference standard(s) Bone or joint TB, fluid
MGIT
Composite reference standard: clinical, laboratory,
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Sun 2019  (Continued)
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Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with signs and
symptoms suggestive of extrapulmonary TB




Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 215
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for
lymph node tissue and pleural tissue; no for pleural fluid,
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Target condition and reference standard(s) Target condition: pleural TB, lymph node TB, TB meningi-
tis, peritoneal TB, pericardial TB, genitourinary TB, bone
and joint TB
Reference standard TB detection: LJ and MGIT










Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results
of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation
differ from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condi-
tion?
Yes    
Were the reference standard results interpreted without knowledge of
the results of the index tests?
Yes    
Suzana 2016  (Continued)
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For rifampicin resistance testing, were the reference standard results
interpreted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have
introduced bias?
  Low risk  
Are there concerns that the target condition as defined by the refer-
ence standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: people with pre-
sumptive lymph node TB
Age: ≤ 15 years 15%; > 15 years 85%
Sex, female: 53%
Children: 15%
HIV infection: not reported
Clinical setting: university hospital (outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 136
Laboratory level: central
Country: Ethiopia
World Bank Income Classification: low income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Tadesse 2015 
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Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard TB detection: LJ




Flow and timing  
Comparative  




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Unclear    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
Tadesse 2015  (Continued)
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For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients with a pleural effusion
needing thoracentesis




Clinical setting: secondary health facility (inpatient)
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 85
Laboratory level: central
Country: Brazil
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Trajman 2014 
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Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB
Reference standard TB detection: MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: not reported
Decontamination: no
Flow and timing  
Comparative  
Notes Patients were excluded if they had bleeding disorders contraindi-
cating thoracentesis, if the fluid volume was insufficient for stor-
age, or if a final diagnosis could not be ascertained. One of the
main limitations of the study was the high number of presumptive
(non-confirmed) cases. The number of exclusions was also high:
out of 203 eligible patients, 110 were excluded: 21 did not have a
final diagnosis and 89 did not have sufficient fluid to store. "Cul-
tures of pleural tissue, which could significantly improve accuracy
of diagnosis, were not performed"




Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do
not match the review question?
    Low concern
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of
the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have
introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or inter-
pretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Trajman 2014  (Continued)
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target
condition?
Yes    
Were the reference standard results interpreted without knowl-
edge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard
results interpreted without knowledge of the results of the in-
dex test?
Yes    
Could the reference standard, its conduct, or its interpreta-
tion have introduced bias?
  Low risk  
Are there concerns that the target condition as defined by
the reference standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and refer-
ence standard?
Yes    
Did all patients receive the same reference standard? Unclear    
Were all patients included in the analysis? No    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: patients meeting the following cri-
teria: previously TB-treated cases with both positive and negative
smears; failure of Cat-I and Cat-II TB drugs; all smear-positive cases
that remained positive by the end of the second month of TB treat-
ment; TB/HIV co-infection cases; seriously ill patients; contacts of
MDR-TB patients
Age: mean 34 years (SD 19 years), range 3 to 80 years
Sex, female: 51%
Children: 14%
HIV infection: not reported
Clinical setting: tertiary care centre
Past history of TB: 60%
Patients on anti-TB treatment: yes, percentage not reported
Number of specimens evaluated: 168
Ullah 2017 
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Laboratory level: central
Country: Pakistan
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: no
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB, TB meningitis, peritoneal TB, peri-
cardial TB
Reference standard TB detection: Middlebrook 7H10




Flow and timing  
Comparative  
Notes Study included a highly selective population that met specified cri-
teria: previously TB-treated cases with both positive and negative
smears; failure of Cat-I and Cat-II TB drugs; all smear-positive cases
that remained positive by the end of the second month of TB treat-
ment; TB/HIV co-infection cases; seriously ill patients; contacts of
MDR-TB patients
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   High risk  
Are there concerns that the included patients and set-
ting do not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Ullah 2017  (Continued)
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Were the index test results interpreted without knowledge
of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct, or in-
terpretation differ from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the tar-
get condition?
Yes    
Were the reference standard results interpreted without
knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference stan-
dard results interpreted without knowledge of the results
of the index test?
Yes    
Could the reference standard, its conduct, or its inter-
pretation have introduced bias?
  Low risk  
Are there concerns that the target condition as defined
by the reference standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and
reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: suspected extrapulmonary TB based on
symptoms: brain: irritability, restlessness, neck stiffness, headache persis-
tent for 2 to 3 weeks, vomiting, seizures, changes in mental condition or
behaviour; intestinal tract, abdomen: abdominal pain, diarrhoea; lymph
nodes: enlargement of lymph nodes, mass formation in the neck; car-
diorespiratory: shortness of breath, hypertension, chest pain, dyspnoea;
Vadwai 2011 
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endometrium: pelvic pain, pelvic mass, irregular periods, infertility; skin
(cutaneous): visible presence of ulcers or lesions, tender nodules




Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 60
Laboratory level: central
Country: India
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for pleural fluid, peri-
toneal fluid, pericardial fluid; no for CSF
Manufacturer's involvement: yes, in design, analysis, or manuscript pro-
duction (David Alland is among a group of co-investigators who invent-
ed molecular beacons and receive income from licensees, including to
Cepheid, for M tuberculosis detection)
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal TB, pericardial TB
Reference standard TB detection: LJ and MGIT
Reference standard rifampicin resistance detection: MGIT-DST
Speciation: yes
Decontamination: yes, NALC-NaOH
Flow and timing  
Comparative  
Notes "Patients were enrolled only if they could provide detailed clinical history
and radiological and histology/cytology reports, along with an adequate
amount of specimen material"
Methodological quality
Item Authors' judgement Risk of bias Applicability con-
cerns
Vadwai 2011  (Continued)
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients en-
rolled?
Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced
bias?
  Low risk  
Are there concerns that the included patients and
setting do not match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowl-
edge of the results of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test
have introduced bias?
  Low risk  
Are there concerns that the index test, its conduct,
or interpretation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the
target condition?
Unclear    
Were the reference standard results interpreted with-
out knowledge of the results of the index tests?
Yes    
For rifampicin resistance testing, were the reference
standard results interpreted without knowledge of the
results of the index test?
Yes    
Could the reference standard, its conduct, or its in-
terpretation have introduced bias?
  Unclear risk  
Are there concerns that the target condition as de-
fined by the reference standard does not match the
question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test
and reference standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Vadwai 2011  (Continued)
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Patient Sampling Cross-sectional, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: HIV-infected patients
with suspicion of LNTB




Clinical setting: tertiary care centre (inpatient and
outpatient)
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 344
Laboratory level: central
Country: South Africa
World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: lymph node TB
Reference standard TB detection: MGIT




Flow and timing  
Comparative  
Van Rie 2013 
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Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Van Rie 2013  (Continued)
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Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: adults who were of-
fered lumbar puncture as a part of routine care for
suspected brain infection; TB symptoms, chest pain,
radiological evidence of pleural effusion, thoraco-
scopic examination that suggested TB
Age: 15 years and older; pleural tuberculosis TB 37
years (range, 15 to 89); TB meningitis 33 years (range,
15 to 83)




Clinical setting: national level tuberculosis referral
centre
Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: not reported
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Prevalence of TB cases in the study:
Index tests Xpert MTB/RIF and Xpert Ultra
Target condition and reference standard(s) LJ and MGIT
Composite reference standard for pleural TB: com-
posed of clinical, laboratory, histopathological, and
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Speciation: not reported
Decontamination: no






Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Wang 2019  (Continued)
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Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Unclear    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, consecutive, prospective
Patient characteristics and setting Presenting signs and symptoms: suspected pleural tu-
berculosis





Past history of TB: not reported
Participants on anti-TB treatment: not reported
Number of specimens evaluated: 139
Laboratory level: central
Country: China
World Bank Income Classification: middle income
High TB burden country: yes
High MDR-TB burden country: yes
High TB/HIV burden country: yes
Wang 2020 
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Index tests Xpert MTB/RIF and Xpert Ultra
WHO SOP or manufacturer's protocol followed: yes
Manufacturer's involvement: no




Flow and timing  
Comparative  
Notes This study used fresh specimens for Xpert and frozen




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? No    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
     
If a threshold was used, was it pre-specified?      
Could the conduct or interpretation of the index test have introduced
bias?
     
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
     
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Wang 2020  (Continued)
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Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    Low concern
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Unclear    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
Yes    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Unclear risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    





Patient Sampling Cohort, manner of selection not reported, consecu-
tive
Patient characteristics and setting Presenting signs and symptoms: patients with suspi-
cion of extrapulmonary tuberculosis; diagnostic cri-
teria followed the WHO guidelines and was based on
a combination of clinical symptoms, radiological evi-
dence compatible with active TB, histological obser-
vations, lack of improvement in response to a course
of broad-spectrum antibiotics




Clinical setting: tertiary-care hospital
Wu 2019 
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Past history of TB: not reported
Participants on anti-TB treatment: not reported




World Bank Income Classification: middle income
High TB burden: yes
High TB/HIV burden: yes
High MDR-TB burden: yes
Index tests Xpert MTB/RIF and Xpert Ultra
WHO SOP or manufacturer's protocol followed: no
(see note)
Target condition and reference standard(s) Lymph node tuberculosis; pleural tuberculosis
MGIT
Speciation: not reported
Sterile specimens were directly processed. Non-ster-
ile specimens were pretreated with N-acetyl-L-cys-
teine-NaOH-Na citrate
Flow and timing  
Comparative  
Notes 4 ml GeneXpert sample reagent was added to the re-




Risk of bias Applicability
concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Wu 2019  (Continued)
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Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
     
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
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Patient Sampling Cross-sectional, consecutive, retrospective
Patient characteristics and setting Presenting signs and symptoms: clinical findings of
possible TB




Clinical setting: tertiary care centre
Past history of TB: not reported
Patients on anti-TB treatment: no
Number of specimens evaluated: 149
Laboratory level: central
Country: Turkey
World Bank Income Classification: middle income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: no
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, genitouri-
nary TB, peritoneal TB, pericardial TB
Reference standard TB detection: LJ and BacT liquid
medium




Flow and timing  
Comparative  




Risk of bias Applicability
concerns
Zeka 2011  (Continued)
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DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Low risk  
Are there concerns that the included patients and setting do not match
the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the results of
the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have introduced
bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpretation dif-
fer from the review question?
    High
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? Yes    
Were the reference standard results interpreted without knowledge of the
results of the index tests?
Yes    
For rifampicin resistance testing, were the reference standard results inter-
preted without knowledge of the results of the index test?
No    
Could the reference standard, its conduct, or its interpretation have in-
troduced bias?
  Low risk  
Are there concerns that the target condition as defined by the reference
standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference stan-
dard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Could the patient flow have introduced bias?   Low risk  
Zeka 2011  (Continued)
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Study characteristics
Patient Sampling Cross-sectional, manner of participant selection not reported,
prospective
Patient characteristics and setting Presenting signs and symptoms: patients suspected of EPTB
Age: 15 years and older
Sex, female: not reported
Children: 13%
HIV infection: not reported
Clinical setting: laboratory-based evaluation
Past history of TB: not reported
Patients on anti-TB treatment: not reported
Number of specimens evaluated: 176
Laboratory level: central
Country: Croatia
World Bank Income Classification: high income
High TB burden: no
High TB/HIV burden: no
High MDR-TB burden: no
Index tests Xpert MTB/RIF
WHO SOP or manufacturer's protocol followed: yes for pleur-
al fluid, urine, peritoneal fluid, pericardial fluid, and blood; no
for CSF
Manufacturer's involvement: no
Target condition and reference standard(s) Target condition: pleural TB, TB meningitis, peritoneal TB,
pericardial TB, genitourinary TB, disseminated TB
Reference standard TB detection: LJ, Stonebrink, and MGIT
Reference standard rifampicin resistance detection: LJ-DST
Speciation: yes
Decontamination: no
Flow and timing  
Comparative  
Notes "Although the NRL performs a third-level laboratory service
for the whole country, it is actually also involved in first and
second-level laboratory work for several counties"
Methodological quality
Zmak 2013 
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Item Authors' judge-
ment
Risk of bias Applicability con-
cerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Unclear    
Was a case-control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Could the selection of patients have introduced bias?   Unclear risk  
Are there concerns that the included patients and setting do not
match the review question?
    Unclear
DOMAIN 2: Index Test (Xpert MTB/RIF)
Were the index test results interpreted without knowledge of the re-
sults of the reference standard?
Yes    
If a threshold was used, was it pre-specified? Yes    
Could the conduct or interpretation of the index test have intro-
duced bias?
  Low risk  
Are there concerns that the index test, its conduct, or interpre-
tation differ from the review question?
    Low concern
DOMAIN 2: Index Test (Xpert Ultra)
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target con-
dition?
Yes    
Were the reference standard results interpreted without knowledge
of the results of the index tests?
No    
For rifampicin resistance testing, were the reference standard re-
sults interpreted without knowledge of the results of the index test?
No    
Could the reference standard, its conduct, or its interpretation
have introduced bias?
  High risk  
Are there concerns that the target condition as defined by the
reference standard does not match the question?
    Low concern
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference
standard?
Yes    
Did all patients receive the same reference standard? Yes    
Were all patients included in the analysis? Yes    
Zmak 2013  (Continued)
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Could the patient flow have introduced bias?   Low risk  
Zmak 2013  (Continued)
CSF: cerebrospinal fluid; DST: drug susceptibility testing; EBUS: endobronchial ultrasound; EPTB: extrapulmonary tuberculosis: IQR:
interquartile ratio; LJ: Löwenstein-Jensen; LN: lymph node; MDR-TB: multi-drug-resistant tuberculosis; MGIT: mycobacteria growth
indicator tube; NALC-NaOH: N-acetyl-L-cysteine-sodium hydroxide; SD: standard deviation; SOP: standard operating procedure; TB:
tuberculosis; TBM: tuberculous meningitis; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abong 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Adejumo 2018 Did not contain specimen for extrapulmonary TB
Afsar 2018 Did not contain data by site for extrapulmonary TB
Ahmad 2018 Inadequate reference standard
Akhter 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Ali 2018 Inadequate reference standard
Allahyartorkaman 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Alvarez Uria 2012 Inappropriate reference standard
Andrey 2015 Case report
Armand 2011 Case-control study
Arockiaraj 2015 Abstract; we included the published study (Arockiaraj 2017) in the review
Arockiaraj 2017 Includes both adults and children or no information about age of enrolment
Arockiaraj 2019a Case-control study
Arockiaraj 2019b Children
Atherton 2018 Case report
Aydemir 2019 Could not obtain; same publication as Terzi 2019
Bablishvili 2015 Did not contain specimen for extrapulmonary TB
Bahr 2018a Test other than Xpert MTB/RIF and Xpert Ultra
Bahr 2018b Duplicate data for Bahr 2017
Bahr 2019 Review
Baikunje 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Bajrami 2016 Could not extract 2 × 2 values
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Study Reason for exclusion
Balcha 2014 Did not contain specimen for extrapulmonary TB
Bankar 2018 Includes both adults and children or no information about age of enrolment
Bemba 2017 Inappropriate reference standard
Ben Saad 2018 Could not extract 2 × 2 values
Bhardwaj 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Bhatia 2016 Could not extract 2 × 2 values
Bholla 2016 Children
Biadglegne 2013 Could not extract 2 × 2 values
Bilgin 2016 Could not extract 2 × 2 values
Borraz-Noriega 2018 Could not extract 2 × 2 values
Boyles 2018 Correspondence without original data
Bunsow 2014 Could not extract 2 × 2 values
Celik 2015 Could not extract 2 × 2 values
Chaidir 2018 Inappropriate reference standard
Chakraborty 2019 Xpert Ultra was not evaluated
Chen 2016 Could not extract 2 × 2 values
Chhajed 2019 Xpert Ultra was not evaluated
Christopher 2018 Could not extract 2 x 2 values
Coetzee 2014 Children
Coleman 2015 Case-control study
Creswell 2019 Did not contain specimen for extrapulmonary TB
Dahale 2019 Case-control study
Das 2019 Children
Deggim 2013 Fewer than 5 specimens for a given type of specimen (only 1 pleural fluid specimen)
Dharan 2016 Did not contain specimen for extrapulmonary TB
Diallo 2016 Includes both adults and children or no information about age of enrolment
Diop 2016 Inappropriate reference standard
Edwards 2016 Case report
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Study Reason for exclusion
Ejeta 2018 Could not extract 2 x 2 values
Erdem 2014 Index test other than Xpert MTB/RIF
Fanosie 2016 Did not contain specimen for extrapulmonary TB
Fantahun 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Floridia 2017 Could not extract 2 x 2 values
García 2017 Duplicate data for García Cañete 2017
García Cañete 2017 Includes both adults and children or no information about age of enrolment
Gascoyne-Binzi 2012 Abstract; we could not extract data by form of extrapulmonary TB
Gati 2018 Could not extract 2 x 2 values
Gautam 2018 Inappropriate reference standard
Gautam 2019 Inappropriate reference standard
Gounden 2018 Could not extract 2 x 2 values
Gulla 2019 Could not extract 2 x 2 values
Gursoy 2016 Includes both adults and children or no information about age of enrolment
Habeenzu 2017 Did not contain specimen for extrapulmonary TB
Habous 2019 Includes both adults and children or no information about age of enrolment
Hanifa 2017 Could not extract 2 x 2 values
Held 2014 Bone tissue, specimen not included
Held 2016 Bone tissue, specimen not included
Held 2017 Bone tissue, specimen not included
Ioannidis 2010 Duplicate data
Ioannidis 2011 Includes both adults and children or no information about age of enrolment
Jain 2017 Inappropriate reference standard
Jing 2017 Includes both adults and children or no information about age of enrolment
Jipa 2017 Could not extract 2 x 2 values
Jorstad 2018 Inappropriate reference standard
Joythi 2019 Children
Kanade 2018 Did not contain data by site for extrapulmonary TB
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Study Reason for exclusion
Kashyap 2019 Inappropriate reference standard
Kendall 2019 Case-control study
Kerkhoff 2017 Did not contain specimen for extrapulmonary TB
Khadka 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Khan 2018 Includes both adults and children or no information about age of enrolment
Kilfoil 2015 Could not extract 2 × 2 values
Kim 2014 Could not extract 2 × 2 values; unclear if culture-positive; pleural fluid (3), CSF (2); peritoneal fluid
(1)
Kim 2015b Case-control study
Kim 2015c Could not extract 2 × 2 values
Kotovich 2018 Inappropriate reference standard
Koul 2018 Could not extract 2 × 2 values
Kumar 2017 Case-control study
Kumari 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Kurbaniyazova 2017 Did not contain specimen for extrapulmonary TB
Kwak 2015 Duplicate data
Lawn 2012 Screening study
Lawn 2013 Could not extract 2 × 2 values
Lawn 2015 Screening study
Lawn 2017 Could not extract 2 × 2 values
Lee 2017 Duplicate data
Lemus-Minor 2018 Did not contain specimen for extrapulmonary TB
Li 2018 Inappropriate reference standard
Li 2020 Test other than Xpert MTB/RIF and Xpert Ultra
Liu 2015 Duplicate data
Liu 2019 Did not contain specimen for extrapulmonary TB
Lombardi 2017 Could not extract data by site of extrapulmonary TB
Marouane 2014 Abstract; we excluded the publication, Marouane 2016, because we could not extract 2 × 2 values
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Study Reason for exclusion
Marouane 2016 Could not extract 2 × 2 values
Massi 2017 Includes both adults and children or no information about age of enrolment
Mathew 2018 Did not contain data by site for extrapulmonary TB
Mazzola 2016 Includes both adults and children or no information about age of enrolment
McMillen 2018 Did not contain data by site for extrapulmonary TB
Mechal 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Metaferia 2018 Could not extract 2 × 2 values
Miller 2011 Fewer than 5 specimens for a given type of specimen; lymph node biopsy (3 specimens, of which 1
was culture-positive) and endometrial biopsy (1 specimen that was culture-positive)
Mishra 2017 Abstract; we did not identify a published study
Moure 2011 Fewer than 5 specimens for a given type of specimen: CSF (3 specimens, all culture-negative);
pleural fluid (4 specimens, 2 culture-positive); lymph node aspirate (1 specimen, culture-negative);
urine (2 specimens, both culture-positive); peritoneal fluid (2, both culture-negative)
Moure 2012 Case-control study
Negi 2019 Case-control study
Nhu 2013 Inappropriate reference standard
Omar 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Pandey 2017 Includes both adults and children or no information about age of enrolment
Paramitha 2018 Could not extract 2 × 2 values
Park 2019 Inappropriate reference standard
Patel 2014 Duplicate data
Patel 2020 Test other than Xpert MTB/RIF and Xpert Ultra
Peter 2012 Case-control study
Philip 2017 Inappropriate reference standard
Piersimoni 2019 Could not extract 2 x 2 tables
Pink 2016 Includes both adults and children or no information about age of enrolment
Pohl 2016 Children
Porcel 2013 Case-control study
Rachow 2012 Did not contain specimen for extrapulmonary TB
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Study Reason for exclusion
Raizada 2015 Inappropriate reference standard
Raizada 2018 Children
Ramamurthy 2016 Could not extract data by site of extrapulmonary TB
Rathour 2019 Children
Razack 2014 Test other than Xpert MTB/RIF and Xpert Ultra
Rebecca 2018 Children
Reddy 2017 Could not extract 2 × 2 values
Rindi 2017 Case-control study
Rossato Silva 2018 Did not contain specimen for extrapulmonary TB
Ruiz 2017 Did not contain data by site for extrapulmonary TB
Sachdeva 2018 Includes both adults and children or no information about age of enrolment
Saeed 2017a Includes both adults and children or no information about age of enrolment
Saeed 2017b Could not extract 2 × 2 values
Saeed 2018 Did not contain data by site for extrapulmonary TB
Salvador 2015 Case-control study
Samuel 2018 Inappropriate reference standard
Sanjuan Jimenez 2015 Case-control study
Schutz 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Sekyere 2019 Could not extract 2 x 2 data
Set 2018 Did not contain data by site for extrapulmonary TB
Set 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Shah 2016a Case-control study
Shakeel 2018 Did not contain data by site for extrapulmonary TB
Sharma 2017a Did not contain data by site for extrapulmonary TB
Sharma 2019 Did not include specimen of interest
Singanayagam 2014 Could not extract 2 × 2 values
Singh 2016 Could not extract 2 × 2 values
Smith 2014 Did not contain specimen for extrapulmonary TB
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Study Reason for exclusion
Solomons 2015 Duplicate data
Solomons 2016 Includes both adults and children or no information about age of enrolment
Soomro 2017 Could not extract 2 × 2 values
Sumayya 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Tahseen 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Talib 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Tang 2017 Could not extract 2 × 2 values
Tang 2018 Case-control study
Teo 2011 Includes both adults and children or no information about age of enrolment
Terzi 2019 Could not obtain; same publication as Aydemir 2019
Theron 2014b Duplicate data
Tortoli 2012 Includes both adults and children or no information about age of enrolment
Toure 2017 Could not extract 2 × 2 values
Uddin 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Vallejo 2015 Could not extract 2 × 2 values
Verghese 2016 Abstract; we did not identify a published study
Wang 2016a Could not extract 2 × 2 values
Wang 2016b Includes both adults and children or no information about age of enrolment
Wang 2018 Inadequate reference standard
Wei 2016 Inappropriate reference standard
Yang 2017 Could not obtain 2 x 2 values
Yang 2019 Test other than Xpert MTB/RIF and Xpert Ultra
Yu 2020 Test other than Xpert MTB/RIF and Xpert Ultra
Yuan 2016 Inappropriate reference standard
Zhang 2016 Could not extract 2 × 2 values
Zhou 2020 Test other than Xpert MTB/RIF and Xpert Ultra
Zurcher 2019 Test other than Xpert MTB/RIF and Xpert Ultra
TB: tuberculosis.
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D A T A
Presented below are all the data for all of the tests entered into the review.
 
Table Tests.   Data tables by test
Test No. of studies No. of participants
1 Cerebrospinal fluid, Xpert Ultra, culture 6 475
2 Cerebrospinal fluid, Xpert Ultra, composite reference standard 4 496
3 Cerebrospinal fluid, Xpert MTB/RIF, culture 33 3434
4 Cerebrospinal fluid, Xpert MTB/RIF, composite reference standard 14 2203
5 Cerebrospinal fluid, Xpert Ultra, HIV positive 2 333
6 Cerebrospinal fluid, Xpert MTB/RIF, HIV positive 3 413
7 Pleural fluid, Xpert Ultra, culture 4 398
8 Pleural fluid, Xpert Ultra, composite reference standard 2 263
9 Pleural fluid, Xpert MTB/RIF, culture 28 3268
10 Pleural fluid, Xpert MTB/RIF, composite reference standard 10 1024
11 Pleural tissue, Xpert MTB/RIF, culture 4 214
12 Pleural tissue, Xpert MTB/RIF, composite reference standard 1 55
13 Lymph node aspirate, Xpert Ultra, culture 1 73
14 Lymph node aspirate, Xpert Ultra, composite reference standard 1 73
15 Lymph node aspirate, Xpert MTB/RIF, culture 15 1595
16 Lymph node aspirate, Xpert MTB/RIF, composite reference standard 4 679
17 Lymph node biopsy, Xpert Ultra, culture 2 131
18 Lymph node biopsy, Xpert Ultra, composite reference standard 1 79
19 Lymph node biopsy, Xpert MTB/RIF, culture 11 786
20 Lymph node biopsy, Xpert MTB/RIF, composite 2 288
21 Urine, Xpert Ultra, culture 1 24
22 Urine, Xpert MTB/RIF, culture 15 1068
23 Urine, Xpert MTB/RIF, composite reference standard 2 463
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Test No. of studies No. of participants
24 Bone or joint aspirate, Xpert Ultra, culture 2 94
25 Bone or joint aspirate, Xpert Ultra, composite reference standard 1 145
26 Bone or joint aspirate, Xpert MTB/RIF, culture 12 492
27 Bone or Joint aspirate, Xpert MTB/RIF, composite reference standard 2 205
28 Bone or joint tissue, Xpert MTB/RIF, culture 3 30
29 Peritoneal fluid, Xpert Ultra, culture 1 3
30 Peritoneal fluid, Xpert MTB/RIF, culture 17 619
31 Peritoneal tissue, Xpert MTB/RIF, culture 1 28
32 Pericardial fluid, Xpert MTB/RIF, culture 14 258
33 Pericardial fluid, Xpert MTB/RIF, composite reference standard 2 77
34 Blood, Xpert MTB/RIF, culture 2 85
35 Rifampicin resistance, Xpert Ultra 5 132
36 Rifampicin resistance, Xpert MTB/RIF 33 1246
 
 
Test 1.   Cerebrospinal fluid, Xpert Ultra, culture
 
 
Test 2.   Cerebrospinal fluid, Xpert Ultra, composite reference standard
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Test 3.   Cerebrospinal fluid, Xpert MTB/RIF, culture
 
 
Test 4.   Cerebrospinal fluid, Xpert MTB/RIF, composite reference standard
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Test 5.   Cerebrospinal fluid, Xpert Ultra, HIV positive
 
 
Test 6.   Cerebrospinal fluid, Xpert MTB/RIF, HIV positive
 
 
Test 7.   Pleural fluid, Xpert Ultra, culture
 
 
Test 8.   Pleural fluid, Xpert Ultra, composite reference standard
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Test 9.   Pleural fluid, Xpert MTB/RIF, culture
 
 
Test 10.   Pleural fluid, Xpert MTB/RIF, composite reference standard
 
 
Test 11.   Pleural tissue, Xpert MTB/RIF, culture
 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)










Cochrane Database of Systematic Reviews
 
Test 12.   Pleural tissue, Xpert MTB/RIF, composite reference standard
 
 
Test 13.   Lymph node aspirate, Xpert Ultra, culture
 
 
Test 14.   Lymph node aspirate, Xpert Ultra, composite reference standard
 
 
Test 15.   Lymph node aspirate, Xpert MTB/RIF, culture
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Test 16.   Lymph node aspirate, Xpert MTB/RIF, composite reference standard
 
 
Test 17.   Lymph node biopsy, Xpert Ultra, culture
 
 
Test 18.   Lymph node biopsy, Xpert Ultra, composite reference standard
 
 
Test 19.   Lymph node biopsy, Xpert MTB/RIF, culture
 
 
Test 20.   Lymph node biopsy, Xpert MTB/RIF, composite
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Test 21.   Urine, Xpert Ultra, culture
 
 
Test 22.   Urine, Xpert MTB/RIF, culture
 
 
Test 23.   Urine, Xpert MTB/RIF, composite reference standard
 
 
Test 24.   Bone or joint aspirate, Xpert Ultra, culture
 
 
Test 25.   Bone or joint aspirate, Xpert Ultra, composite reference standard
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Test 26.   Bone or joint aspirate, Xpert MTB/RIF, culture
 
 
Test 27.   Bone or Joint aspirate, Xpert MTB/RIF, composite reference standard
 
 
Test 28.   Bone or joint tissue, Xpert MTB/RIF, culture
 
 
Test 29.   Peritoneal fluid, Xpert Ultra, culture
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Test 30.   Peritoneal fluid, Xpert MTB/RIF, culture
 
 
Test 31.   Peritoneal tissue, Xpert MTB/RIF, culture
 
 
Test 32.   Pericardial fluid, Xpert MTB/RIF, culture
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Test 33.   Pericardial fluid, Xpert MTB/RIF, composite reference standard
 
 
Test 34.   Blood, Xpert MTB/RIF, culture
 
 
Test 35.   Rifampicin resistance, Xpert Ultra
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Test 36.   Rifampicin resistance, Xpert MTB/RIF
 
 









Tuberculosis of the meninges affects people of all ages but is most common among
children and people with untreated HIV infection. In adults, tuberculous meningitis
presents with gradual onset of headache, neck stiffness, malaise, and fever, and if
untreated can progress to altered sensorium, focal neurological deficits, coma, and
death. Young children may present with poor weight gain, low-grade fever, and list-
lessness. Infants may present with fever, cough (related to the primary pulmonary
infection that occurs before tuberculous meningitis develops), change of conscious-
ness at presentation, bulging anterior fontanel, and seizures (Thwaites 2013). Tuber-
culous meningitis is sometimes associated with a concurrent cerebral tuberculoma,
or, more rarely, a tuberculous abscess
Cerebrospinal flu-







sis, also called TB
pleurisy
TB infection of the pleura presents with gradual onset of pleuritic chest pain, short-
ness of breath, fever, night sweats, and weight loss. Chest X-ray may demonstrate
unilateral or occasionally bilateral pleural effusion. The severity of symptoms is
highly variable, with many patients experiencing spontaneous resolution of symp-
toms, while others may develop severe pleural effusions requiring drainage. Pleu-
ro-pulmonary tuberculosis, in which parenchymal lung involvement is visible on a
Pleural fluid; pleur-





Table 1.   Forms of extrapulmonary TB 
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chest X-ray, is associated with higher mortality than isolated pleural infection, which






Tuberculosis of the lymph nodes may affect one node or a group of nodes, or mul-
tiple groups within a chain. Lymph node tuberculosis is relatively more common
among children than adults. The most common presentation is of a single, firm,
non-tender enlarged node in the neck, although any lymph node group can be af-
fected. This may be accompanied by fever, weight loss, and night sweats, particu-
larly in people with HIV. Patients with tuberculosis in deep lymph nodes, such as
the mediastinal or mesenteric lymph nodes, may present with fever, night sweats,
and weight loss, or, more rarely, with symptoms related to compression of adjacent
structures. Over time lymph nodes become fluctuant and may discharge via a sinus
to the skin or an adjacent viscus. It should be noted that lymphadenopathy may al-
so be seen in other forms of tuberculosis as part of the immune response, but this is
not usually caused by direct infection of the lymph nodes
Fine-needle aspira-
tion of fluid from af-
fected lymph node,





ic biopsy of deep
lymph nodes with ul-
trasound guidance
Bone or joint tuber-
culosis
Tuberculosis of bones or joints or both causes chronic pain, deformity, and disabil-
ity, and tuberculosis of the cervical spine can be life-threatening. The usual pre-
senting symptom is pain. Fever and weight loss, with or without signs of spinal cord
compression, may be present. Patients with advanced disease may have severe
pain, spinal deformity, paraspinal muscle wasting, and neurological deficit. Children












Tuberculosis of the genitourinary tract includes renal tuberculosis and tuberculo-
sis of the reproductive system. Renal tuberculosis presents with flank pain, haema-
turia, and dysuria. Female genital tuberculosis presents with infertility (and may be
otherwise asymptomatic), pelvic pain, and vaginal bleeding. Testicular tuberculosis
presents with a scrotal mass and infertility






losis, also called TB
pericarditis
Tuberculosis of the pericardium presents with fever, malaise, night sweats, and
weight loss. Chest pain and shortness of breath are also commonly-experienced
symptoms. Pericardial tuberculosis may be associated with pericardial effusion,
which can be severe and lead to life-threatening tamponade. Some patients go on
to develop pericardial constriction, which can lead to heart failure and death and









Tuberculosis of the peritoneum usually presents with pain and abdominal swelling,








sis. It has been pro-
posed that the desig-
nation ‘miliary TB' be
restricted to dissemi-




Disseminated tuberculosis involves two or more distinctly separate sites. Manifes-
tations may be varied, ranging from acute fulminant disease to non-specific symp-
toms of fever, weight loss, and weakness. HIV-positive people are more likely to
have disseminated tuberculosis than HIV-negative people. In a systematic review
of the prevalence of tuberculosis in post mortem evaluations of HIV-positive peo-
ple, among adults disseminated tuberculosis was found in 88% of tuberculosis cas-




Table 1.   Forms of extrapulmonary TB  (Continued)
Abbreviations: TB: tuberculosis.
We adapted the table from Sharma 2017b.
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CSF Xpert Ultra culture 6 (475) 89 (18.7) 89.4% (79.1 to 95.6) 91.2% (83.2 to 95.7) 53.0% (36.6 to 69.6) 98.7% (97.5 to 99.5)
CSF Xpert Ultra composite 4 (496) 160 (32.2) 62.7% (45.7 to 77.0) 99.1% (96.6 to 99.9) 87.9% (65.5 to 99.0) 96.0% (94.2 to 97.5)
CSF Xpert MTB/
RIF
culture 30 (3395) 571 (16.8) 71.1% (62.8 to 79.1) 96.9% (95.4 to 98.0) 71.8% (62.3 to 80.7) 96.8% (95.9 to 97.7)
CSF Xpert MTB/
RIF
composite 14 (2203) 862 (39.1) 42.3% (32.1 to 52.8) 99.8% (99.3 to 100.0) 96.3% (87.2 to 100.0) 94.0% (93.0 to 95.0)
CSF Ultra, direct
comparison




culture 5 (471) 87 (18.5) 62.2% (43.7 to 78.1) 96.8% (93.4 to 98.6) 68.4% (49.0 to 83.6) 95.8% (93.9 to 97.5)
Pleural flu-
id






























71.0% (51.1 to 86.1) 97.9% (95.8 to 99.2)









































































































































































































31.6% (18.7 to 51.8) 97.6% (96.2 to 98.6)
Urine Xpert MTB/
RIF
































39.4% (18.3 to 88.0) 95.4% (92.1 to 97.9)
Rifampicin
resistance










DSTor LPA 19 (970) 148 (15.3) 96.5% (91.9 to 98.8) 99.1% (98.0 to 99.7) 92.0% (84.3 to 97.3) 99.6% (99.1 to 99.9)
Table 2.   Summary accuracy of Xpert MTB/RIF and Xpert Ultra for detection of extrapulmonary tuberculosis and rifampicin resistance  (Continued)
Abbreviations: Crl: credible interval; CSF: cerebrospinal fluid; LPA: Line probe assay; TB: tuberculosis.
Studies included in the table are limited to those that report data for both sensitivity and specificity; thus the number of studies (specimens) may diLer slightly from those
reported in the main text of the review. For tuberculosis detection, the reference standard was culture and a composite reference standard. For rifampicin resistance detection,
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Form of extrapulmonary tu-








































































































Table 3.   Latent class meta-analysis 
Abbreviations: Crl: credible interval.
We generally used non-informative priors in the latent class model.
Accuracy estimates were determined using a bivariate random-eLects approach for comparison.
 
 
Detection of tuberculosis in CSF
Test (studies,
participants)





Sensitivity 89.0% (77.9 to 95.2) 62.2% (43.7 to 78.1) 26.2% (9.1 to 44.4) 0.997
Specificity 91.0% (82.7 to 95.6) 96.8% (93.4 to 98.6) −5.6% (−12.9 to −0.1) 0.022
Table 4.   Accuracy of Xpert Ultra versus Xpert MTB/RIF in cerebrospinal fluid 
 
 
Covariate (number of studies, participants) Pooled sensitivity (95% CrI) Pooled specificity (95%
CrI)
Concentration step, Xpert Ultra
Table 5.   Impact of concentrating cerebrospinal fluid on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)
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Concentrated specimen (3, 421) 90.5% (76.7 to 97.0) 91.9% (84.5 to 96.1)
Unconcentrated specimen (3, 54) 88.4% (67.8 to 97.5) 88.6% (58.4 to 99.0)
Difference (concentrated minus unconcentrated) 2.6% (−13.9 to 24.1) 3.4% (−9.5 to 32.8)
Probability (concentrated minus unconcentrated) 0.630 0.653
Concentration step, Xpert MTB/RIF
Concentrated specimen (14, 2279) 77.6% (67.2 to 85.9) 97.4% (96.1 to 98.4)
Unconcentrated specimen (17, 1123) 59.4% (48.3 to 70.5) 96.8% (94.0 to 98.7)
Difference (concentrated minus unconcentrated) 18.4% (2.8 to 32.1) 0.6% (−1.7 to 3.6)
Probability (concentrated minus unconcentrated) 0.989 0.696
Table 5.   Impact of concentrating cerebrospinal fluid on Xpert Ultra and Xpert MTB/RIF sensitivity and
specificity  (Continued)
Abbreviations: Crl: credible interval.
 
 




Cerebrospinal fluid, Xpert Ultra
Among studies with prevalence ≥ 30% (3, 54) 88.3% (68.3 to 97.0) 88.0% (64.3 to 97.9)
Among studies with prevalence < 30% (3, 421) 90.8% (77.3 to 96.9) 91.9% (82.5 to 96.6)
Difference (≥ 30% group minus < 30% group) −2.2% (−23.0 to 13.5) −3.8% (−27.7 to 9.8)
Probability (≥ 30% group minus < 30% group) 0.390 0.308
Cerebrospinal fluid, Xpert MTB/RIF
Among studies with prevalence ≥ 30% (6, 610) 67.0% (49.0 to 81.5) 94.1% (86.8 to 97.9)
Among studies with prevalence < 30% (24, 2785) 72.0% (62.4 to 81.2) 97.3% (95.9 to 98.3)
Difference (≥ 30% group minus < 30% group) −4.8% (−25.5 to 12.1) −3.1% (−10.5 to 0.8)
Probability (≥ 30% group minus < 30% group) 0.296 0.071
Cerebrospinal fluid, Xpert MTB/RIF
Among studies with prevalence ≥ 10% (19, 2190) 68.7% (58.5 to 78.0) 95.1% (92.7 to 96.8)
Among studies with prevalence < 10% (11, 1205) 74.2% (57.4 to 86.6) 98.6% (97.5 to 99.3)
Difference (≥ 10% group minus < 10% group) -5.5% (-21.2 to 13.3) -3.5% (-6.0 to -1.5)
Probability (≥ 10% group minus < 10% group) 0.272 0.001
Table 6.   Impact of tuberculosis prevalence on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)
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Pleural fluid, Xpert MTB/RIF
Among studies with prevalence ≥ 50% (6, 627) 20.7% (11.2 to 33.7) 99.6% (97.9 to 99.9)
Among studies with prevalence < 50% (4, 397) 15.5% (6.5 to 30.1) 99.0% (96.9 to 99.8)
Difference (≥ 50% group minus < 50% group) 5.1% (−11.8 to 21.2) 0.5% (−1.2 to 2.7)
Probability (≥ 50% group minus < 50% group) 0.757 0.759
Lymph node aspirate, Xpert MTB/RIF
Among studies with prevalence ≥ 35 (9, 911) 93.1% (88.9 to 96.3) 83.2% (69.5 to 92.1)
Among studies with prevalence < 35% (5, 677) 72.2% (64.9 to 87.2) 90.0% (78.3 to 95.9)
Difference (≥ 35% group minus < 35% group) 15.7% (5.4 to 28.6) −6.4% (−21.3 to 76)
Probability (≥ 35% group minus < 35% group) 0.999 0.158
Table 6.   Impact of tuberculosis prevalence on Xpert Ultra and Xpert MTB/RIF sensitivity and specificity  (Continued)
Abbreviations: Crl: credible interval.
Prevalence refers to the percentage of culture-confirmed tuberculosis specimens or confirmed rifampicin-resistant specimens in the study.
We selected prevalence levels to approximate the lower bound of the interquartile range or in consideration of the range of prevalences
reported in the included studies.
 
 













All participants 6 (475) 89.4% (79.1 to 95.6) 91.2% (83.2 to 95.7) 53.0% (36.6 to 69.6) 98.7% (97.5 to 99.5)
Consecutive partici-
pant selection
5 (471) 87.9% (76.4 to 94.6) 90.4% (81.1 to 95.1) 88.0% (65.2 to 96.7) 90.5% (65.5 to 97.7)
Reference standard
blinding
4 (432) 88.5% (74.7 to 95.6) 89.1% (76.9 to 94.3) 88.6% (63.4 to 97.2) 89.2% (61.0 to 97.1)
Single specimen per
participant
4 (432) 88.5% (74.7 to 95.6) 89.1% (76.9 to 94.3) 88.6% (63.4 to 97.2) 89.2% (61.0 to 97.1)
Table 7.   Sensitivity analyses, Xpert Ultra in cerebrospinal fluid 
Abbreviations: Crl: credible interval.
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Accuracy against culture reference standardSystematic
review







monary TB or types






Chang 2012 a Up to 1 October
2011
Xpert MTB/RIF 7 (1058) Multiple forms com-
bined
















Up to 6 Novem-
ber 2013
Xpert MTB/RIF 27 (6026) Lymph node, pleural
fluid, CSF, other forms
Median sensitivi-








Penz 2015 Up to 15 August
2014
Xpert MTB/RIF 36 (9523) Lymph node, pleural







Sehgal 2016 Up to 31 August
2015
Xpert MTB/RIF 24 (2486) Pleural fluid Not applicable Sensitivity 51%;
specificity 99%
Not applicable
Li Y 2017 c Up to 20 June
2015




Not reported Not reported Not reported
Gupta 2018 Up to 25 March
2017
Xpert MTB/RIF 33 (8977) CSF Sensitivity 57%;
specificity 98%
Not reported Not reported
Pormoham-
mad 2019




Not reported Not reported
Yu 2019 Up to 6 July 2018 Xpert MTB/RIF 21(1629) Lymph node Not reported Not reported Sensitivity 84%;
specificity: 91%
Zhang 2020 d Up to 20 May
2019
Xpert Ultra 7 (1500) Multiple specimens Not reported Not reported Not reported
Table 8.   Systematic reviews of Xpert MTB/RIF and Xpert Ultra for extrapulmonary tuberculosis 
































































































































































































aFor all forms of extrapulmonary tuberculosis combined, Chang 2012 reported pooled sensitivity and specificity of 80.4% (95% confidence interval (CI) 75.0 to 85.1) and 86.1%
(95% CI 83.5 to 88.4), respectively.
bUsing a composite reference standard, Denkinger 2014 found the following pooled sensitivity and specificity estimates: lymph node tuberculosis (aspirate or tissue) 81.2% (95%
CI 72.4 to 87.7) and 99.1% (95% CI 94.5 to 99.9); pleural tuberculosis 21.4% (95% CI 8.8 to 33.9) and 100% (95% CI 99.4 to 100); and meningeal TB 62.8% (95% CI 47.7 to 75.8)
and 98.8% (95% CI 95.7 to 100), respectively.
cFor both pulmonary and extrapulmonary tuberculosis, review authors included 106 studies involving 52,410 specimens. For all forms of extrapulmonary tuberculosis combined,
Li Y 2017 reported pooled sensitivity and specificity of 80% (95% CI 69 to 88) and 97% (95% CI 94 to 98), respectively.
d Zhang 2020 included 7 studies involving 1500 specimens. For all forms of extrapulmonary tuberculosis combined, pooled sensitivity and specificity were 85.1% (95% CI 76.7
to 90.8%) and 95.7% (95% CI 87.9 to 98.6%), respectively.
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Protocol section Appraisal points Address here
Background and re-
search question
• Review and update Back-
ground section, including
supporting references to
take account of any changes
that may have occurred. This
should include updating any
new information and current
policy debates on the topic
This review update will describe the burden of extrapulmonary tuberculosis
worldwide based on the latest WHO Global Tuberculosis Report. The Back-
ground will describe the updated WHO guidelines on molecular methods
for diagnosing tuberculosis, including Xpert MTB/RIF and Xpert Ultra. The
WHO Meeting to update the guidelines took place 3 - 6 December 2019. This
Cochrane Review update will have informed these guidelines
Inclusion criteria • Review current PICO(s) and
amend in light of new knowl-
edge.
• Identify any changes in usu-
al-care standards.
• Check for standardised
core outcomes sets, such as
those developed in collab-
oration with the core out-
come measures in effective-
ness trials (COMET) initiative
(www.comet-initiative.org) or
by guideline groups since the
original review.
• Check for any relevant pa-
tient-reported outcomes to
include subsequent to the
original review.
• Consider any new stud-
ies with less risk of bias that
might warrant a stricter study
design inclusion criterion
(where the older version,




This is a diagnostic test accuracy review.
Participants, index tests, and target condition, will be the same as in Kohli
2018 except as follows:
The update will be restricted to adults (15 years and older). The reason for
this is that we have a separate Cochrane Review underway that is evaluat-
ing the tests for extrapulmonary tuberculosis in children.
We will add a composite reference standard, defined as culture or clinical
criteria as defined by the primary study authors. The addition of a compos-
ite reference standard was specifically requested by the WHO and Guideline
members.
The primary objectives are to assess the diagnostic accuracy of Xpert Ul-
tra for the diagnosis of extrapulmonary tuberculosis and to assess the diag-
nostic accuracy of Xpert Ultra for the detection of rifampicin resistance in
adults.
Secondary objectives are the following.
- to investigate potential sources of heterogeneity in test accuracy, includ-
ing volume of CSF for TB meningitis and processing methods for lymph
node TB
- to compare the accuracy of Xpert Ultra and Xpert MTB/RIF in studies that
evaluated both tests.
Concerning patient outcomes, the Discussion will summarize and refer to
key findings in the test-treatment Cochrane Review by Haraka et al. (cur-
rently undergoing peer review). Although the Haraka review relates to pul-
monary tuberculosis, it is the only evidence on patient outcomes of which
we are aware.
Methods - We will use QUADAS-2 to appraise methodological quality of included stud-
ies consistent with Kohli 2018.
If data are sufficient, we will perform meta-analyses using a bivariate ran-
dom-effects model. The analyses will include:
1. Xpert Ultra for different forms of extrapulmonary tuberculosis, culture
reference standard
2. Xpert Ultra for different forms of extrapulmonary tuberculosis, composite
reference standard
3. Accuracy of Xpert Ultra versus Xpert MTB/RIF in studies that evaluated
both tests
4. Xpert Ultra for detecting rifampicin resistance
Table 9.   Prespecified changes for review update 2021 
Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (Review)
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The different forms (and corresponding specimens for diagnosis) of extra-
pulmonary TB include: tuberculous meningitis, lymph node tuberculosis,
pleural tuberculosis, genitourinary tuberculosis, bone or joint tuberculosis.
We will create 'Summary of findings' tables for the two primary objectives
of the review.
Table 9.   Prespecified changes for review update 2021  (Continued)
TB: tuberculosis.
This table was approved by the CIDG editorial team on 17 December 2019.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
MEDLINE (OVID)
1 Mycobacterium tuberculosis/
2 Tuberculosis/ or "Tuberculosis, Multidrug-Resistant"/ or Extensively Drug-Resistant Tuberculosis/
3 (Tuberculosis or MDR-TB or XDR-TB or "Multidrug Resistant Tuberculosis" or "Extensively Drug Resistant Tuberculosis" or tuberculous).ti.
ab .
4 (extrapulmonary or extra-pulmonary or EPTB).ti. ab .
5 (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal
or splenic or genitourinary or pericardial).ti. ab .
6 "Tuberculosis, Central Nervous System"/ or "Tuberculosis, Urogenital"/ or "Tuberculosis, Splenic"/ or "Tuberculosis, Spinal"/ or
"Tuberculosis, Renal"/ or "Tuberculosis, Pleural"/ or "Tuberculosis, Osteoarticular"/ or "Tuberculosis, Oral"/ or "Tuberculosis, Ocular"/ or
"Tuberculosis, Meningeal"/ or "Tuberculosis, Lymph Node"/ or "Tuberculosis, Laryngeal"/ or "Tuberculosis, Hepatic"/ or "Tuberculosis,
Gastrointestinal"/ or "Tuberculosis, Female Genital"/ or "Tuberculosis, Endocrine"/ or "Tuberculosis, Cutaneous"/ or "Tuberculosis,
Cardiovascular"/ or Tuberculosis, Miliary/ or Tuberculosis, Male Genital/
7 1 or 2 or 3
8 4 or 5
9 7 and 8
10 9 or 6
11 Xpert*.ti. ab .
12 (GeneXpert or cepheid).ti.ab .
13 (near* patient or near-patient).ti.ab
14 11 or 12 or 13
15 10 and 14
Embase (OVID)
1 Tuberculosis, Multidrug-Resistant/ or Extensively Drug-Resistant Tuberculosis/ or Tuberculosis/ or tuberculosis.mp. or Mycobacterium
tuberculosis/
2 (MDR-TB or XDR-TB).mp.
3 1 or 2
4 (extrapulmonary or extra-pulmonary or EPTB).ti. or (extrapulmonary or extra-pulmonary or EPTB).ab.
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5 (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal
or genitourinary or pericardial).ti. or (lymphadenitis or disseminated or miliary or pleur* or skeletal or spine or mening* or intracranial or
intra-ocular or ocular or abdominal or genitourinary or pericardial).ab.
6 tuberculous.ti. or tuberculous.ab.
7 3 or 6
8 Tuberculosis, Central Nervous System/ or Tuberculosis, Hepatic/ or Tuberculosis, Male Genital/ or Tuberculosis, Spinal/ or Tuberculosis,
Cutaneous/ or Tuberculosis, Urogenital/ or Tuberculosis, Osteoarticular/ or Tuberculosis, Endocrine/ or Tuberculosis, Renal/ or
Tuberculosis, Splenic/ or Tuberculosis, Ocular/ or Tuberculosis, Laryngeal/ or Tuberculosis, Gastrointestinal/ or Tuberculosis/ or
Tuberculosis, Meningeal/ or Tuberculosis, Oral/ or Tuberculosis, Pleural/ or Tuberculosis, Lymph Node/ or Tuberculosis, Female Genital/
or Tuberculosis, Miliary/ or Tuberculosis, Cardiovascular/
9 4 or 5 or 8
10 7 and 9
11 xpert*TB.mp.
12 Xpert* MTB RIF.ti. or Xpert* MTB RIF.ab.
13 (GeneXpert or cepheid).ti. or (GeneXpert or cepheid).ab.
14 (near* patient or near-patient).ti. or (near* patient or near-patient).ab.
15 12 or 13 or 14
16 10 and 15
Indexes=SCI-EXPANDED, CPCI-S, Biosis previews
TOPIC
(tuberculosis or tuberculous) AND TOPIC: (extrapulmonary or extra-pulmonary or EPTB or lymphadenitis or disseminated or miliary or
pleur* or skeletal or spine or mening* or intracranial or intra-ocular or ocular or abdominal or genitourinary or pericardial) AND TOPIC:
(Xpert* or Genexpert or cepheid)
LILACS
tuberculosis or tuberculous [Words] and Xpert$ or Genexpert or cepheid [Words]
SCOPUS
( TITLE-ABS-KEY ( tuberculosis OR tuberculous ) AND TITLE-ABS-KEY ( extrapulmonary OR extra-pulmonary OR eptb OR lymphadenitis
OR disseminated OR miliary OR pleur* OR skeletal OR spine OR mening* OR intracranial OR intra-ocular OR ocular OR abdominal OR
genitourinary OR pericardial ) AND TITLE-ABS-KEY ( xpert* OR genexpert OR cepheid ) )
Cochrane Infectious Diseases Group Specialist Register; ClinicalTrials.gov, WHO ICTRP, ISRCTN registry, ProQuest Dissertations &
Theses A&I
tuberculosis and Xpert$; tuberculosis and Genexpert; tuberculosis and Cepheid.
Appendix 2. Data extraction form
 
Data extractor MK KRS
First study author  
Corresponding study author and email  
Title of paper  
Journal  
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Type of study: randomized controlled trial; cross-sectional cohort (with follow-up); case-control (exclude); unclear/not reported
Study data collection: prospective; retrospective; unclear/not reported
Participant selection: convenience; consecutive; random; other; unclear/not reported
Country:
Country income status: low; middle; high
II. Presenting signs and symptoms, setting
Presenting signs and symptoms?
Clinical setting: inpatient; outpatient; both; unclear/not reported
Level of laboratory running Xpert? peripheral; intermediate; central (reference)
Comments, describe exclusions
(Tests at laboratory levels)
Peripheral: AFB (Ziehl-Neelsen, Auramine-rhodamine, Auramine-O staining) and Xpert MTB/RIF
Intermediate: peripheral laboratory tests and culture on solid media and line probe assay (LPA) from smear-positive sputum
Central: intermediate laboratory tests and culture on liquid media and DST (first- and second-line anti-TB drugs) on solid or in liquid media
and LPA on positive cultures and rapid speciation tests
III. Other demographics
HIV patients included? yes; no; unclear/not reported; if yes ## and percentage? (denominator is number tested, when possible)
Age? Median age in years (IQR); mean (SD); range; unclear/not reported
Children (< 15 years old) included: yes; no; unclear/not reported; if yes, percentage?
Percentage female included? Unclear/not reported
Past history of TB? yes; no; unclear/not reported; if yes, percentage?
Only patients who received TB treatment for ≤ 7 days were included? yes; no; unclear/not reported; if no, percentage on treatment included?
IV. Reference standard
A. Reference standard for TB detection
Solid culture (specify): LJ 7H10 7H11; other
Liquid culture (specify): MGIT Bactec 460; other
Solid and liquid culture (indicate which kind above)
Were reference standard results interpreted without knowledge of index test results? yes; no; unclear/not reported
B. Composite reference standard for pleural TB
Solid culture (specify): LJ 7H10 7H11; other
Liquid culture (specify): MGIT Bactec 460; other
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Solid and liquid culture (indicate which kind above)
Histopathology (specify): granulomas; caseating granulomas
Were reference standard results interpreted without knowledge of index test results? yes; no; unclear/not reported
Did all patients receive the same reference standard? yes; no; unclear/not reported; if no, describe
C. Reference standard for rifampicin resistance
LJ DST MGIT DST MTBDRplus
Were reference standard results interpreted without knowledge of index test results? yes; no; unclear/not reported
V. Sites with more than five specimens (check all that apply)
A. Lymph node TB fluid; tissue; both fluid and tissue
B. Pleural TB fluid; tissue; both fluid and tissue
C. TB meningitis CSF
D. Bone or joint TB fluid; tissue; both fluid and tissue
E. Genitourinary TB urine; other, specify
F. Peritoneal TB fluid; tissue; both fluid and tissue
G. Pericardial TB fluid; tissue; both fluid and tissue
H. Disseminated TB blood
I. Other, specify
VI. Specimen processing for Xpert
Condition of specimens: fresh frozen
If frozen for > 7 days, indicate WHO not followed
For a given site, how many specimens were collected per patient? one; multiple; unclear/not reported
A. Lymph node tissue, other tissue
Was the WHO standard operating procedure (SOP) followed for each specimen type?
1a. Lymph node tissue WHO followed: yes; no; unclear
1b. Lymph node tissue homogenization step for tissue specimens: yes; no; unclear/not reported
2a. Other tissue, specify WHO followed: yes; no; unclear
2b. Other tissue homogenization step for tissue specimens: yes; no; unclear/not reported
(For tissue, if WHO SOP not followed, briefly describe specimen processing in comments.)
WHO SOPs for specimen processing; lymph node and other tissue; sterile specimen
1. Cut the tissue specimen into small pieces in a sterile mortar.
2. Add approximately 2 mL of sterile phosphate bu>ered saline (PBS).
3. Grind solution of tissue and PBS until homogeneous suspension has been obtained.
4. Place approximately 0.7 mL of the homogenized tissue in a sterile, conical screw-capped tube.
5. Double volume of specimen with Xpert® Sample Reagent (1.4 mL Sample Reagent to 0.7 mL of homogenized tissue).
6. Shake tube vigorously 10 to 20 times or vortex for at least 10 seconds.
7. Incubate specimen for 10 minutes at room temperature, and again shake specimen 10 to 20 times or vortex for at least 10 seconds.
8. Incubate specimen at room temperature for an additional 5 minutes.
9. Transfer 2mL to Xpert® MTB/RIF cartridge.
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10.Load into GeneXpert and per manufacturer’s instructions.
(Note: For specimens not collected in a sterile manner, WHO SOP suggests an NaOH decontamination/concentration protocol similar to
that used for sputum.)
B. CSF
3a. CSF WHO followed: yes; no; unclear
3b. CSF concentration step: yes; no; unclear/not reported
3c. CSF sample input volume: specify; unclear/not reported
(For CSF, if WHO SOP not followed, briefly describe specimen processing in comments.)
WHO SOPs for CSF
If more than 5 mL of CSF is available for testing.
1. Transfer all of the CSF specimen to a conical centrifuge tube and concentrate the specimen at 3000 × g for 15 minutes.
2. Resuspend the pellet to a final volume of 2 mL by adding Xpert® MTB/RIF Sample Reagent.
3. Transfer 2 mL of the resuspended CSF sample to the Xpert® MTB/RIF cartridge.
4. Load the cartridge into the GeneXpert instrument according to the manufacturer’s instructions.
If 1 mL to 5 mL of CSF is available.
1. Add an equal volume of Sample Reagent to the CSF.
2. Mix the specimen and the Sample Reagent by vortexing as described above. ARer seven to eight minutes at room temperature, vortex the
sample as above a second time.
3. Incubate for an additional seven to eight minutes (15 minutes total incubation) at room temperature.
4. Add 2 mL of the sample mixture directly to the Xpert® MTB/RIF cartridge.
5. Load the cartridge into the GeneXpert instrument according to the manufacturer’s instructions.
C. Body fluids, other than CSF
4a. Body fluid: specify; processed as per manufacturer for sputum
Yes/No/Unclear
4b. Body fluid: specify; sample input volume: specify; unclear/not reported
5a. Body fluid: specify; processed as per manufacturer for sputum (WHO followed)
Yes/No/Unclear
5b. Body fluid: specify; sample input volume: specify; unclear/not reported
(Add additional specimens as needed.)
(For body fluids other than CSF, if manufacturer’s instructions not followed, briefly describe specimen processing in comments.)
Manufacturer’s instructions for sputum
Raw specimen
1. Pour or pipette (pipette not provided) approximately 2 times the volume of Sample Reagent into the specimen (2:1 dilution, Sample
Reagent: specimen).
2. Shake vigorously 10 to 20 times or vortex for at least 10 seconds.
3. Incubate sample for a total of 15 minutes at 20°C to 30°C.
4. Between 5 and 10 minutes into the incubation period, shake vigorously 10 to 20 times or vortex for at least 10 seconds.
Specimen sediment
Assay requires at least 0.5 mL of resuspended specimen sediment aRer digestion, decontamination, and concentration.
1. Use the method of Kent and Kubica and resuspend the sediment in a 67 mM phosphate/H2O bu>er.
2. ARer resuspension, keep at least 0.5 mL of the resuspended sediment for the Xpert® MTB/RIF assay.
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3. Add 1.5 mL of Sample Reagent to 0.5 mL of the resuspended sediment (3:1 dilution, Sample Reagent: specimen)
4. Follow steps 2 to 4 above.
Comments on specimen processing.
VII. Specimen processing for culture
Specimen collected from sterile site: Yes/No/Unclear
Specimen processed for culture as per American Thoracic Society Diagnostic Standards? Yes/No/Unclear
(ATS guidelines: specimens collected from normally sterile sites may be placed directly into the culture medium.)
Note: All specimens such as CSF, pleura, lymph node aspirates and tissues, peritoneal fluid, pericardial fluid, bone or joint fluid and tissue,
and urine are considered sterile.
VIII. Results
TB detection: number error or invalid or both Xpert® MTB/RIF results over total number of cultures performed. The denominator includes
contaminated cultures and results that were inconclusive.
Unclear/not reported.
RIF resistance: number indeterminate Xpert results (over total number of cultures performed).
Unclear/not reported.
Non-tuberculous mycobacteria (NTM): number of cultures with NTM (over total number of cultures performed).
Unclear/not reported.
IX. Tables
(Non-tuberculous mycobacteria (NTM) should be included as not TB)
Tuberculosis detection (example for Xpert Ultra against culture reference standard; provide additional tables Xpert MTB/RIF and for
other extrapulmonary specimens; extract trace results for Xpert Ultra)
 
Definite TBXpert Ultra in lymph node aspirate
Yes No Total
Positive      
Negative      
Total      
Xpert Ultra result
Error/invalid      
 
 
Rifampicin resistance detection (for all culture-positive, extrapulmonary specimens)
 
Rifampicin resistanceRifampicin resistance detection
Yes No Total
Xpert result Positive      
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Negative      
Total      




Appendix 3. Rules for QUADAS-2
Domain 1: patient selection
Risk of bias: could the selection of patients have introduced bias?
Signalling question 1: was a consecutive or random sample of patients enrolled?
We scored "yes" if the study enrolled a consecutive or random sample of eligible patients, "no" if the study selected patients by
convenience, and "unclear" if the study did not report the manner of patient selection or we could not tell.
Signalling question 2: was a case-control design avoided?
We did not include in the review studies using a case-control design because this study design, especially when used to compare results in
severely ill patients versus those in relatively healthy individuals, may lead to overestimation of accuracy in diagnostic studies. We scored
"yes" for all studies.
Signalling question 3: did the study avoid inappropriate exclusions?
We scored "yes" if the study included both smear-positive and smear-negative specimens or included only smear-negative specimens. We
judged "no" if the study included only smear-positive specimens or excluded specimens based on physical appearance (such as purulence)
or a biochemical analysis (e.g. adenosine deaminase (ADA), cytology (cell analysis)). We scored "unclear" if we could not tell.
Applicability: are there concerns that the included patients and setting do not match the review question?
We were interested in how the index tests performed in patients presumed to have extrapulmonary tuberculosis who were evaluated as
they would be in routine practice. We scored "low concern" if patients were evaluated at local hospitals or primary care centres. We scored
"high concern" if patients were evaluated exclusively as inpatients at tertiary care centres, except for tuberculous meningitis (we judged
low concern) where we would expect patients to be evaluated in tertiary care settings. We scored "unclear concern" if the clinical setting
was not reported or if information was insuLicient to allow a decision. We also scored "unclear concern” if Xpert testing was done at a
reference laboratory and the clinical setting was not reported for the following reason. It was diLicult to tell if a given reference laboratory
provided services mainly to very sick patients (inpatients in tertiary care) or to all patients, including very sick patients and those with less
severe disease (primary, secondary, and tertiary care).
Domain 2: index test
Risk of bias: could the conduct or interpretation of the index test have introduced bias?
Signalling question 1: were the index test results interpreted without knowledge of results of the reference standard?
We answered this question "yes" for all studies because Xpert test results are automatically generated and the user is provided with
printable test results. Thus, there is no room for subjective interpretation of test results.
Signalling question 2: If a threshold was used, was it pre-specified?
As the threshold is pre-specified in all versions of Xpert, we answered this question "yes" for all studies.
Applicability: are there concerns that the index test, its conduct, or its interpretation diLer from the review question?
We note that variations in execution of the test might aLect accuracy estimates. We judged "low concern" if the test was performed
according to WHO standard operating procedures (WHO 2014), or if the index test was performed as recommended by the manufacturer
for sputum. We scored "high concern" if the test was performed in a way that deviated from these recommendations. We scored "unclear
concern" if we could not tell. In studies that evaluated several diLerent types of specimens, we used the following rule: if ≥ 75% of the
specimen types were processed per WHO standard operating procedure (SOP) or as per the manufacturer's instructions, we judged "low
concern"; if < 50% of the specimen types were processed per WHO SOP or as per the manufacturer's instructions, we scored "high concern";
and if at least 50% to 74% of the specimen types were processed per WHO SOP or as per the manufacturer's instructions, or if we could
not tell, we scored "unclear concern".
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Domain 3: reference standard
Risk of bias: could the reference standard, its conduct, or its interpretation have introduced bias?
We considered this domain separately for the reference standard for detection of extrapulmonary tuberculosis and the reference standard
for detection of rifampicin resistance.
Signalling question 1: is the reference standard likely to correctly classify the target condition?
For detection of extrapulmonary tuberculosis, culture is generally considered the best reference standard. However, limitations are
associated with culture; bacterial load is usually low in extrapulmonary tuberculosis, leading to a reduction in the sensitivity of culture.
Concerning the conduct of the reference standard (preparation of the specimen for culture), N-acetyl-L-cysteine-sodium hydroxide is
routinely used to homogenize, decontaminate, and liquefy non-sterile specimens for TB culture (American Thoracic Society 2000).
However, CSF, pleural fluid, and lymph node aspirates are usually considered sterile, and standards specify, "specimens collected from
normally sterile sites may be placed directly into the culture medium” (American Thoracic Society 2000). Overly processing (sterile)
specimens with N-acetyl-L-cysteine-sodium hydroxide may lead to a decrease in viable TB bacteria and consequently false-negative
cultures. We scored "yes" if studies did not use N-acetyl-L-cysteine-sodium hydroxide for processing specimens and "unclear" if studies
used N-acetyl-L-cysteine-sodium hydroxide. We discussed this further under Discussion and Strengths and weaknesses of the review.
For detection of rifampicin resistance, culture-based drug susceptibility testing (DST, also called conventional phenotypic method) is
considered to be the best reference standard. Line probe assays are also WHO-recommended tests for rifampicin resistance. As we extracted
data only for studies that used culture-based DST or line probe assays (most oNen MTBDRplus), we answered this question "yes" for all
studies.
Signalling question 2: were the reference standard results interpreted without knowledge of results of the index test?
We scored "yes" if the reference test provided an automated result (e.g. MGIT 960), if blinding was explicitly stated, or if it was clear that the
reference standard was performed at a separate laboratory and/or was performed by diLerent people. We scored "no" if the study stated
that the reference standard result was interpreted with knowledge of the Xpert Ultra or Xpert MTB/RIF test result. We scored "unclear" if
we could not tell.
Signalling question 3: (rifampicin resistance) were the reference standard results interpreted without knowledge of results of the index test?
We added a signalling question for rifampicin resistance detection. We scored "yes" if the reference test provided an automated result
(e.g. MGIT 960), if solid culture was performed followed by speciation, if blinding was explicitly stated, or if it was clear that the reference
standard was performed at a separate laboratory or was performed by diLerent people, or both. We scored "no" if the study stated that the
reference standard result was interpreted with knowledge of the Xpert test result. We scored "unclear" if we could not tell. Not all studies
evaluated detection of rifampicin resistance; therefore this question was not applicable to all studies.
Applicability: are there concerns that the target condition as defined by the reference standard does not match the question?
We judged "high concern" if included studies did not speciate mycobacteria isolated in culture, "low concern" if speciation was performed,
and "unclear concern" if we could not tell. If a study performed sequencing, we considered the speciation yes. If the study only used a
composite reference standard, we considered applicability unclear.
Domain 4: flow and timing
Risk of bias: could the patient flow have introduced bias?
Signalling question 1: was there an appropriate interval between the index test and the reference standard?
In most included studies, we expected that specimens for index test and verification by culture (or a composite reference standard) would
be obtained at the same time, when patients were evaluated for presumptive extrapulmonary tuberculosis. However, even if there were
a delay of several days between index test and reference standard, tuberculosis is a chronic disease, and we considered misclassification
of disease status to be unlikely, as long as treatment was not initiated in the interim. We judged "yes" if the index test and the reference
standard were performed at the same time or if the time interval was less than or equal to seven days, "no" if the time interval was greater
than seven days, and "unclear" if we could not tell.
Signalling question 2: did all patients receive the same reference standard?
For the diagnosis of any form of extrapulmonary tuberculosis we answered this question "yes" if all participants in the study or a subset of
participants in the study (for whom we extracted data) received the acceptable reference standard either culture or a composite reference
standard. Regarding culture, we acknowledge that it is possible that some specimens could undergo solid culture and others liquid culture
as the reference standard. This could potentially result in variations in accuracy, but we think the variation would be minimal.
For rifampicin resistance detection, we answered "yes" if all participants received the same reference standard (either culture-based DST
or MTBDRplus), "no" if not all participants received the same reference standard, and "unclear" if we could not tell.
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Signalling question 3: were all patients included in the analysis?
We determined the answer to this question by comparing the number of patients enrolled with the number of patients included in the 2
× 2 tables. We answered "yes" if the numbers matched and "no" if there were patients enrolled in the study who were not included in the
analysis. We answered "unclear" if we could not tell.
Judgements for overall ʽRisk of bias' assessments.
• If we answered all signalling questions for a domain "yes", then we scored risk of bias as "low".
• If we answered all or most signalling questions for a domain "no", then we scored risk of bias as "high".
• If we answered only one signalling question for a domain "no", we discussed further the "risk of bias" judgement.
• If we answered all or most signalling questions for a domain "unclear", then we scored risk of bias as "unclear".
• If we answered only one signalling question for a domain "unclear", we discussed further the "risk of bias" judgement for the doma
Appendix 4. OpenBugs
In this section we provide OpenBUGS models for the bivariate meta-analysis as well as the latent class meta-analysis. Any alternative prior
distributions used are provided in the comments within each model.
BIVARIATE MODEL ASSUMING PERFECT CULTURE REFERENCE TEST
model {










l[i,1:2] ~ dmnorm(mu[1:2], T[1:2,1:2])
}
############################# HYPER PRIOR DISTRIBUTIONS
mu[1] ~ dnorm(0,0.25) # replaced by mu[1] ~ dnorm(0, 0.01) in sensitivity analysis to check impact of less informative prior
mu[2] ~ dnorm(0,0.25) # replaced by mu[2] ~ dnorm(0, 0.01) in sensitivity analysis to check impact of less informative prior
T[1:2,1:2]<-inverse(TAU[1:2,1:2])





tau[1]<-pow(prec[1],-0.5) # replaced by tau[1] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
tau[2]<-pow(prec[2],-0.5) # replaced by tau[2] ~ dunif(0,3) in sensitivity analysis to check impact of less informative prior
sigma.sq[1] <- pow(tau[1], 2)
sigma.sq[2] <- pow(tau[2], 2)
#### prec = between-study precision in the logit(sensitivity) and logit(specificity)
prec[1] ~ dgamma(2,0.5) # replaced by prec[1] <- 1/pow(tau[1],-2) in sensitivity analysis to check impact of less informative prior
prec[2] ~ dgamma(2,0.5) # replaced by prec[2] <- 1/pow(tau[2],-2) in sensitivity analysis to check impact of less informative prior
rho ~ dunif(-1,1)
############################# OTHER PARAMETERS OF INTEREST
#### POOLED SENSITIVITY AND SPECIFICITY
Pooled_S<-1/(1+exp(-mu[1]))
Pooled_C<-1/(1+exp(-mu[2]))
#### POOLED POSITIVE AND NEGATIVE LIKELIHOOD RATIOS
PLR <- Pooled_S/(1-Pooled_C)
NLR <- (1-Pooled_S)/Pooled_C
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} #### END OF PROGRAM
LATENT CLASS META-ANALYSIS MODEL
# WinBUGS PROGRAM FOR ESTIMATING A BIVARIATE HIERARCHICAL META-ANALYSIS MODEL
# FOR SENSITIVITY AND SPECIFICITY ALLOWING FOR HETEROGENEITY BETWEEN STUDIES
model {
############################# #############################
for(i in 1:N) {# N is the number of studies
############################# LIKELIHOOD
logit(p[1, i]) <- l[i,1]
logit(p[2, i]) <- -l[i,2]
prob[i,1] <- pi[i]*(p[1,i]* s2[i] + covp[i]) + (1-pi[i])*(p[2,i]*(1-c2[i]) + covn[i])
prob[i,2] <- pi[i]*(p[1,i]* (1-s2[i]) - covp[i]) + (1-pi[i])*(p[2,i]*c2[i] - covn[i])
prob[i,3] <- pi[i]*((1-p[1,i])*s2[i] - covp[i]) + (1-pi[i])*((1-p[2,i])*(1-c2[i]) - covn[i])

























# NON-INFORMATIVE HIERARCHICAL PRIOR DISTRIBUTION OVER REF STD PROPERTIES
# ==================================
for(j in 1:29) {
logit(s2[j]) <- l2[j,1]
logit(c2[j]) <- l2[j,2]
l2[j,1:2] ~ dmnorm(mu2[1:2], T2[1:2,1:2])
}









mu[2] ~ dnorm(0,0.25) #dnorm(4.59512,10)
T[1:2,1:2]<-inverse(TAU[1:2,1:2])
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sigma.sq[1] <- pow(tau[1], 2)
sigma.sq[2] <- pow(tau[2], 2)




############################# OTHER PARAMETERS OF INTEREST
#### POOLED SENSITIVITY AND SPECIFICITY OF XPERT
Pooled_S<-1/(1+exp(-mu[1]))
Pooled_C<-1/(1+exp(-mu[2]))
#### POOLED POSITIVE AND NEGATIVE LIKELIHOOD RATIOS
PLR <- Pooled_S/(1-Pooled_C)
NLR <- (1-Pooled_S)/Pooled_C





















sigma.sq2[1] <- pow(tau2[1], 2)
sigma.sq2[2] <- pow(tau2[2], 2)












Appendix 5. Risk of bias and applicability concerns graph for tuberculous meningitis
Figure 18.
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Figure 18.   Risk of bias and applicability concerns graph for tuberculous meningitis (cerebrospinal fluid): review
authors' judgements about each domain presented as percentages across included studies.
 
Appendix 6. Risk of bias and applicability concerns graph for pleural tuberculosis
Figure 19.
 
Figure 19.   Risk of bias and applicability concerns graph for pleural tuberculosis (pleural fluid): review authors'
judgements about each domain presented as percentages across included studies.
 
Appendix 7. Risk of bias and applicability concerns graph for lymph node tuberculosis
Figure 20.
 
Figure 20.   Risk of bias and applicability concerns graph for lymph node tuberculosis (lymph node aspirate): review
authors' judgements about each domain presented as percentages across included studies.
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Appendix 8. Receiver operating characteristic plot for pleural fluid, Xpert Ultra
Figure 21 displays the receiver operating characteristic (SROC) plots for Xpert Ultra (4 studies) and Xpert MTB/RIF (25 studies) in pleural
fluid for pleural tuberculosis.
 
Figure 21.   Summary plots of the sensitivity and specificity of Xpert Ultra (A) (4 studies) and Xpert MTB/RIF
(B) (25 studies) in pleural fluid for detection of pleural tuberculosis. Each individual study is represented by a
shaded square. The size of the square is proportional to the sample size of the study such that larger studies are
represented by larger squares. The filled circle is the median pooled estimate for sensitivity and specificity. The
solid curves represent the 95% credible region around the summary estimate; the dashed curves represent the 95%
prediction region.
 
Appendix 9. Bone or joint tuberculosis, Xpert Ultra and Xpert MTB/RIF
Figure 22 displays forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in bone or joint aspirate and tissue.
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Figure 22.   Forest plots of Xpert MTB/RIF and Xpert Ultra sensitivity and specificity in bone or joint fluid and
tissue by reference standard. The squares represent the sensitivity and specificity of one study, the black line its
confidence interval. FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.
 
Appendix 10. Peritoneal, pericardial, disseminated tuberculosis, Xpert Ultra and Xpert MTB/RIF
Figure 16 displays forest plots of Xpert Ultra and Xpert MTB/RIF sensitivity and specificity in peritoneal fluid and tissue, pericardial fluid,
and blood.
W H A T ' S   N E W
 
Date Event Description
11 January 2021 New citation required but conclusions
have not changed
We updated the literature search and included 22 new studies.
11 January 2021 New search has been performed We have updated the review with more information. There are
no major changes to the conclusions.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Table 9 describes prespecified changes for this review update.
Selection criteria: We included studies where at least 85% of the participants enrolled were adults, aged 15 years or older, with presumptive
extrapulmonary tuberculosis or rifampicin-resistant tuberculosis from all settings and countries. Restricting the age group to adults diLers
from the original review, where we also included children (Kohli 2018). We did this because children are now included in a separate
Cochrane Review, Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children (Kay 2020). We
excluded studies where we could not disaggregate data on adults from those in children and studies where we could not tell the age of
the participants enrolled.
QUADAS-2: we modified QUADAS-2 as follows.
Participant selection domain, applicability: For tuberculous meningitis, owing to the severity of the illness, we judged 'low concern' if
participants were evaluated as inpatients at tertiary care centres. In the original review, we judged tertiary care to be a setting of high
concern.
Reference standard domain: We clarified that CSF, pleural fluid, and lymph node aspirates are usually considered to be sterile, and
standards specify that these specimens may be placed directly into the culture medium. Overly processing specimens may lead to false-
negative cultures. We scored ‘yes' if studies did not use N-acetyl-L-cysteine-sodium hydroxide for processing sterile specimens and 'unclear'
if studies used N-acetyl-L-cysteine-sodium hydroxide.
Investigations of heterogeneity: For specimen volume, we restricted this analysis to CSF because it was most clinically meaningful. For
other fluid specimen types, the manufacturer's instructions for sputum were usually followed, requiring 2 mL of input fluid for the Xpert
cartridge. In terms of the WHO standard operating procedure for lymph node tissue, we did not investigate this further because 80% (8/10)
of the included studies followed the WHO recommendations. In performing the review, it became clear that because a homogenization
step is part of the WHO standard operating procedure for preparing tissue specimens, there was no need to perform an additional separate
analysis to confirm the presence of a homogenization step. We removed condition of specimen (fresh or frozen) from the analysis, because
we identified only six studies in the current review that used frozen specimens, and we had already performed an analysis of this possible
source of heterogeneity for the Cochrane Review on Xpert for pulmonary tuberculosis (Steingart 2014).
We have tried to eliminate stigmatizing language, for example, by changing ‘suspected tuberculosis' to ‘presumptive tuberculosis'.
For Xpert Ultra accuracy for lymph node tuberculosis, owing to insuLicient data, we were unable to investigate processing methods for
lymph node aspirate.
GRADE: We elaborated on the means of applying GRADE to publication bias: We rated publication bias as undetected (not serious) for
several reasons: the comprehensiveness of the literature search and extensive outreach to tuberculosis researchers to identify studies; the
presence of only studies that produced precise estimates of high accuracy despite small sample size; and our knowledge about studies
that were conducted but not published.
Unlike our previous review, in this update we did not extract information on manufacturers’ involvement and funding. As both Xpert Ultra
and Xpert MTB/RIF are available at a concessional price for researchers in resource-limited settings, and well-established tests, especially
Xpert MTB/RIF, industry donation is rarely pursued. We acknowledge that, in addition to funding, there are other reasons for conflicts of
interest, but we did not have time to pursue these. We are aware of a new tool being developed for this purpose: TACIT (Tool for Addressing
Conflicts of Interest in Trials: tacit.one). We plan to avail ourselves of this new tool in future updates.
Sensitivity analyses: We stated in our protocol that for Xpert Ultra we would perform a sensitivity analysis by limiting studies to those that
included only untreated participants. This information was oNen not reported in the publications and we did not contact primary study
authors specifically about this question. We were therefore unable to confirm that studies met this criterion.
For the 'Summary of findings' tables, we prioritised culture as the reference standard (best reference standard for tuberculosis), apart
from lymph node aspirate where we provide evidence using a composite reference standard, because, based on findings from the original
review (Kohli 2018), we believe a composite reference is preferable for estimating accuracy.
We added post hoc a sensitivity analysis limiting inclusion to studies that used one specimen per participant.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antibiotics, Antitubercular  [*therapeutic use];  Bacterial Proteins  [*genetics];  DNA-Directed RNA Polymerases  [*genetics];  Drug
Resistance, Bacterial  [*genetics];  False Negative Reactions;  False Positive Reactions;  Mycobacterium tuberculosis  [drug eLects]
 [*genetics]  [isolation & purification];  *Reagent Kits, Diagnostic;  Reference Standards;  Rifampin  [*therapeutic use];  Sensitivity and
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